<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006663.pub5" GROUP_ID="CF" ID="894406081213292979" MERGED_FROM="" MODIFIED="2017-06-29 10:28:02 +0100" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0080" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2017-06-29 10:28:00 +0100" MODIFIED_BY="Nikki Jahnke">
<TITLE>Enzyme replacement therapy for Anderson-Fabry disease</TITLE>
<CONTACT MODIFIED="2017-06-29 10:28:00 +0100" MODIFIED_BY="Nikki Jahnke"><PERSON ID="9DA0FCBF82E26AA2007D5B6E4992F15C" ROLE="AUTHOR"><FIRST_NAME>Regina</FIRST_NAME><LAST_NAME>El Dib</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>eldib@fmb.unesp.br</EMAIL_1><EMAIL_2>re.lucci@terra.com.br</EMAIL_2><MOBILE_PHONE>+55 11 9999 6647</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Biosciences and Oral Diagnosis</DEPARTMENT><ORGANISATION>Institute of Science and Technology, Unesp - Univ Estadual Paulista</ORGANISATION><CITY>Botucatu</CITY><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-06-29 10:28:00 +0100" MODIFIED_BY="Nikki Jahnke"><PERSON ID="9DA0FCBF82E26AA2007D5B6E4992F15C" ROLE="AUTHOR"><FIRST_NAME>Regina</FIRST_NAME><LAST_NAME>El Dib</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Assistant Professor</POSITION><EMAIL_1>eldib@fmb.unesp.br</EMAIL_1><EMAIL_2>re.lucci@terra.com.br</EMAIL_2><MOBILE_PHONE>+55 11 9999 6647</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Biosciences and Oral Diagnosis</DEPARTMENT><ORGANISATION>Institute of Science and Technology, Unesp - Univ Estadual Paulista</ORGANISATION><CITY>Botucatu</CITY><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON><PERSON ID="z1305231126254386112261410426805" ROLE="AUTHOR"><FIRST_NAME>Huda</FIRST_NAME><LAST_NAME>Gomaa</LAST_NAME><EMAIL_1>hudapharm@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Department of Pharmacy,Tanta Chest Hospital</ORGANISATION><ADDRESS_1>3 Ahmed Kamal Street,</ADDRESS_1><CITY>Tanta</CITY><ZIP>112311</ZIP><REGION>Gharbia</REGION><COUNTRY CODE="EG">Egypt</COUNTRY><PHONE_1>002/01116360388</PHONE_1></ADDRESS></PERSON><PERSON ID="z1310032135302719862734731216594" ROLE="AUTHOR"><FIRST_NAME>Raíssa Pierri</FIRST_NAME><LAST_NAME>Carvalho</LAST_NAME><EMAIL_1>raissa_pcarvalho@hotmail.com</EMAIL_1><ADDRESS><ORGANISATION>Botucatu Medical School, UNESP - Univ Estadual Paulista</ORGANISATION><ADDRESS_1>Avenida Camilo Mazoni, 1055 - F23</ADDRESS_1><ADDRESS_2>Jardim Paraiso</ADDRESS_2><CITY>Botucatu</CITY><ZIP>18610-285</ZIP><REGION>Sao Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON><PERSON ID="z1506191304274569050637981120890" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Samira</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Camargo</LAST_NAME><EMAIL_1>samira@fosjc.unesp.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Biosciences and Oral Diagnosis</DEPARTMENT><ORGANISATION>São Paulo State University - UNESP</ORGANISATION><ADDRESS_1>777 Francisco Jose Longo</ADDRESS_1><ADDRESS_2>São Jose dos Campos</ADDRESS_2><CITY>São Paulo</CITY><ZIP>12245-000</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 12 3947-9384</PHONE_1><FAX_1>+55 12 3947-9010</FAX_1></ADDRESS></PERSON><PERSON ID="z1305240955051684546689507946973" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Rodrigo</FIRST_NAME><LAST_NAME>Bazan</LAST_NAME><EMAIL_1>bazanr@operamail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Botucatu Medical School, Universidade Estadual Paulista (UNESP)</ORGANISATION><ADDRESS_1>District of Rubiao Junior</ADDRESS_1><CITY>Botucatu, São Paulo</CITY><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON><PERSON ID="z1309091635544856211260048338868" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Pasqual</FIRST_NAME><LAST_NAME>Barretti</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>pbarretti@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Medicine</DEPARTMENT><ORGANISATION>Botucatu Medical School, UNESP - Univ Estadual Paulista</ORGANISATION><ADDRESS_2>Distrito de Rubião Junior, s/n</ADDRESS_2><CITY>Botucatu</CITY><ZIP>18618-900</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+ 55 14 9 9631-6520</PHONE_1></ADDRESS></PERSON><PERSON ID="z1510221157036750405538456489083" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Fellype</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Barreto</LAST_NAME><POSITION>Professor de Nefrologia</POSITION><EMAIL_1>fellype.barreto@terra.com.br</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine Pontifícia</DEPARTMENT><ORGANISATION>Universidade Católica do Paraná</ORGANISATION><ADDRESS_1>Rua Imaculada Conceição, 1155</ADDRESS_1><CITY>Curitiba</CITY><ZIP>80215-901</ZIP><REGION>Paraná</REGION><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-07-21 10:05:25 +0100" MODIFIED_BY="Tracey Remmington">
<UP_TO_DATE>
<DATE DAY="21" MONTH="7" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="8" MONTH="7" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="7" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="5" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-06-29 10:28:00 +0100" MODIFIED_BY="Nikki Jahnke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2017-06-29 10:28:00 +0100" MODIFIED_BY="Nikki Jahnke"><DATE DAY="29" MONTH="6" YEAR="2017"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>


</WHATS_NEW>
<HISTORY MODIFIED="2017-06-29 10:28:00 +0100" MODIFIED_BY="Nikki Jahnke"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-06-29 10:28:00 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="14" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>The review update includes three new trials (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>; <LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>). One trial compares agalsidase alfa to agalsidase beta (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>), and two compared multiple dosage regimens of agalsidase alfa (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>). The inclusion of these trials did not significantly alter the conclusions of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-06-29 10:28:00 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="14" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>A total of 17 potentially relevant references were identified by the search of the Group's Inborn Errors of Metabolism Register. We selected all references for careful consideration and obtained them in full text, when available. Following assessment of the full articles, we included three new clinical trials (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>; <LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>) and excluded 12 further studies (<LINK REF="STD-Tsuboi-2014" TYPE="STUDY">Tsuboi 2014</LINK>; <LINK REF="STD-Benjamin-2014" TYPE="STUDY">Benjamin 2014</LINK>; <LINK REF="STD-Fellgiebel-2014" TYPE="STUDY">Fellgiebel 2014</LINK>; <LINK REF="STD-Hughes-2014" TYPE="STUDY">Hughes 2014</LINK>; <LINK REF="STD-Kim-2014" TYPE="STUDY">Kim 2014</LINK>; <LINK REF="STD-Schiffmann-2014" TYPE="STUDY">Schiffmann 2014</LINK>; <LINK REF="STD-Weidemann-2014" TYPE="STUDY">Weidemann 2014</LINK>; <LINK REF="STD-Germain-2013" TYPE="STUDY">Germain 2013</LINK>; <LINK REF="STD-T_x00f8_ndel-2013" TYPE="STUDY">Tøndel 2013</LINK>; <LINK REF="STD-Schiffmann-2013" TYPE="STUDY">Schiffmann 2013</LINK>; <LINK REF="STD-Rombach-2012" TYPE="STUDY">Rombach 2012</LINK>; <LINK REF="STD-Sirrs-2011" TYPE="STUDY">Sirrs 2011</LINK>). On further study has been added to studies awaiting classification (<LINK REF="STD-Wijburg-2015" TYPE="STUDY">Wijburg 2015</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-11-07 11:29:47 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="12" YEAR="2012"/>
<DESCRIPTION>
<P>Despite the addition of one new included trial, the conclusions remain the same as those in the original review (<LINK REF="REF-El-Dib-2010" TYPE="REFERENCE">El Dib 2010</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-11-07 11:29:49 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="12" YEAR="2012"/>
<DESCRIPTION>
<P>One new trial has been included in the review (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>). Two trials have been added to the excluded studies (<LINK REF="STD-Fernhoff-2011" TYPE="STUDY">Fernhoff 2011</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>).</P>
<P>Data and information have been included for a 'Agalsidase alfa versus agalsidase beta' comparison group (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-02-23 09:52:57 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="15" MONTH="2" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2012-02-15 15:36:13 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="15" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>Feedback, along with a response has been added to this review.</P>
<P>In the <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK> section, the study IDs previously listed as Thurberg 2004 and Moore 2002 have been changed to <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK> and <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>, to more accurately reflect the primary study reports. Furthermore, all outcomes reported by Hughes are now listed in full in the tables (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>) (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>).</P>
<P>The <LINK TAG="CONFLICT_OF_INTEREST" TYPE="SECTION">Declarations of interest</LINK> section has been updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="20" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Provided by CAPES</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-07-21 10:08:48 +0100" MODIFIED_BY="Tracey Remmington">
<SUMMARY MODIFIED="2016-07-14 13:09:47 +0100" MODIFIED_BY="Tracey Remmington">
<TITLE MODIFIED="2016-01-10 18:59:41 +0000" MODIFIED_BY="[Empty name]">Treatment for Anderson-Fabry disease</TITLE>
<SUMMARY_BODY MODIFIED="2016-07-14 13:09:47 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Background</B>
</P>
<P>Anderson-Fabry disease, a rare disorder, is caused by a deficiency of the enzyme alpha-galactosidase A. This leads to the build-up of a fatty material called globotriaosylceramide in various cells in the body. Globotriaosylceramide is formed of three sugars and a fatty substance called ceramide, and is found in most cells of the body. Untreated individuals may suffer from pain, skin, eye and gastrointestinal problems. Fabry disease may cause potentially life-threatening complications such as kidney damage, heart attack and stroke. One type of treatment available is enzyme replacement therapy with either agalsidase alfa or beta, which replaces the missing or deficient enzyme.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is current to: 08 July 2016.</P>
<P>
<B>Study characteristics</B>
</P>
<P>Nine studies enrolled 351 participants. The studies used different formulations of the enzyme, Agalsidase alfa or beta, and compared them to placebo (a 'dummy' treatment) or to each other. Comparison was also made in regard to different dosing schedules.</P>
<P>
<B>Key results</B>
</P>
<P>Two studies comparing agalsidase alfa to placebo reported on globotriaosylceramide concentration in plasma. The combined effects were not significant between the treatment and placebo groups. The study that reported pain and pain-related quality of life showed an improvement for participants receiving treatment over the six-month observation period. Death was not an outcome in either study.</P>
<P>One of the three studies comparing agalsidase beta to placebo reported on globotriaosylceramide and showed improvement in kidney, heart and composite results. There was no significant difference for death and no studies reported on pain.</P>
<P>Only two studies compared agalsidase alfa to agalsidase beta. One of them showed no significant difference for any adverse events such as dyspnoea, hypertension and gastrointestinal symptoms - these are not adverse events as gastrointestinal problems are actually a symptom, as may be hypertension in the context of renal disease.</P>
<P>Two studies compared different dosing schedules of agalsidase alfa. No differences were found among the schedules for self-assessed health state or for pain scores.</P>
<P>In summary, studies comparing enzyme replacement therapy to placebo show significant results in regard to microvascular endothelial deposits of globotriaosylceramide and in pain-related quality of life. There is, however, no evidence identifying if the alfa or beta form is superior, though included trials were small in sample size. With regards to safety, adverse events (i.e., rigors, fever) were more significant with agalsidase beta as compared to placebo.</P>
<P>
<B>Quality of the evidence</B>
<BR/>From the information available in most of the study reports, we were not able to clearly judge whether all volunteers had equal chances of being in either of the treatment groups and whether they would have known in advance or during the study which treatment they were receiving.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-07-14 14:39:33 +0100" MODIFIED_BY="Tracey Remmington">
<ABS_BACKGROUND MODIFIED="2015-05-21 14:17:16 +0100" MODIFIED_BY="[Empty name]">
<P>Anderson-Fabry disease is an X-linked defect of glycosphingolipid metabolism. Progressive renal insufficiency is a major source of morbidity, additional complications result from cardio- and cerebro-vascular involvement. Survival is reduced among affected males and symptomatic female carriers.</P>
<P>This is an update of a Cochrane review first published in 2010, and previously updated in 2013.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-04-08 16:42:55 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effectiveness and safety of enzyme replacement therapy compared to other interventions, placebo or no interventions, for treating Anderson-Fabry disease.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-07-14 12:05:06 +0100" MODIFIED_BY="Tracey Remmington">
<P>We searched the Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register (date of the most recent search: 08 July 2016). We also searched 'Clinical Trials' on <I>The Cochrane Library</I>, MEDLINE, Embase and LILACS (date of the most recent search: 24 September 2015).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-04-08 16:43:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials of agalsidase alfa or beta in participants diagnosed with Anderson-Fabry disease.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-04 14:30:30 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors selected relevant trials, assessed methodological quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-07-14 14:39:33 +0100" MODIFIED_BY="Tracey Remmington">
<P>Nine trials comparing either agalsidase alfa or beta in 351 participants fulfilled the selection criteria.</P>
<P>Both trials comparing agalsidase alfa to placebo reported on globotriaosylceramide concentration in plasma and tissue; aggregate results were non-significant. One trial reported pain scores measured by the Brief Pain Inventory severity, there was a statistically significant improvement for participants receiving treatment at up to three months, mean difference -2.10 (95% confidence interval -3.79 to -0.41; at up to five months, mean difference -1.90 (95% confidence interval -3.65 to -0.15); and at up to six months, mean difference -2.00 (95% confidence interval -3.66 to -0.34). There was a significant difference in the Brief Pain Inventory pain-related quality of life at over five months and up to six months, mean difference -2.10 (95% confidence interval -3.92 to -0.28) but not at other time points. Death was not an outcome in either of the trials.</P>
<P>One of the three trials comparing agalsidase beta to placebo reported on globotriaosylceramide concentration in plasma and tissue and showed significant improvement: kidney, mean difference -1.70 (95% confidence interval -2.09 to -1.31); heart, mean difference -0.90 (95% confidence interval -1.18 to -0.62); and composite results (renal, cardiac, and cerebrovascular complications and death), mean difference -4.80 (95% confidence interval -5.45 to -4.15). There was no significant difference between groups for death; no trials reported on pain.</P>
<P>Only two trials compared agalsidase alfa to agalsidase beta. One of them showed no significant difference between the groups regarding adverse events, risk ratio 0.36 (95% confidence interval 0.08 to 1.59), or any serious adverse events; risk ratio 0.30; (95% confidence interval 0.03 to 2.57).</P>
<P>Two trials compared different dosing schedules of agalsidase alfa. One of them involved three different doses (0.2 mg/kg every two weeks; 0.1 mg/kg weekly and; 0.2 mg/kg weekly), the other trial evaluated two further doses to the dosage schedules: 0.4 mg/kg every week and every other week. Both trials failed to show significant differences with various dosing schedules on globotriaosylceramide levels. No significant differences were found among the schedules for the primary efficacy outcome of self-assessed health state, or for pain scores.</P>
<P>One trial comparing agalsidase alfa to agalsidase beta showed no significant difference for any adverse events such as dyspnoea and hypertension.</P>
<P>The methodological quality of the included trials was generally unclear for the random sequence generation and allocation concealment.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-07-14 14:32:39 +0100" MODIFIED_BY="Tracey Remmington">
<P>Trials comparing enzyme replacement therapy to placebo show significant improvement with enzyme replacement therapy in regard to microvascular endothelial deposits of globotriaosylceramide and in pain-related quality of life. There is, however, no evidence identifying if the alfa or beta form is superior or the optimal dose or frequency of enzyme replacement therapy. With regards to safety, adverse events (i.e., rigors, fever) were more significant in the agalsidase beta as compared to placebo. The long-term influence of enzyme replacement therapy on risk of morbidity and mortality related to Anderson-Fabry disease remains to be established. This review highlights the need for continued research into the use of enzyme replacement therapy for Anderson-Fabry disease.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-07-15 09:54:34 +0100" MODIFIED_BY="Tracey Remmington">
<BACKGROUND MODIFIED="2016-07-14 14:33:36 +0100" MODIFIED_BY="Tracey Remmington">
<P>Please see glossary in the appendices for definition of terms used throughout the review (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<P>This is a second update of a Cochrane review first published in <I>The Cochrane Library </I>in 2010 (<LINK REF="REF-El-Dib-2010" TYPE="REFERENCE">El Dib 2010</LINK>), which included five studies that did not provide evidence on patient-important outcome measures. The first update of this review was then published in 2013 (<LINK REF="REF-El-Dib-2013" TYPE="REFERENCE">El Dib 2013</LINK>), which included only one new study and no information was changed. For this current version, a further three clinical trials not previously reviewed were included but they did not significantly alter the conclusions.</P>
<CONDITION MODIFIED="2016-07-14 14:33:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>Anderson-Fabry disease (AFD) is an X-linked, multi-system disorder caused by a deficiency of the lysosomal enzyme alpha&#8211;galactosidase A (AGAL). The incidence of AFD is estimated at 1 in 117,000 live births for males (<LINK REF="REF-Meikle-1999" TYPE="REFERENCE">Meikle 1999</LINK>); although recent newborn screening surveys suggest the incidence may be much higher, up to 1 in 3,100 (<LINK REF="REF-Spada-2006" TYPE="REFERENCE">Spada 2006</LINK>). One reasonable explanation for this difference in the incidence of AFD between these studies is that the first (<LINK REF="REF-Meikle-1999" TYPE="REFERENCE">Meikle 1999</LINK>) refers to the incidence of classic AFD while the latter (<LINK REF="REF-Spada-2006" TYPE="REFERENCE">Spada 2006</LINK>) refers to the full phenotypic spectrum reflecting the expansion in phenotypic variation identified in the last decade.Variants include those with sole involvement of the heart, kidneys or brain. For instance, the renal variant was first described in 2003. Although the vast majority of reports have focused on symptomatic males, females with AFD can develop disease-related problems (<LINK REF="REF-Wilcox-2008" TYPE="REFERENCE">Wilcox 2008</LINK>).</P>
<P>Clinically, AFD is characterized by major renal, cardiac and cerebrovascular complications consequent to the progressive deposition of incompletely metabolized glycosphingolipids, mainly globotrysilceramide (Gb<SUB>3</SUB>) in multiple cell types. The precise mechanism of tissue injury remains unclear though alterations in vascular reactivity and a propensity for thrombo-embolic disease are believed to play a role in the increased risk for particular problems, such as stroke. Gb3 has been used as a biomarker in AFD being measured in plasma and urine by tandem mass spectrometry. The reference ranges for plasma and urinary Gb3 levels are 5.6 (3.6-7.5) &#956;g/ml and 0.016 (0.01 - 0.03) mg/mmol of creatinine respectively. Gb3 levels are consistently elevated in most people with AFD and decrease after treatment initiation with ERT. Thus, it has been proposed to consider Gb3 levels as part of the diagnostic process as well as a biomarker of response to ERT. This said, the reliability of Gb3 levels as a surrogate marker of disease severity and of treatment response has been questioned by some investigators (<LINK REF="REF-Young-2005" TYPE="REFERENCE">Young 2005</LINK>). Recently studies have shown that a deacylated form of Gb<SUB>3</SUB> (globotriaosylsphingosine, lyso-Gb<SUB>3</SUB>) is elevated in plasma obtained from individuals with AFD. Lyso-Gb<SUB>3</SUB> is a potent inhibitor of AGAL and alpha&#8211;galactosidase B (N-acetylgalactosaminidase), and it has been found to promote smooth muscle cell proliferation in vitro (<LINK REF="REF-Aerts-2008" TYPE="REFERENCE">Aerts 2008</LINK>). Furthermore, it has been suggested lyso-Gb3 may identify the agalA mutations leading to classic Fabry disease (<LINK REF="REF-Niemann-2014" TYPE="REFERENCE">Niemann 2014</LINK>).</P>
<P>Renal and cardiac failure represent major sources of morbidity, and account for the reduced survival among affected males and females compared to the normal population (median age of death is 50 to 57 years and 70 to 72 years, respectively). The pain crises, acroparaesthesia, hearing loss and gastrointestinal problems experienced lead to significant reduction in health-related quality of life. While the majority of reports focus on males, females with AFD can develop disease-related problems. Clinical expression among females tends to be more variable and onset of symptoms tends to occur at a later age. The expression of the disease in females appears to be influenced by the particular <I>AGAL </I>mutation and the pattern of X chromosome inactivation in each organ (<LINK REF="REF-Niemann-2014" TYPE="REFERENCE">Niemann 2014</LINK>; <LINK REF="REF-Wang-2007" TYPE="REFERENCE">Wang 2007</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-07-14 14:33:36 +0100" MODIFIED_BY="Tracey Remmington">
<P>Enzyme replacement therapy (ERT) for AFD consists of the regular intravenous infusion of a recombinant enzyme formulation. Two forms of recombinant AGAL exist; agalsidase alfa (Replagal&#8482;), Shire Human Genetic Therapies, Cambridge, MA) and agalsidase beta (Fabrazyme<SUP>®</SUP>, Genzyme Corporation, Cambridge, MA). Agalsidase alfa is generated by the activation of the AGAL gene in a continuous human cell line; whereas agalsidase beta is produced in a Chinese hamster ovary (CHO) mammalian cell expression system transduced with the human AGAL sequence. Both enzyme preparations are approved in Europe and many other countries, but in the United States the Federal Drug Administration approved only agalsidase beta (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>). Administration of ERT is usually once every two weeks, using a dose of 0.2 mg/kg body weight when using agalsidase alfa or 1 mg/kg for agalsidase beta.</P>
<P>Intravenous enzyme infusions appear to be reasonably well tolerated, with reported infusion reactions of about 10%; mostly consisting of fever and transient rigours of mild to moderate intensity. A proportion of people with AFD receiving ERT have sero-converted (i.e. developed antibodies); the frequency of antibodies against agalsidase alfa and agalsidase beta has been reported at 55% and 83% of individuals treated respectively (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>). Antibody formation did not influence clinical efficacy or outcomes in either of the initial clinical studies undertaken, and antibody titres usually decreased over time. In a few cases, IgE antibodies have been reported after infusion of agalsidase beta (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>). Recent studies have shown the presence of antibodies may influence the Gb<SUB>3</SUB> storage in skin capillaries and Gb<SUB>3</SUB> excretion in urine, although no relation between antibody formation and plasma Gb<SUB>3</SUB> levels or clinical outcome has been established thus far (<LINK REF="REF-Hollack-2009" TYPE="REFERENCE">Hollack 2009</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-06-08 14:05:16 +0100" MODIFIED_BY="Tracey Remmington">
<P>Treatment of Fabry disease consists of symptom management and replacement of the deficient or dysfunctional enzyme with enzyme replacement therapy. ERT supplies the organs with recombinant enzyme and therefore reduces the amount of Gb3 accumulation in tissues with consecutive multisystem damage. ERT is available since 2001, in the form of two recombinant GLA preparations: agalsidase alfa (Replagal, Shire Human Genetic Therapies, Cambridge, MA, 0.2 mg/kg per infusion), and agalsidase beta (Fabrazyme, Genzyme Corporation, Cambridge, MA, 1 mg/kg per infusion). ERT is administered intravenously either through a peripheral line or central access device, infusions typically occur once every two weeks.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-06-08 14:05:21 +0100" MODIFIED_BY="Tracey Remmington">
<P>A systematic review is needed to establish the evidence base for the effectiveness and safety of ERT for treating AFD. This review is of particular relevance since ERT has now been available for almost 15 years and a review of the most recent data may provide more guidance in its use.</P>
<P>This is an update of a Cochrane review first published in 2010, and previously updated in 2013 (<LINK REF="REF-El-Dib-2010" TYPE="REFERENCE">El Dib 2010</LINK>; <LINK REF="REF-El-Dib-2013" TYPE="REFERENCE">El Dib 2013</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-05-27 16:44:44 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effectiveness and safety of ERT compared to other interventions, placebo or no interventions for treating AFD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-07-14 14:52:45 +0100" MODIFIED_BY="Tracey Remmington">
<SELECTION_CRITERIA MODIFIED="2016-07-14 13:15:38 +0100" MODIFIED_BY="Tracey Remmington">
<CRIT_STUDIES MODIFIED="2010-04-14 08:52:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized and quasi-randomized controlled clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-08-04 15:43:53 +0100" MODIFIED_BY="[Empty name]">
<P>Individuals with AFD of any age and any degree of disease severity. Diagnosis should be established either by accepted criteria based on concentration of enzyme activity or by mutation analysis.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-01-30 15:10:49 +0000" MODIFIED_BY="Tracey Remmington">
<P>Enzyme replacement therapy (agalsidase beta or agalsidase alfa) in any amount given for a period of at least one month compared to: each other; another intervention (fat-restricted diet, drugs, exercises, etc); no intervention; or to placebo. <B>
<I>
<BR/>
</I>
</B>
</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-07-14 13:15:38 +0100" MODIFIED_BY="Tracey Remmington">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-10-30 16:42:00 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Changes in globotriaosylceramide (Gb<SUB>3</SUB>) concentration in plasma and tissue (i.e. endothelial cells)</LI>
<LI>All-cause death</LI>
<LI>Pain (measured by the McGill Pain Questionnaire*)</LI>
<OL>
<LI>Acroparaesthesia (measured by the intensity and duration of acroparaesthesia as reported by the individual)</LI>
<LI>Fabry crises</LI>
</OL>
</OL>
<P>*<I>Post hoc </I>change: we also considered other validated pain questionnaires.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-07-14 13:15:38 +0100" MODIFIED_BY="Tracey Remmington">
<OL>
<LI>Effect of therapy on renal function (e.g. reduction in serum creatinine and proteinuria; creatinine and inulin clearance)</LI>
<LI>Symptoms and complications of disease such as occurrence of renal failure, skin, cerebrovascular and cardiac complications based on the following observations: serum creatinine level, proteinuria (ratio of urinary protein to urinary creatinine in mg/dL), 12-lead electrocardiography, echocardiography parameters (such as thickness of cardiac structures, left ventricular volume, measures of systolic and diastolic function, heart rate), neurologic examination, head magnetic resonance imaging, exercise tolerance, and AFD symptom assessment</LI>
<LI>Histologic analysis of microvascular capillary endothelial deposits of Gb<SUB>3</SUB> in biopsy specimens</LI>
<LI>Adverse effects of treatment (including severe adverse effects such as dyspnoea, malaise, hypertension and gastrointestinal symptoms, and antibody formation), based on the type and frequency of adverse events in treated participants and those on placebo.</LI>
<LI>Quality of life (QoL) (as determined by the Short Form 36 (SF-36) and the impact of clinical variables on domain scores within the SF-36* (<LINK REF="REF-Smith-2000" TYPE="REFERENCE">Smith 2000</LINK>).</LI>
</OL>
<P>*<I>Post hoc </I>change: we also considered other validated QoL questionnaires.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-07-14 12:05:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>There was no language restriction and the trials were identified from the sources listed below.</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-07-14 12:05:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>Relevant trials were identified from the Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register using the term: fabry disease.</P>
<P>The Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated with each new issue of <I>The Cochrane Library</I>), weekly searches of MEDLINE and the prospective handsearching of one journal - <I>Journal of Inherited Metabolic Disease</I>. Unpublished work were identified by searching through the abstract books of the Society for the Study of Inborn Errors of Metabolism conference and the SHS Inborn Error Review Series. For full details of all searching activities for the register, please see the relevant section of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/cf/frame.html">Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of the most recent search of the Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register: 08 July 2016.</P>
<P>We also searched Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 9, 2015, <A HREF="http://www.cochranelibrary.com">www.cochranelibrary.com</A>) Ovid Embase (1980 to 24 September 2015), PubMed (1980 to 24 September 2015; <A HREF="http://www.ncbi.nlm.nih.gov/pubmed">www.ncbi.nlm.nih.gov/pubmed</A>) and the Literature Latino-Americana e do Caribe em Ciências da Saúde - LILACS (1982 to 24 September 2015; <A HREF="http://lilacs.bvsalud.org">http://lilacs.bvsalud.org</A>). These search strategies are listed in the appendices (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-10-30 16:42:30 +0000" MODIFIED_BY="[Empty name]">
<P>Reference lists of the identified relevant trials were scrutinized for additional citations.</P>
<P>Specialists in the field and authors of the included trials were contacted for any possible unpublished data.</P>
<P>We also searched the abstract books of WORLD LDN.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-07-14 14:52:45 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_SELECTION MODIFIED="2016-05-27 16:49:28 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors (RED and HG) independently screened the trials identified. Discrepancies were resolved by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-07-14 14:52:45 +0100" MODIFIED_BY="Tracey Remmington">
<P>Two authors (RED and HG) independently extracted data and discrepancies were resolved by discussion. We used a standard form to extract the following information: characteristics of the trial (design, methods of randomisation), participants, interventions and outcomes (types of outcome measures, timing of outcomes, adverse events).</P>
<P>We presented different enzyme therapies (alfa and beta) as well as different control groups (placebo or active controls) as separate interventions as we did not judge these sufficiently comparable to combine.</P>
<P>When possible, outcome data were grouped into those measured at up to one month, over one month and up to three months, over three months and up to six months and over six months and up to 12 months and annually thereafter. In a <I>post hoc</I> change, we also considered other time points such as 'over five months and up to six months' where multiple data sets from an individual trial were available for a single planned time point.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-07-14 14:14:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>We assessed every trial using a simple form and followed the domain-based evaluation as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We assessed the following domains as having either low, unclear or high risk of bias:</P>
<OL>
<LI>randomisation</LI>
<LI>concealment of allocation</LI>
<LI>blinding (of participants, caregivers and outcome assessors)</LI>
<LI>incomplete outcome data</LI>
<LI>selective reporting</LI>
<LI>other potential sources of bias</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">1. Randomisation</HEADING>
<P>Low risk: adequate generation of allocation<BR/>Unclear risk: not described in the paper or by contacting authors<BR/>High risk: inadequate generation of allocation</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Concealment of allocation</HEADING>
<P>Low risk: adequate allocation concealment<BR/>Unclear risk: not described in the paper or by contacting authors<BR/>High risk: inadequate allocation concealment</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Blinding (of participants, caregivers and outcome assessors)</HEADING>
<P>Low risk: adequately described; adequate method<BR/>Unclear risk: described as blinded, but no information provided<BR/>High risk: not blinded; inadequate method</P>
<P>If a trial measured an objective outcome then lack of blinding was rated as low risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Incomplete outcome data</HEADING>
<P>We recorded the rates of withdrawal for each outcome as follows.<BR/>Low risk: less than 20% and equal for both groups;<BR/>Unclear risk: not reported in paper or by authors;<BR/>High risk: greater than 20% or not equal for any comparison groups or both.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Selective reporting</HEADING>
<P>We considered the possibility of selective reporting of outcomes when data were not available in the 'Results' section of the published paper, but according to the 'Methods' section these outcome data were collected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Other potential sources of bias</HEADING>
<P>We recorded any other factors we felt might cause bias.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-07-14 14:46:17 +0100" MODIFIED_BY="Tracey Remmington">
<P>For dichotomous data (such as death, presence or absence of Fabry crises and adverse effects), we used the risk ratio (RR), with 95% confidence intervals (95% CIs) as the effect measure.</P>
<P>For continuous data (such as changes in Gb<SUB>3</SUB> concentration, echocardiographic parameters, pain and quality of life scores) we used the mean difference (MD) (in which the effect estimates of individual trials are weighted by dispersion measures), with 95% CIs. When standard errors (SE) were reported within the trial reports, we converted these to standard deviations (SD) (SD = SE x  square root of n). For future updates of this review we plan to use standardized mean difference (SDM).</P>
<P>For time-to-event data (such as effects on renal function) we planned to consider a joint model for longitudinal and discrete time-to-event data in which the discrete event time distribution is modelled as a linear function of the slope of an individual's longitudinal process on the probit scale (<LINK REF="REF-Jones-2009" TYPE="REFERENCE">Jones 2009</LINK>). Effect of therapy on renal function (e.g. increase in serum creatinine and proteinuria; creatinine and inulin clearance) could be measured as time-to-event-data or number of events. However, the only trial reporting on this outcome only reported on one time point, which has been presented as continuous data (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-10-30 17:34:46 +0000" MODIFIED_BY="[Empty name]">
<P>We have included data from an eligible cross-over trial and analysed this according to a method recommended by Elbourne, whereby we inserted the mean and SD of the participant-specific differences between the intervention and control measurements taking all these measurements from intervention periods and all measurements from control periods and, we analysed these as if the trial was a parallel group trial of intervention versus control group (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). We appreciate that this is a conservative method and will overestimate the SE of the MD by treating (paired) within differences as independent data.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-05-21 14:19:01 +0100" MODIFIED_BY="[Empty name]">
<P>For any new trial which may be included in a future update of this review, we will contact authors, as necessary, to clarify methodological issues (such as generation and allocation concealment, blind method and withdrawals) as well as for any missing outcome data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-11-15 12:32:54 +0000" MODIFIED_BY="Nikki Jahnke">
<P>We planned to qualify inconsistency among the pooled estimates using the I<SUP>2 </SUP>statistic. This illustrates the percentage of the variability in effect estimates resulting from heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We considered there to be a low degree of heterogeneity if I<SUP>2</SUP> was below 25%, a moderate degree if I<SUP>2 </SUP>between 25% and 50%, and a high degree if I<SUP>2</SUP> was over 50%.<BR/>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-12-12 15:41:25 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to assess publication bias by drawing a funnel plot (trial effect versus trial size), but there were not sufficient trials included in the review. In future analysis, funnel plots will be used in an exploratory data analysis to assess for the potential existence of small trial bias. There are a number of explanations for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design of small trials (<LINK REF="REF-Sterne-2001" TYPE="REFERENCE">Sterne 2001</LINK>) and publication bias and selective reporting of outcomes. Thus, this exploratory data tool may be misleading (<LINK REF="REF-Tang-2000" TYPE="REFERENCE">Tang 2000</LINK>; <LINK REF="REF-Thornton-2000" TYPE="REFERENCE">Thornton 2000</LINK>) and we will not place undue emphasis on this tool.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-12-12 15:41:29 +0000" MODIFIED_BY="Nikki Jahnke">
<P>We used the fixed-effect model to analyse data, if in future updates, significant heterogeneity (e.g. I<SUP>2</SUP> higher than 50%) is identified, we will compute pooled estimates of the treatment effect for each outcome under a random-effects model (with two or more trials).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-07-14 14:14:51 +0100" MODIFIED_BY="Tracey Remmington">
<P>For future reviews (including 10 or more trials) we plan to investigate heterogeneity by conducting meta-analyses by subgroups as described below.</P>
<OL>
<LI>Dose. We plan to sub-divide dose in to lower dose (less than 0.2 mg/kg) and higher dose (more than 0.2 mg/kg). These cut off doses were chosen arbitrarily.</LI>
<LI>Duration of intervention. We plan to sub-divide duration of intervention up to one year and more than one year. These time divisions were chosen arbitrarily.</LI>
<LI>Age at commencement of treatment, for example, up to the age of 18 years and over age 18 years.</LI>
<LI>Severity of disease as stratified into less severe and more severe (as reported within the trials).</LI>
</OL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-07-14 14:16:10 +0100" MODIFIED_BY="Tracey Remmington">
<P>If we had included an adequate number of trials, we planned to perform a sensitivity analysis to test the robustness of analyses to certain assumptions in the results. In future analysis, we will include the following factors in the sensitivity analysis, separating trials according to:</P>
<OL>
<LI>allocation concealment quality (low risk, high risk or unclear risk);</LI>
<LI>blinding of participants, caregiver and outcome assessment (low risk, high risk or unclear risk);</LI>
<LI>rates of withdrawal for each outcome.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings tables</HEADING>
<P>In our review, we used the principles of the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) to assess the quality of the body of evidence associated with specific outcomes (changes in globotriaosylceramide (Gb<SUB>3</SUB>) concentration in plasma and tissue; death; pain; renal function; and symptoms and complications of disease (i.e., cardiac and cerebrovascular events)) and constructed a summary of findings (SoF) table using GRADE software. The GRADE approach appraises the quality of a body of evidence according to the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Assessment of the quality of a body of evidence considers within-trial risk of bias (methodological quality), directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias. The quality of the evidence for a specific outcome will be altered by a level according to the performance of trials against these five factors.</P>
<P>
<B>High-quality evidence</B>: findings are consistent among at least 75% of RCTs with low risk of bias; data are consistent, direct and precise, and no publication biases are known or suspected. Further research is unlikely to change the estimate or our confidence in the results.</P>
<P>
<B>Moderate-quality evidence</B>: one of the domains is not met. Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</P>
<P>
<B>Low-quality evidence</B>: two of the domains are not met. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</P>
<P>
<B>Very low-quality evidence</B>: three of the domains are not met. We are very uncertain about the results.</P>
<P>
<B>No evidence</B>: no RCTs that addressed this outcome were identified.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-07-15 09:50:44 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_DESCRIPTION MODIFIED="2016-07-15 09:50:22 +0100" MODIFIED_BY="Tracey Remmington">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. <B>
<I>
<BR/>
</I>
</B>
</P>
<SEARCH_RESULTS MODIFIED="2016-07-14 14:17:33 +0100" MODIFIED_BY="Tracey Remmington">
<P>For the original review, we identified 273 references from the electronic searches (<LINK REF="REF-El-Dib-2010" TYPE="REFERENCE">El Dib 2010</LINK>). After initial assessment of these references, 56 were looked at in more detail. A total of 31 were excluded from the review (<LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>). Thus, five trials (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>) (represented by 25 individual references), which enrolled 187 participants were included (<LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>).</P>
<P>For the first update of the review in 2012, 368 references were identified by the searches. After an initial assessment seven references were considered. Of these we included one new trial (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>) (represented by five individual references) and, excluded two further trials (<LINK REF="STD-Fernhoff-2011" TYPE="STUDY">Fernhoff 2011</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>).</P>
<P>For the second update of the review in 2016, 19 references were identified. We selected all references for careful consideration and obtained them in full text, where available. Following assessment of the full articles, we included three new clinical trials (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>; <LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>) (represented by four individual references) and, we excluded 12 further studies (<LINK REF="STD-Benjamin-2014" TYPE="STUDY">Benjamin 2014</LINK>; <LINK REF="STD-Fellgiebel-2014" TYPE="STUDY">Fellgiebel 2014</LINK>; <LINK REF="STD-Germain-2013" TYPE="STUDY">Germain 2013</LINK>; <LINK REF="STD-Hughes-2014" TYPE="STUDY">Hughes 2014</LINK>; <LINK REF="STD-Kim-2014" TYPE="STUDY">Kim 2014</LINK>; <LINK REF="STD-Rombach-2012" TYPE="STUDY">Rombach 2012</LINK>; <LINK REF="STD-Schiffmann-2013" TYPE="STUDY">Schiffmann 2013</LINK>; <LINK REF="STD-Schiffmann-2014" TYPE="STUDY">Schiffmann 2014</LINK>; <LINK REF="STD-Sirrs-2011" TYPE="STUDY">Sirrs 2011</LINK>; <LINK REF="STD-T_x00f8_ndel-2013" TYPE="STUDY">Tøndel 2013</LINK>; <LINK REF="STD-Tsuboi-2014" TYPE="STUDY">Tsuboi 2014</LINK>; <LINK REF="STD-Weidemann-2014" TYPE="STUDY">Weidemann 2014</LINK>). One further trial is currently listed in '<LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>' (represented by three individual references) and will be fully assessed in the next update of this review (<LINK REF="STD-Wijburg-2015" TYPE="STUDY">Wijburg 2015</LINK>).</P>
<P>Therefore, for this second update we have a total of nine included trials (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>; <LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>; <LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>; <LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>) (represented by 34 individual references) (<LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>) involving a total of 351 participants (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), 43 excluded trials (<LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>) and three trials awaiting assessment (<LINK REF="STD-Benjamin-2014" TYPE="STUDY">Benjamin 2014</LINK>; <LINK REF="STD-Hughes-2014" TYPE="STUDY">Hughes 2014</LINK>; <LINK REF="STD-Wijburg-2015" TYPE="STUDY">Wijburg 2015</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-07-15 09:50:22 +0100" MODIFIED_BY="Tracey Remmington">
<SUBSECTION>
<HEADING LEVEL="4">Agalsidase alfa versus placebo</HEADING>
<P>Two trials (n = 41) were included in this comparison and are described in detail below (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Trial design</HEADING>
<P>Both trials were described as randomized, double-blind, placebo-controlled, clinical trials (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>). Both trials were for six months (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>), but one had an additional 24 months open-label follow up (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>).</P>
<P>Both trials recruited only males and included 15 and 26 participants respectively (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>). The ratio of participants in the treatment and placebo groups varied; the Schiffmann trial achieved an almost equal split, randomising 14 participants to treatment and 12 to placebo (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>); and in the Hughes trial seven and eight participants were randomised to the treatment and to the placebo groups respectively (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Types of interventions</HEADING>
<P>Both trials compared ERT to placebo and used the same dose regime of Agalsidase alfa (Replagal&#8482;) administered intravenously at a dose of 0.2 mg/kg over a period of 20 or 40 minutes for six months. The treatment regimen was the same for the additional 24-month open-label follow up (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Types of outcomes measured</HEADING>
<P>Moore (in a report of the Schiffmann trial) evaluated transversal doppler measurements, left ventricular volume, heart rate and stroke volume. The following Doppler parameters were obtained: peak flow velocity, mean flow velocity, end-diastolic velocity, pulsatility index, and resistance index (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
<P>At baseline and six months, left ventricular mass assessed by magnetic resonance imaging (MRI), QRS duration, levels of Gb3 in cardiac tissue, urine sediment and plasma, and adverse effects were evaluated in the Hughes trial (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Agalsidase beta versus placebo</HEADING>
<P>Three trials (n = 146) were included in this comparison and are described in detail below (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Trial design</HEADING>
<P>All three trials were described as randomized, placebo-controlled, clinical trials (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>); and two of these were described as double blind (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>). Trial duration ranged from five (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>) to 35 months (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>).</P>
<P>The number of participants included in each trial ranged from six (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>) to 82 (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>) and the three trials randomized mostly males (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>). The ratio of participants in the treatment and placebo groups varied across trials; two had a ratio of 2:1 treatment-to-placebo (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>); and one had an even split of 29 participants in each group (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
<P>In one trial, the investigators were part of the Genzyme Corporation in Cambridge, Massachussetts (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>). Only one trial was described as multicenter; with there being 26 referral centers from six countries from North America and Europe (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Types of interventions</HEADING>
<P>All three trials compared ERT - agalsidase beta (recombinant human alfa-galactosidase A) - to placebo (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>). The treatment regimen was the same in these trials with Agalsidase beta administered at a dose of 1mg/kg intravenously every two weeks. Duration of the treatment varied from 20 weeks (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>), to 35 months (median 18.5 months) (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>), and 18 months (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Types of outcomes measured</HEADING>
<P>Thurberg (in a report of the Eng trial) evaluated urinary creatinine, urinary protein excretion, renal function and dermatologic characteristics of Gb3 accumulation in the dermis (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>). Measurements were taken at baseline and after infusion 11 at five months.</P>
<P>Banikazemi measured the time to first clinical event (renal, cardiac, cerebrovascular event or death) (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>). The following measures were taken: serum creatinine level, proteinuria (ratio of urinary albumin to urinary creatinine), 12-lead electrocardiography, echocardiography, neurologic examination, head MRI, Brief Pain Inventory, exercise tolerance, plasma Gb3 level, Fabry symptom assessment, physical examination, blood chemistry, urinalysis, IgG antibody titers to agalsidase beta and optional skin biopsy. All measurements were taken at baseline. Serum creatinine levels were measured every four weeks aechocardiography, head MRI, and exercise tolerance,were repeated every 24 weeks and all other baseline measurements were repeated every 12 weeks. The estimated glomerular filtration rate (GFR) was determined by using the 4-variable Modification of Diet in Renal Disease formula.</P>
<P>Bierer measured cardiopulmonary exercise performance, forced expiratory volume and forced vital capacity every three months over an 18-month period (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Agalsidase alfa versus agalsidase beta</HEADING>
<P>Two trials (n = 184) were included in this comparison and are described in detail below (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>; <LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
<P>
<B>Trial design</B>
</P>
<P>The trial conducted by Vedder was a randomized clinical trial with participants being treated for a period of at least 12 months. A total of 36 participants (18 males and 18 females) were included. A total of 34 participants had at least 12 months of follow up and a subgroup of participants (25 out of 34) was followed up for more than 24 months of treatment. Two female participants withdrew after six months of agalsidase alfa or agalsidase beta treatment (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
<P>The Sirrs trial was a nationwide study of all individuals in Canada with Fabry disease between ages five and 85 years old. This trial looked at the two Canadian Fabry Disease Initiative (CFDI) cohorts of enzyme replacement (ERT) treated individuals. Cohort 1a: participants on ERT when the CFDI began who maintained their baseline treatment assignment (these participants were not randomised and therefore not included in the review). Cohort 1b: participants newly meeting criteria for ERT and randomized 1:1 to agalsidase beta (1.0 mg/kg every two weeks) or agalsidase alfa (0.2 mg/kg every two weeks). A total of 67 participants were randomized; mean follow up was at 23.00 months (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
<P>
<B>Types of interventions</B>
</P>
<P>In one trial, participants were treated with either agalsidase alfa or agalsidase beta at an equal dose of 0.2 mg/kg bi-weekly (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>). In the other trial participants were randomized 1:1 to agalsidase beta 1.0 mg/kg every two weeks or agalsidase alfa 0.2 mg/kg every two weeks (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
<P>
<B>Types of outcomes measured</B>
</P>
<P>In the Vedder trial, reduction in left ventricular mass after 12 and 24 months of treatment was considered the primary outcome. The authors also evaluated the occurrence of treatment failure (defined as progression of cardiac, renal or cerebral disease), GFR, pain, anti-agalsidase antibodies and GL3 levels in plasma and urine (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
<P>In the Sirrs trial comparison was made between the effects of agalsidase alfa and agalsidase beta on a composite clinical outcome consisting of renal (dialysis, transplant, or reduction in GFR by 50%), cardiac (admission for cardiac event), neurologic (stroke or sudden unilateral hearing loss) or death (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Multiple agalsidase alfa dosing schedules</HEADING>
<P>Two trials (n = 36) were included in this comparison and are described in detail below (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
<P>
<B>Trial design</B>
</P>
<P>Both trials were described as randomized, double-blind, placebo controlled, clinical trials (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>). One trial was 10 weeks in length (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>), while the other was four weeks (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>). Each trial recruited 18 participants all of whom were male in one trial (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>), while in the other participants of both genders were included (12 males and 6 females). One trial was a cross-over design where all participants received the same interventions sequentially (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>). The other achieved an almost equal split between five arms (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>).</P>
<P>
<B>Types of interventions</B>
</P>
<P>Both trials compared ERT at different dosage regimens. The Hughes trial used three treatment schedules: treatment A 0.2 mg/kg every other week; treatment B, 0.1 mg/kg weekly and treatment C, 0.2 mg/kg weekly (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>). The Clarke trial compared five different dosage regimens of agalsidase alfa: 0.1, 0.2, or 0.4 mg/kg weekly; 0.2 mg/kg every other week (the approved dose) or 0.4 mg/kg every other week (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>).</P>
<P>
<B>Types of outcomes measured</B>
</P>
<P>For the Hughes trial, the primary outcome variable was self-assessed health state measured by the visual analogue scale (&#8216;thermometer&#8217;) item of the European quality of life questionnaire (the EQ-5D: Euroqol Group 1990). </P>
<P>Secondary outcome variables were:</P>
<OL>
<LI>pain as assessed as the average composite pain severity dimension of the brief pain inventory (BPI) short form, a standard pain assessment tool, each individual item of the BPI short form, health state as calculated from items 1&#8211;5 of the EQ-5D questionnaire (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each individual item of the EQ-5D questionnaire;</LI>
<LI>results of quantitative sudomotor axon reflex test (QSART) testing which tests for abnormalities of resting and evoked sweat production;</LI>
<LI>the Mainz severity score index (MSSI), a scoring system to measure the severity of Fabry disease;</LI>
<LI>plasma and urine Gb3; and</LI>
<LI>analgesic use.</LI>
</OL>
<P>All questionnaire-based data were completed by the participant on a daily diary sheet (health state, pain and analgesic use) and using weekly investigator administered questionnaires (BPI and EQ-5D). Safety assessments included physical examination, 12-lead ECG, clinical laboratory testing, and vital sign measurements. Adverse events (AEs) and concomitant medications were recorded throughout the trial. Anti-agalsidase alfa antibodies were assayed at baseline using an enzyme-linked immunosorbent assay (ELISA) (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
<P>The primary efficacy endpoint variable for the Clarke trial was change in plasma Gb3 level from baseline to the day of the final infusion (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-05-27 16:57:48 +0100" MODIFIED_BY="[Empty name]">
<P>A total of 43 studies were excluded from the review (<LINK REF="STD-Alamartine-2005" TYPE="STUDY">Alamartine 2005</LINK>; <LINK REF="STD-Banikasemi-2005" TYPE="STUDY">Banikasemi 2005</LINK>; <LINK REF="STD-Beck-2004" TYPE="STUDY">Beck 2004</LINK>; <LINK REF="STD-Beer-2006" TYPE="STUDY">Beer 2006</LINK>; <LINK REF="STD-Breunig-2006" TYPE="STUDY">Breunig 2006</LINK>; <LINK REF="STD-Cartwright-2004" TYPE="STUDY">Cartwright 2004</LINK>; <LINK REF="STD-Elliott-2006" TYPE="STUDY">Elliott 2006</LINK>; <LINK REF="STD-Eto-2005" TYPE="STUDY">Eto 2005</LINK>; <LINK REF="STD-Fellgiebel-2014" TYPE="STUDY">Fellgiebel 2014</LINK>; <LINK REF="STD-Fernhoff-2011" TYPE="STUDY">Fernhoff 2011</LINK>; <LINK REF="STD-Germain-2007" TYPE="STUDY">Germain 2007</LINK>; <LINK REF="STD-Guffon-2002" TYPE="STUDY">Guffon 2002</LINK>; <LINK REF="STD-Guffon-2004" TYPE="STUDY">Guffon 2004</LINK>; <LINK REF="STD-Hajioff-2006" TYPE="STUDY">Hajioff 2006</LINK>; <LINK REF="STD-Hilz--2004" TYPE="STUDY">Hilz 2004</LINK>; <LINK REF="STD-Jardim-2006" TYPE="STUDY">Jardim 2006</LINK>; <LINK REF="STD-Jardim-2006b" TYPE="STUDY">Jardim 2006b</LINK>; <LINK REF="STD-Kalliokoshi-2006" TYPE="STUDY">Kalliokoshi 2006</LINK>; <LINK REF="STD-Kampmann-2002" TYPE="STUDY">Kampmann 2002</LINK>; <LINK REF="STD-Kobayashi-2005" TYPE="STUDY">Kobayashi 2005</LINK>; <LINK REF="STD-Kosch-2004" TYPE="STUDY">Kosch 2004</LINK>; <LINK REF="STD-Linthorst-2004" TYPE="STUDY">Linthorst 2004</LINK>; <LINK REF="STD-Linthorst-2006" TYPE="STUDY">Linthorst 2006</LINK>; <LINK REF="STD-Mignani-2004" TYPE="STUDY">Mignani 2004</LINK>; <LINK REF="STD-Mills-2004" TYPE="STUDY">Mills 2004</LINK>; <LINK REF="STD-Pisani-2005" TYPE="STUDY">Pisani 2005</LINK>; <LINK REF="STD-Ramaswami-2007" TYPE="STUDY">Ramaswami 2007</LINK>; <LINK REF="STD-Ries-2006" TYPE="STUDY">Ries 2006</LINK>; <LINK REF="STD-Schiffmann-2003" TYPE="STUDY">Schiffmann 2003</LINK>; <LINK REF="STD-Schiffmann-2006" TYPE="STUDY">Schiffmann 2006</LINK>; <LINK REF="STD-Schiffmann-2014" TYPE="STUDY">Schiffmann 2014</LINK>; <LINK REF="STD-Sirrs-2011" TYPE="STUDY">Sirrs 2011</LINK>; <LINK REF="STD-Spinelli-2004" TYPE="STUDY">Spinelli 2004</LINK>; <LINK REF="STD-Tsuboi-2014" TYPE="STUDY">Tsuboi 2014</LINK>; <LINK REF="STD-Utsumi-2005" TYPE="STUDY">Utsumi 2005</LINK>; <LINK REF="STD-Weidemann-2003" TYPE="STUDY">Weidemann 2003</LINK>; <LINK REF="STD-Weidemann-2014" TYPE="STUDY">Weidemann 2014</LINK>; <LINK REF="STD-West-2011" TYPE="STUDY">West 2011</LINK>). The main reasons for exclusion being that these were case series, cohort studies, retrospective studies or non-randomized trials.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-07-14 15:15:29 +0100" MODIFIED_BY="Tracey Remmington">
<P>See: <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Agalsidase alfa versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Generation of randomization sequence</HEADING>
<P>The Hughes trial did not describe the generation of allocation, thus, this trial was classified as having an unclear risk of bias (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>). The Schiffmann trial reported the generation of allocation was made by random tables and, therefore we rated this trial as low risk of bias for this domain (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>The Hughes trial did not describe the concealment of allocation so this was judged to have an unclear risk of bias (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>). The Schiffmann trial reported that randomization was provided by an unblinded pharmacist and, therefore we rated this trial as low risk of bias for this domain (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<P>The Hughes trial reported data remained blinded until the database was unlocked and the statistical analyses performed (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>). We therefore judge this to be at a low risk of bias regarding this domain. However, the Schiffmann trial did not describe any blinding process and, therefore it was classified as having an unclear risk of bias (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<P>The Hughes trial did not describe withdrawals, dropouts or ITT, therefore we judged this to have an unclear risk of bias (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>). The Schiffmann trial describes only four withdrawals and, therefore we rated this trial as low risk of bias for this domain (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting</HEADING>
<P>We judged both included trials to be free of selective reporting and having a low risk of bias (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other potential sources of bias</HEADING>
<P>We did not identify any other potential sources of bias (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Agalsidase beta versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Generation of randomization sequence</HEADING>
<P>The Banikazemi trial described the generation of randomization as computer-generated and, therefore we rated this trial as low risk of bias (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>).The Bierer and Eng trials did not describe details on how the sequences were generated; therefore these trials presented an unclear risk of bias (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>The Banikazemi trial was classified as having a low risk of bias since the randomization codes were maintained centrally at a secure location (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>). The Bierer and Eng trials did not describe details regarding the concealment of allocation; thus, these trials were classified as having an unclear risk of bias (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<P>The Banikazemi trial described that the sponsor staff, investigators, and participants were blinded to treatment allocation leading to a low risk of bias (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>). The Bierer and Eng trials were described as double blind, but provided no further details, we therefore judge these two trials to have an unclear risk of bias (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<P>The Banikazemi trial reported less than 20% of withdrawals and dropouts, we therefore assessed this as having a low risk of bias (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>). The Bierer and Eng trials did not describe withdrawals, dropouts or ITT, therefore we judged this to have an unclear risk of bias (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting</HEADING>
<P>We judged all three included trials to be free of selective reporting (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other potential sources of bias</HEADING>
<P>We judged all three included trials to be at high risk of bias as the investigators were part of the Genzyme Corporation (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Agalsidase alfa versus agalsidase beta</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Generation of randomization sequence</HEADING>
<P>Both trials described the generation of randomization as manual randomization and, therefore we rated this domain as low risk of bias (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>; <LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>The Vedder trial was classified as having a low risk of bias since the investigators used envelopes that were checked by two people not involved in obtaining informed consent, thus we classified the trial as having a low risk of bias (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>). The Sirrs trial reported that a third party was involved in the generation of allocation; thus, this trial was classified as having a low risk of bias (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<P>The Vedder trial was classified as having a high risk of bias since there was no blinding (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>). The Sirrs trial was not blinded but the composite outcome consisting of renal, cardiac, neurologic and, death is unlikely to be affected by lack of blinding, hence it was judged to have low risk of bias (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<P>The Vedder trial reported more than 20% of withdrawals and dropouts, we therefore assessed this as having a high risk of bias (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>). The Sirrs trial did not describe withdrawals, dropouts or ITT, therefore we judged this to have an unclear risk of bias (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting</HEADING>
<P>he Vedder trial reported quality of life as an outcome in the protocol, but this was not stated in the paper, we therefore assessed this as having a high risk of bias (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>). The Sirrs trial was free of selective reporting and, therefore we classified this domain as having a low risk of bias (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other potential sources of bias</HEADING>
<P>We did not identify any other potential sources of bias (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>; <LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Agalsidase alfa multiple dose schedules comparison</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Generation of randomisation sequence</HEADING>
<P>The Clarke and Hughes trials did not provide a description regarding the generation of allocation; thus, they were classified as having an unclear risk of bias (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>The Clarke and Hughes trials did not provide a description regarding the concealment of allocation; thus, they were judged to have an unclear risk of bias (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<P>The Hughes trial was classified as having a low risk of bias since there was blinding (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>). The Clarke trial was also classified as having a low risk of bias, although this was an open-label trial, the outcome was objective (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<P>The Clarke and Hughes trials reported less than 20% of withdrawals and dropouts, we therefore assessed this as having a low risk of bias (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting</HEADING>
<P>We judged both included trials to be free of selective reporting (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other potential sources of bias</HEADING>
<P>We did not identify any other potential sources of bias (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-07-15 09:50:44 +0100" MODIFIED_BY="Tracey Remmington">
<P>We presented the data from agalsidase alfa and agalsidase beta separately because of differences in trial design and treatment doses.</P>
<SUBSECTION>
<HEADING LEVEL="3">Agalsidase alfa versus placebo</HEADING>
<P>Two trials were included in this comparison with a total of 41 participants. 15 and 26 participants were enrolled in the trial conducted by Hughes and Schiffmann respectively (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1<I>.</I> Changes in globotriaosylceramide (Gb3) concentration in plasma and tissue</HEADING>
<P>Two trials reported on this outcome at six months (end of treatment) (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>). There was no statistically significant difference between treatment groups in the plasma Gb3 concentration, pooled MD -2.07 (95% CI -6.64 to 2.50) (with data entered from 39 of 41 participants) (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). There were no statistically significant differences between treatment groups regarding the subcategories: urine sediment Gb3, MD -812.00 (95% CI -1897.83 to 273.83); and kidney, MD -2.50 (95% CI -9.47 to -4.47) (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Hughes reported a statistically significant difference between the participants receiving agalsidase alfa and those receiving placebo for myocardial Gb3 levels at over three months and up to six months, MD 0.07 (95% CI -0.35 to 0.49) (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Death</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Pain (measured by the McGill Pain Questionnaire)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Acroparaesthesia</HEADING>
<P>We intended to measure this outcome by the intensity and duration of acroparaesthesia as reported by the individual, however none of the included trials reported on this outcome (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Fabry crises</HEADING>
<P>We planned to present the presence or absence of crises as a binary outcome, but none of the included trials reported on this outcome (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c. The Brief Pain Inventory severity</HEADING>
<P>One trial reported on this outcome (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>). There was a statistically significant difference favouring the participants receiving agalsidase alfa versus placebo in all the subcategories studied at over one month and up to three months, MD -2.10 (95% CI -3.79 to -0.41), at over three months and up to five months, MD -1.90 (95% CI -3.65 to -0.15), and at over five months and up to six months, MD -2.00 (95% CI -3.66 to -0.34) (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d. The Brief Pain Inventory pain-related quality of life</HEADING>
<P>One trial reported on this outcome (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>). There was no statistically significant difference between groups in the subcategories studied at over one month and up to three months, MD -0.90 (95% CI -2.73 to 0.93) and at over three months and up to five months, MD -1.80 (95% CI -3.77 to 0.17). However, at over five months and up to six months a significant difference favouring agalsidase alfa was noted, MD -2.10 (95% CI -3.92 to -0.28) (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1<I>.</I> Effect of therapy on renal function</HEADING>
<P>One trial reported on this outcome (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>). Creatinine clearance and inulin clearance were used to estimate glomerular filtration rate. There were no statistically significant difference between both groups in the subcategories creatinine clearance at end of treatment (up to six months), and inulin clearance (up to six months) respectively, MD 10.30 (95% CI -15.37 to 35.97) and MD -0.50 (95% CI -21.36 to 20.36) (data entered for 24 of 26 participants) (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
<P>There was no statistically significant difference between groups in the subcategories: glomeruli with mesangial widening at up to six months, MD -14.70 (95% CI -36.72 to 7.32); glomeruli with segmental sclerosis at up to six months and obsolescent glomeruli at up to six months; MD 3.80 (95% CI -2.35 to 9.95) and MD 6.50 (95% CI -8.93 to 21.93) (data entered for 21 out of 26 participants) (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Symptoms and complications of disease (such as renal failure, skin, cerebrovascular and cardiac complications)</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3<I>.</I> Parameters: echocardiographic</HEADING>
<P>There was no statistically significant difference between groups for mean left ventricular wall thickness, MD -0.79 (95% CI -3.62 to 2.04); left ventricular internal diameter (diastolic), MD -3.70 (95% CI -11.73 to 4.33); left ventricular internal diameter (systolic), MD -2.70 (95%CI -9.91 to 4.51); and left ventricular ejection fraction, MD 1.88 (95%CI -4.68 to 8.44) (data entered for 14 out of 15 participants) (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Histologic analysis of microvascular capillary endothelial deposits of Gb3 in biopsy specimens</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Adverse effects of treatment</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6<I>.</I> Quality of life (as determined by the Short Form 36 (SF-36) and the impact of clinical variables on domain scores within the SF-36 (Smith 2000))</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Agalsidase beta versus placebo</HEADING>
<P>Three trials were included in this comparison with a total of 146 participants. Banikazemi enrolled 82 participants, Bierer enrolled six participants and Eng enrolled 58 participants (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1<I>.</I> Changes in globotriaosylceramide (Gb3) concentration in plasma and tissue</HEADING>
<P>One of the included trials reported on this outcome in tissue (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>)<I>. </I>There was a statistically significant difference favouring the participants receiving agalsidase beta versus placebo in three subcategories: kidney, MD -1.70 (95% CI -2.09 to -1.31); heart, MD -0.90 (95% CI -1.18 to -0.62); and composite, MD -4.80 (95% CI -5.45 to -4.15) (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
<P>None of the included trials reported the effect on plasma concentrations (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Death</HEADING>
<P>There was no statistically significant difference in death as reported in one trial, RR 1.85 (95% CI 0.08 to 43.96) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). There was one death from a total of 51 participants in agalsidase beta and no deaths in the placebo group (n = 31) (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Pain (measured by the McGill Pain Questionnaire)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Acroparaesthesia</HEADING>
<P>We intended to measure this outcome by the intensity and duration of acroparaesthesia as reported by the individual however none of the included trials reported this outcome (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Fabry crises</HEADING>
<P>We planned to present whether the participants had reported the presence or absence of crises as a binary outcome, but none of the included trials reported this outcome (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
<P>Only one trial reported chest pain and fatigue; there was no statistically significant difference for any of these at 24 months; chest pain,RR 6.77 (95% CI 0.39 to 118.36) and fatigue, RR 6.77 (95% CI 0.39 to 118.36) (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>) (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>; <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>). Eng reported on pain related to Fabry disease at over three months and up to six months; there was no statistically significant difference with pain related to Fabry disease, RR 3.00 (95% CI 0.33 to 27.18) (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>) (<LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Effect of therapy on renal function</HEADING>
<P>The number of renal events, defined by the authors as 33% increase in serum creatinine level; end-stage renal disease, were reported by Banikazemi. There was no statistically significant difference in the number of events between groups, RR 0.87 (95% CI 0.37 to 2.04) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Symptoms and complications of disease (such as renal failure, skin, cerebrovascular and cardiac complications)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Cardiac events</HEADING>
<P>Bierer reported cardiopulmonary exercise testing (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>). There were no significant differences between groups in any of the sub-categories evaluated (average heart rate reserve, MD 21.30 (95% CI -1.28 to 43.88); average maximum oxygen uptake measured at peak exercise (in mL/(kg·min)), MD 0.22 (95% CI -0.94 to 1.38); maximum oxygen uptake measured at peak exercise, MD 2.60 (95% CI -13.16 to 18.36); and oxygen pulse average at peak exercise, MD 2.10 (95% CI -3.67 to 7.87)) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). </P>
<P>There were no significant differences in decrease in cardiopulmonary exercise test, RR 1.50 (95% CI 0.34 to 6.70) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>) (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>).</P>
<P>Banikazemi reported cardiac events and there was no significant differences between studied groups, RR 0.46 (95% CI 0.11 to 1.90) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>) (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Cerebrovascular events</HEADING>
<P>There was no significant difference in the number of cerebrovascular events between groups in the Banikazemi trial, RR 0.12 (95% CI 0.01 to 2.48) (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>). (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c. Percentage of participants achieving zero scores in microvascular endothelial deposits of globotriaosylceramide in the skin</HEADING>
<P>For participants achieving zero scores in skin at five months, there was a statistically significant difference between groups in the Eng trial favouring the participants receiving agalsidase beta versus placebo in two subcategories: superficial endothelial cells, RR 19.67 (95% CI 4.13 to 93.63) and deep endothelial cells, RR 11.00 (95% CI 2.88 to 42.08) (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>). There was no significant difference between the analysed participants in each group in two further sub-categories: smooth muscle cells, RR 1.50 (95% CI 0.10 to 22.62), three and one participants contributed to this analysis in the agalsidase beta and placebo groups, respectively; or in perineurium cells, RR 1.04 (95% CI 0.07 to 15.72) (note not all the trial participants contribute to the analyses, please refer to the forest plot) (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>) (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
<P>Eng reported data for participants achieving a zero score or a reduction in microvascular endothelial deposits of globotriaosylceramide in the skin (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>). There was a statistically significant difference favouring the participants receiving agalsidase beta versus placebo in two sub-categories: superficial endothelial cells, RR 2.81 (95% CI 1.72 to 4.59); and deep endothelial cells, RR 2.79 (95% CI 1.67 to 4.67) (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>). There was no significant difference between groups in two further sub-categories: smooth muscle cells, RR 1.50 (95% CI 0.10 to 22.62) and in perineurium cells, RR 1.49 (95% CI 0.68 to 3.25). Three and one participants contributed to this analysis in the agalsidase beta and placebo groups, respectively.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Parameters echocardiographic</HEADING>
<P>None of the included trials reported this outcome (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Histologic analysis of microvascular capillary endothelial deposits of Gb3 in biopsy specimens</HEADING>
<P>None of the included trials reported this outcome (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5<I>.</I> Adverse effects of treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Any adverse event</HEADING>
<P>Two trials reported adverse events; one at over three month and up to six months (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>) and one at 24 months (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>).</P>
<P>There were statistically significant differences in favour of placebo regarding rigours at the following: over three and up to six months, RR 29.00 (95% CI 1.81 to 464.38) and, at 24 months, RR 10.94 (95% CI 1.54 to 77.95) (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>). Over three and up to six months there was no statistically significant difference comparing agalsidase beta to placebo, RR 7.00 (95% CI 0.92 to 53.36); however, at 24 months there was a statistically significant difference in favour of agalsidase beta compared to placebo in the reduction of fever, RR 8.51 (95% CI 1.18 to 61.58) (<LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>). One trial reported chills and there was no statistically significant difference at over three months and up to six months, RR 9.00 (95% CI 0.51 to 159.94) (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>) (<LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>). With regards to hypertension, there were no statistically significant differences between groups at both studied time points: over three and up to six months, RR 7.00 (95% CI 0.38 to 129.74); and at 24 months, RR 2.13 (95% CI 0.47 to 9.60) (<LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>).</P>
<P>Only one trial reported vomiting; there was no statistically significant difference at 24 months with vomiting, RR 8.00 (95% CI 0.47 to 137.27) (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>) (<LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>). Eng reported on headache at over three months and up to six months; there was no statistically significant difference with headache, RR 2.50 (95% CI 0.53 to 11.86) (<LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>) (<LINK REF="CMP-002.18" TYPE="ANALYSIS">Analysis 2.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Any serious adverse events</HEADING>
<P>None of the included trials reported this outcome (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6<I>.</I> Quality of life (as determined by the Short Form 36 (SF-36) and the impact of clinical variables on domain scores within the SF-36 (Smith 2000))</HEADING>
<P>None of the included trials reported this outcome (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Agalsidase alfa versus agalsidase beta</HEADING>
<P>Two trials were included in this comparison with a total of 103 participants (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>; <LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1<I>.</I> Changes in globotriaosylceramide (Gb3) concentration in plasma and tissue</HEADING>
<P>The Vedder trial reported a median of 3.3 umol/l (range 1.45 to 6.42) and 3 umol/l (range 1.89 to 7.85) for 12 and 24 months of treatment, respectively in agalsidase alfa arm, while there was a median of 2.48 umol/l (range 1.40 to 3.93) and 2.23 umol/l (range 0.92 to 4.3) for 12 and 24 months of treatment, respectively in agalsidase beta arm (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
<P>Sirrs did not report on this outcome (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Death</HEADING>
<P>There was a death from multiple cerebral infarctions after 20 months in the agalsidase alfa treatment group, RR 3.00 (95% CI 0.13 to 69.09) (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). There was one death from a total of 18 participants in agalsidase alfa and no deaths in agalsidase beta (n = 18) (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Pain (measured by BPI-3)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Acroparaesthesia and Fabry crises</HEADING>
<P>One trial described no significant reduction of pain score (BPI-3) after 12 months of treatment in either of the studied groups: alfa 0 (range 25 to 1); and beta 21.5 (range 24 to 3). The values did not change for analysis at the 24 month time point (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>). The Sirrs trial did not evaluate pain (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Fabry crises</HEADING>
<P>We planned to present whether the participants had reported the presence or absence of crises as a binary outcome, but neither of the included trials reported this outcome (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>; <LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Effect of therapy on renal function</HEADING>
<P>The trial reported that renal insufficiency, defined as an increase of serum creatinine greater than 33%, progressed in two participants treated with agalsidase alfa, who had baseline GFR measurements of 22 and 30 ml/min (within 24 months). In the agalsidase alfa group, progression of renal insufficiency was seen in one other participant after 30 months of treatment (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Symptoms and complications of disease (such as renal failure, skin, cerebrovascular and cardiac complications)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Cardiac events</HEADING>
<P>Two participants suffered from atrial fibrillation after 42 and 36 months of agalsidase beta treatment (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>). Atrial fibrillation occurred in a male participant treated with agalsidase alfa for 30 months. There was no statistically significant difference for cardiac events, RR 0.47 (95% CI 0.05 to 4.60) (26 out of 29 participants analysed) (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Cerebrovascular events</HEADING>
<P>One of the included trials did not report this outcome (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">c. Percentage of participants achieving zero scores in skin</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>; <LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Echocradiographic Parameters</HEADING>
<P>The Vedder trial reported LV Mass (g). There was a median of 244 g (range 157 to 424) and 294 g (range 196 to 502) for 12 and 24 months of treatment, respectively in the agalsidase alfa arm, while there was a median of 296 g (range 169 to 401) and 308 g (range 196 to 471) for 12 and 24 months of treatment, respectively in the agalsidase beta arm (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
<P>The Sirrs trial did not report on this outcome (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Histologic analysis of microvascular capillary endothelial deposits of Gb3 in biopsy specimens</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>; <LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5<I>.</I> Adverse effects of treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Any adverse event</HEADING>
<P>There was no significant difference in the number of any adverse events between groups in the Vedder trial, RR 0.36 (95% CI 0.08 to 1.59) (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
<P>The Sirrs trial did not report on this outcome (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Any serious adverse events</HEADING>
<P>There was no significant difference in the number of any serious adverse events between groups in the Vedder trial, RR 0.30 (95% CI 0.03 to 2.57) (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6<I>.</I> Quality of life (as determined by the Short Form 36 (SF-36) and the impact of clinical variables on domain scores within the SF-36 (Smith 2000))</HEADING>
<P>One of the included trials did not report on this outcome, but it is included as an outcome in the protocol (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>). We contacted the main author for further clarification and hope these data can be included in a future update of this review.</P>
<P>Sirrs did not report on this outcome (<LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Multiple dose schedules of agalsidase alfa</HEADING>
<P>Two trials were included in this comparison with a total of 36 participants (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1<I>.</I> Changes in globotriaosylceramide (Gb3) concentration in plasma and tissue</HEADING>
<P>No significant difference was found among the treatment schedules for fasting plasma GB3 levels in the Hughes trial (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
<P>No statistically significant association between the magnitude of the reduction in plasma Gb3 and dose or dose frequency was described in the Clarke trial (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Death</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Pain (measured by BPI-3)</HEADING>
<P>For the cross-over trial by Hughes (18 participants), there were no significant differences comparing 0.2 mg/ kg/ every two weeks versus 0.1 mg/ kg/ every week for mean pain score (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>), MD -0.06 (95% CI -1.26 to 1.38), and for self assessed health state MD -1.20 (95% CI -14.10 to 11.70) (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). There were no significant differences comparing 0.1 mg/kg/every week versus 0.2 mg/kg/every week for mean pain score MD 0.06 (95% CI -1.25 to 1.37) and for self assessed health state, MD 0.30 (95% CI -12.70 to 13.30) (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>).</P>
<P>The Clarke trial did not report on this outcome (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Effect of therapy on renal function</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Symptoms and complications of disease (such as renal failure, skin, cerebrovascular and cardiac complications)</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Echocardiographic Parameters</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Histologic analysis of microvascular capillary endothelial deposits of Gb3 in biopsy specimens</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Adverse effects of treatment</HEADING>
<P>In the trial conducted by Clarke, the incidence of adverse events was not related to dose or dosing frequency (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>).</P>
<P>The majority of moderate and severe AEs were reported by participants after treatment schedule A (0.2 mg/kg every other week) (<LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Quality of life (as determined by the Short Form 36 (SF-36) and the impact of clinical variables on domain scores within the SF-36 (Smith 2000))</HEADING>
<P>Neither of the included trials reported on this outcome (<LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-07-15 09:51:34 +0100" MODIFIED_BY="Tracey Remmington">
<SUMMARY_OF_RESULTS MODIFIED="2016-07-15 09:51:03 +0100" MODIFIED_BY="Tracey Remmington">
<P>This review included nine trials that were split between low and uncertain risk of bias and in addition statistical analysis was difficult due to the manner in which results were presented. Overall though, compared with participants receiving placebo, those treated with either agalsidase alfa or agalsidase beta experienced a reduction in Gb3 concentration in plasma and tissues. Although this finding is indicative of &#8216;proof of concept&#8217;, its clinical significance is uncertain as the trials examined did not provide specific information on correlation with clinical events or survival. In the agalsidase alfa comparison, even though we used a random-effects model (to better deal with heterogeneity), we found a high level of heterogeneity (I<SUP>2</SUP> = 91%) in the outcome plasma Gb<SUB>3</SUB> at up to six months. This method assumes that the effects being estimated in the different trials are not identical, but follow some distribution. In this case the effect may have varied due to different population or intervention characteristics (such the dose, duration and regimen). Trial results indicate a significant effect of enzyme replacement therapy (ERT) on neuropathic pain, cardiac morphology and renal function, and a positive influence on pain-related quality of life. Treatment with ERT appears to be relatively well-tolerated. Infusion-related adverse events may be controlled by the use of pre-medication and the administration of the enzymes at a slower rate. Antibody formation has been reported in a significant proportion of treated individuals with trials indicating that the presence of neutralizing antibodies may potentially influence therapeutic outcome.</P>
<P>The effectiveness of therapy in delaying the onset or reducing the incidence and severity of Anderson-Fabry disease (AFD)-related complications, and its impact on long-term survival remains unclear though clearly it does have a positive effect on some aspects of the disease. Heterogeneity in clinical phenotype means long-term, large cohort studies are required. This is being addressed primarily through patient registries. It will also be important to look in detail at effectiveness and safety of ERT according to patient sub-populations, such as gender, later-onset versus classic phenotypes, type of mutation, age and presence of chronic injury at initiation of treatment.</P>
<P>The low number of eligible trials for this Cochrane analysis together with the low number of participants included in the trials, due to the rare nature of AFD, prevented us performing these sub-analyses. It is likely that advanced disease prior to the start of treatment influences outcome and that the earlier the initiation of treatment the greater the effect on preventing complications. Trials in asymptomatic or minimally affected individuals may provide information on the effectiveness of therapy in preventing or delaying the onset of symptoms or disease-related complications (<LINK REF="STD-Ramaswami-2007" TYPE="STUDY">Ramaswami 2007</LINK>; <LINK REF="STD-Ries-2006" TYPE="STUDY">Ries 2006</LINK>; <LINK REF="REF-Ries-2007" TYPE="REFERENCE">Ries 2007</LINK>; <LINK REF="REF-Wraith-2008" TYPE="REFERENCE">Wraith 2008</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-07-15 09:51:34 +0100" MODIFIED_BY="Tracey Remmington">
<P>A limitation is the fact that pain often does not feature in the trials. It is known that most cases of pain resolve spontaneously, even in the absence of any treatment, and pain is a subjective outcome and thus depends on the self-reports provided by the participants, so it is difficult to provide objective evidence. Only Schiffmann reported the Brief Pain Inventory comparing agalsidase alfa versus placebo (<LINK REF="STD-Schiffmann-2001" TYPE="STUDY">Schiffmann 2001</LINK>). No included trial (<LINK REF="STD-Banikazemi-2007" TYPE="STUDY">Banikazemi 2007</LINK>; <LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK> ) comparing agalsidase beta versus placebo reported on pain and, only <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK> reported on it comparing 0.2 mg/kg/every 2 weeks versus 0.1 mg/kg/every week and, 0.1 mg/kg/every week versus 0.2 mg/kg/every week.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-05-27 17:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>The methodological quality of the included trials was generally unclear for the random sequence generation and allocation concealment (<LINK REF="STD-Bierer-2006" TYPE="STUDY">Bierer 2006</LINK>; <LINK REF="STD-Clarke-2007" TYPE="STUDY">Clarke 2007</LINK>; <LINK REF="STD-Eng-2001" TYPE="STUDY">Eng 2001</LINK>; <LINK REF="STD-Hughes-2008" TYPE="STUDY">Hughes 2008</LINK>; <LINK REF="STD-Hughes-2013" TYPE="STUDY">Hughes 2013</LINK>; <LINK REF="STD-Sirrs-2014" TYPE="STUDY">Sirrs 2014</LINK>). Some methodological aspects of one trial (with inadequate blinding of outcome assessment, participants and caregivers, as well as incomplete outcome data and selective reporting outcome) resulted in this trial having a high risk of bias (<LINK REF="STD-Vedder-2007" TYPE="STUDY">Vedder 2007</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-05-27 12:30:17 +0100" MODIFIED_BY="Tracey Remmington">
<P>Despite our thorough search in various databases we might have overlooked trials, especially with regard to the grey literature. However, we contacted the authors of the included trials to ask whether they had undertaken any other relevant trials comparing ERT to other interventions, placebo or no interventions, for treating AFD.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-07-14 15:22:05 +0100" MODIFIED_BY="Tracey Remmington">
<P>The results of this review reflect those of previous versions of the review (<LINK REF="REF-El-Dib-2010" TYPE="REFERENCE">El Dib 2010</LINK>; <LINK REF="REF-El-Dib-2013" TYPE="REFERENCE">El Dib 2013</LINK>). A recent systematic review undertaken to analyse the currently available data concerning quality of life (QoL) measurement, concluded no definite conclusions could be drawn from the trials on the effect of ERT on QoL (<LINK REF="REF-Arends-2015" TYPE="REFERENCE">Arends 2015</LINK>). A review of the literature comparing two different products the Replagal&#8482;) (agalsidase alfa) and Fabrazyme<SUP>®</SUP> (agalsidase beta) formed the same conclusion as this review in that there is little evidence for choosing one over the other (<LINK REF="REF-Riccio-2013" TYPE="REFERENCE">Riccio 2013</LINK>).</P>
<P>There are some clinical single entity studies demonstrating beneficial effect of ERT. The effect of agalsidase beta 1 mg/kg bi-weekly was assessed in a phase 4 placebo-controlled study of both untreated and treated individuals with Fabry disease with mild-to-moderate renal involvement (i.e., serum creatinine measurements of &#8805;1.2 mg/dl and &lt; 3.0 mg/dl) on progressive white matter lesions and stroke. The authors concluded that "ERT may reduce the progression of vascular disease, even in advanced FD patients, suggesting that early treatment may stabilize WML progression and stroke risk" (<LINK REF="STD-Fellgiebel-2014" TYPE="STUDY">Fellgiebel 2014</LINK>). A cohort study evaluated the progression of left ventricular hypertrophy in untreated men with Fabry disease and assessed the effects of agalsidase beta on left ventricular hypertrophy (<LINK REF="STD-Germain-2013" TYPE="STUDY">Germain 2013</LINK>). The authors analysed 115 men treated with agalsidase beta (1 mg/kg/2 weeks) and 48 untreated men. The authors found for men in whom treatment was initiated at the age of 18 years to under 30 years, mean left ventricular mass slope was -3.6 g/year (n = 31) compared with + 9.5g/year in untreated men of that age (n = 15). The authors also found that untreated men had a higher risk of having faster increases in left ventricular mass compared with treated men (<LINK REF="STD-Germain-2013" TYPE="STUDY">Germain 2013</LINK>).</P>
<P>Schiffmann conducted an open-label study with 11 children who completed 26-weeks of intravenous 0.2 mg/kg agalsidase alfa (<LINK REF="STD-Schiffmann-2014" TYPE="STUDY">Schiffmann 2014</LINK>). The authors found all participants experienced at least one adverse event, but no death occurred and cardiac outcomes remained stable. Tøndel evaluated five years of treatment with agalsidase alfa or agalsidase beta in 12 people aged seven to 33 years (<LINK REF="STD-T_x00f8_ndel-2013" TYPE="STUDY">Tøndel 2013</LINK>). Biopsy findings from all participants showed total clearance of glomerular endothelial and mesangial cell inclusions after a median of follow up of 65 months. Another study assessed 105 adults with Fabry disease who had received agalsidase beta (1.0 mg/kg body weight) for more than a year and, the authors found that "patients receiving regular agalsidase beta dose had a stable disease course, but dose reduction led to worsening of renal function and symptoms" (<LINK REF="STD-Weidemann-2014" TYPE="STUDY">Weidemann 2014</LINK>).</P>
<P>A randomized controlled trial that evaluated pharmacokinetic parameters of a recombinant agalsidase beta (Agal) ERT in 18 healthy adult volunteers found no immunogenicity or any significant infusion-related reactions; although overall there were seven adverse events that were resolved without any complications (<LINK REF="STD-Kim-2014" TYPE="STUDY">Kim 2014</LINK>).</P>
<P>Rombach study evaluated 59 people with Fabry disease treated with either agalsidase alfa or beta for at least one year (<LINK REF="STD-Rombach-2012" TYPE="STUDY">Rombach 2012</LINK>). They found 17 out of 59 individuals developed anti-agalsidase antibodies during the first year of treatment and, the authors concluded that the presence of these antibodies is associated with a less robust decrease in plasma lysoGb3 as well as a negative urinary Gb3 reduction.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-07-15 09:54:34 +0100" MODIFIED_BY="Tracey Remmington">
<IMPLICATIONS_PRACTICE MODIFIED="2016-07-15 09:54:34 +0100" MODIFIED_BY="Tracey Remmington">
<P>Trials comparing ERT to placebo show significant results in regard to microvascular endothelial deposits of globotriaosylceramide and in pain-related quality of life. There is, however, no evidence identifying if the alfa or beta form is superior or the optimal dose or frequency of ERT. It is always difficult to study rare diseases, given the limited population available to study and given that many of these disorders, such a AFD, are long-term, chronic illnesses and a long follow up is required. With regards to safety, adverse events (i.e. rigors, fever) were more significant with agalsidase beta as compared to placebo. The long-term influence of enzyme replacement therapy on risk of morbidity and mortality related to AFD remains to be established. There is also a need to understand prognostic determinants and therapeutic outcome, which may allow stratification of patients and identification of the subset of patients most likely to achieve the best results with treatment.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-06-08 14:01:55 +0100" MODIFIED_BY="Tracey Remmington">
<P>This review highlights the need for continued research into the use of ERT for AFD. Subsequent trials should help define the use of ERT and other therapeutic options, e.g. substrate reduction therapy and pharmacological chaperones, as these become available and should be considered either in combination or as monotherapy in the management of people with AFD.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-03-11 16:18:07 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank Gregory Pastores for his contributions as an author in previous versions of this review (<LINK REF="REF-El-Dib-2010" TYPE="REFERENCE">El Dib 2010</LINK>; <LINK REF="REF-El-Dib-2013" TYPE="REFERENCE">El Dib 2013</LINK>).</P>
<P>We would like to thank Tracey Remmington, Nikki Jahnke, Sarah Nolan and Natalie Hall from the Cystic Fibrosis &amp; Genetics Disorders Group for their outstanding help and Julia Mortimer from the Heart Group for her help during the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-07-21 10:08:48 +0100" MODIFIED_BY="Tracey Remmington">
<P>R El Dib, H Goma, RP Carvalho, SE Camargo, R Bazan, and FC Barreto have no conflicts of interest to declare.</P>
<P>P Barretti is a full professor of Sao Paulo State University at Botucatu School of Medicine and active member of the Regional Latin American Advisory Board of Baxter Healthcare Company.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-11-13 17:47:44 +0000" MODIFIED_BY="[Empty name]">
<P>Regina El Dib (RED) was responsible for the conception of this review and also for the design and overall co-ordination of the protocol. RED is the guarantor of the review.</P>
<P>Huda Goma (HG) and Raíssa Pierri Carvalho (RPC) were responsible for developing the search strategy, undertaking searches, screening search results, organising retrieval of papers. RED, HG and Paulo do Nascimento Junior (PNJ) were responsible for screening retrieved papers against the inclusion criteria, appraising quality of papers and extracting data. Samira Esteves Camargo (SEC) and Pasqual Barretti (PB) wrote to authors of papers for additional information and located potentially relevant unpublished or ongoing trials. SEC, PB and Fellype C Barreto (FCB) provided additional data about papers and obtained and screened data on unpublished trials. RED, HG, RPC and PB were responsible for data management for the review and entering data into RevMan. RED, HG, SEC, PB, PNJ and FCB analysed and interpreted the data and wrote up the results.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-07-14 14:46:35 +0100" MODIFIED_BY="Tracey Remmington">
<P>The <LINK TAG="QUALITY_ASSESSMENT" TYPE="SECTION">Assessment of risk of bias in included studies</LINK> section was updated from the protocol given the new guidelines published in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We decided for our secondary outcomes 'Pain' and 'QoL' we would also consider other validated questionnaires.</P>
<P>We decided that the secondary outcome 'Costs reported narratively' was not an appropriate outcome to be measured in this review of randomised controlled trials.</P>
<P>While analysing available data we agreed to also considered other time points as well as those originally stated where multiple data sets from an individual trial were available for a single <I>a priori</I> planned time point.</P>
<P>We decided for assessment of blinding that if a trial measured an objective outcome then lack of blinding was rated as low risk of bias.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-11-03 12:34:37 +0000" MODIFIED_BY="Tracey Remmington"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-06-29 10:28:02 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDIES MODIFIED="2016-07-15 09:49:55 +0100" MODIFIED_BY="Tracey Remmington">
<INCLUDED_STUDIES MODIFIED="2016-07-15 09:49:55 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY DATA_SOURCE="PUB" ID="STD-Banikazemi-2007" MODIFIED="2010-04-14 12:10:06 +0100" MODIFIED_BY="[Empty name]" NAME="Banikazemi 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-14 12:10:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al</AU>
<TI>Agalsidase-beta therapy for advanced Fabry disease: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>146</VL>
<NO>2</NO>
<PG>77-86</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2943991"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2943990"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bierer-2006" MODIFIED="2015-09-23 13:47:53 +0100" MODIFIED_BY="[Empty name]" NAME="Bierer 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-07 15:37:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bierer G, Balfe D, Wilcox WR, Mosenifar Z</AU>
<TI>Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>4</NO>
<PG>572-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2943993"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-23 13:47:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bierer G, Wilcox WR, Balfe D, Mosenifar Z</AU>
<TI>Improvement in cardiopulmonary exercise testing during enzyme replacement therapy in Fabry disease [abstract]</TI>
<SO>Proceedings of the American Thoracic Society International Conference;2005 May 20-25; San Diego, California</SO>
<YR>2005</YR>
<PG>A493</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="593031"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000002992"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2943994"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2943992"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2007" MODIFIED="2015-04-29 19:04:22 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-04-29 19:04:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke JT, West ML, Bultas J, Schiffmann R</AU>
<TI>The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease</TI>
<SO>Genetics in Medicine</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>8</NO>
<PG>504-9</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="701854"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000085"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2943996"/><IDENTIFIER TYPE="PUBMED" VALUE="17700388"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2943995"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eng-2001" MODIFIED="2015-09-24 22:16:38 +0100" MODIFIED_BY="[Empty name]" NAME="Eng 2001" YEAR="2004">
<REFERENCE MODIFIED="2015-09-22 16:38:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desnick RJ, International FDSG</AU>
<TI>Enzyme therapy for Fabry disease [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2001</YR>
<VL>24 Suppl</VL>
<PG>774</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="593054"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000003012"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2943998"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-22 16:38:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desnick RJ, International Fabry Study Group</AU>
<TI>Fabry disease enzyme therapy: phase 3 and extension results [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2001</YR>
<VL>24 Suppl 1</VL>
<PG>98</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2943999"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-22 16:38:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al</AU>
<TI>Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>1</NO>
<PG>9-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944000"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-07 16:03:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee P, Banikazemi M, Guffon N, Wilcox WR, Waldek S, Germain DP, et al</AU>
<TI>Severe glomerulosclerosis and proteinuria may influence response to therapy in fabry disease [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2003</YR>
<VL>26 Suppl 2</VL>
<PG>158</PG>
<CY>International Congress of the Inborn Errors of Metabolism; 2003 Sept 2-6; Brisbane, Australia</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944001"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-07 15:43:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linthorst GE, Aerts JMFG, Bosman DK, Heymans HSA, Hollack CEM</AU>
<TI>Aenzyme-supplementation therapy for Fabry disease: first possible treatment [abstract]</TI>
<SO>The Netherlands Journal of Medicine</SO>
<YR>2001</YR>
<VL>58</VL>
<PG>A22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944002"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-01 15:49:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thurberg BL, Byers RH, Granter SR, Phelps RG, Gordon RE, O'Callaghan M</AU>
<TI>Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>2004</YR>
<VL>122</VL>
<NO>4</NO>
<PG>900-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944003"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-24 22:16:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW</AU>
<TI>Cardiac Microvascular Pathology in Fabry Disease Evaluation of Endomyocardial Biopsies Before and After Enzyme Replacement Therapy</TI>
<SO>Circulation</SO>
<YR>2009</YR>
<VL>119</VL>
<NO>19</NO>
<PG>2561-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944004"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-07 16:03:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thurberg BL, Phelps R, Granter S, Byers R, Gordon RE, O'Callaghan M</AU>
<TI>Fabrazyme clears globotriaosylceramide from the skin of fabry patients [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2003</YR>
<VL>26 Suppl 2</VL>
<PG>174</PG>
<CY>Boston, USA</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944005"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al</AU>
<TI>Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy</TI>
<SO>Kidney International</SO>
<YR>2002</YR>
<VL>62</VL>
<NO>6</NO>
<PG>1933-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944006"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-07 16:03:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waldek S, Germain D P, Banikazemi M, Guffon N, Lee P, Linthorst G, et al</AU>
<TI>Stabilization of renal function after enzyme replacement therapy in Fabry Disease [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2003</YR>
<VL>18 Suppl 4</VL>
<PG>630</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944007"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-30 15:52:32 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al</AU>
<TI>Long-term safety and efficacy of enzyme replacement therapy for Fabry disease</TI>
<SO>American Journal of Human Genetics</SO>
<YR>2004</YR>
<VL>75</VL>
<NO>1</NO>
<PG>65-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944008"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2943997"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-2008" MODIFIED="2016-07-08 12:39:18 +0100" MODIFIED_BY="Tracey Remmington" NAME="Hughes 2008" YEAR="2008">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A</AU>
<TI>Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>8</NO>
<PG>787-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944010"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hajioff D, Goodwin S, Quiney R, Zuckerman J, MacDermot KD, Mehta A</AU>
<TI>Hearing improvement in patients with Fabry disease treated with agalsidase alfa</TI>
<SO>Acta Paediatrica</SO>
<YR>2003</YR>
<VL>92</VL>
<NO>443</NO>
<PG>28-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944011"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-07 16:02:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hajioff D, Quiney RE, Zuckerman J, McDermott K Mehta A</AU>
<TI>Hearing loss in Fabry's disease: the effect of alpha-galactosidase A replacement therapy [abstract]</TI>
<SO>Annals of Neurology</SO>
<YR>2003</YR>
<VL>54 Suppl 7</VL>
<PG>S26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944012"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-08 12:39:18 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al</AU>
<TI>Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa</TI>
<SO>Heart</SO>
<YR>2008</YR>
<VL>94</VL>
<NO>2</NO>
<PG>153-8</PG>
<IDENTIFIERS MODIFIED="2010-04-07 15:42:36 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944013"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944009"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-2013" MODIFIED="2015-02-11 11:00:54 +0000" MODIFIED_BY="[Empty name]" NAME="Hughes 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-02-11 11:00:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes DA, Deegan PB, Milligan A, Wright N, Butler LH, Jacobs A, et al</AU>
<TI>A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease</TI>
<SO>Molecular Genetics and Metabolism</SO>
<YR>2013</YR>
<VL>109</VL>
<NO>3</NO>
<PG>269-75</PG>
<PB>Academic Press Inc. (1250 Sixth Avenue, San Diego, California CA 92101, United States)</PB>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="960223"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000134"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944015"/><IDENTIFIER TYPE="EMBASE" VALUE="2014003031"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944014"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schiffmann-2001" MODIFIED="2015-11-03 12:49:53 +0000" MODIFIED_BY="Tracey Remmington" NAME="Schiffmann 2001" YEAR="2002a">
<REFERENCE MODIFIED="2014-11-07 11:03:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brady RO, Murray GJ, Moore DF, Schiffmann R</AU>
<TI>Enzyme replacement therapy in Fabry disease</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2001</YR>
<VL>24 Suppl 2</VL>
<PG>18-24</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="444520"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000002339"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944017"/><IDENTIFIER TYPE="PUBMED" VALUE="11758675"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-07 15:42:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore DF, Altarescu G, Herscovitch P, Schiffmann R</AU>
<TI>Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease</TI>
<SO>BMC Neurology</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944018"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-01 15:49:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, et al</AU>
<TI>Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement</TI>
<SO>Stroke</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>2</NO>
<PG>525-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944019"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-07 16:02:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore DF, Scott LTC, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al</AU>
<TI>Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>104</VL>
<NO>13</NO>
<PG>1506-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944020"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffmann R, Hauer P, Freeman B, Ries M, Scott LJ, Polydefkis M, et al</AU>
<TI>Enzyme replacement therapy and intraepidermal innervation density in Fabry disease</TI>
<SO>Muscle Nerve</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944021"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-30 15:49:34 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, et al</AU>
<TI>Clinical effect of enzyme replacement in Fabry disease [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>7</NO>
<PG>775</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944022"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-10-01 15:49:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, et al</AU>
<TI>Enzyme replacement therapy in Fabry disease: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>21</NO>
<PG>2743-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944023"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944016"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sirrs-2014" MODIFIED="2016-07-15 09:49:55 +0100" MODIFIED_BY="Tracey Remmington" NAME="Sirrs 2014" YEAR="2010">
<REFERENCE MODIFIED="2015-09-23 13:58:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K5, Doucette S, et al</AU>
<TI>Outcomes of patients treated through the Canadian Fabry disease initiative</TI>
<SO>Molecular Genetics and Metabolism</SO>
<YR>2014</YR>
<VL>111</VL>
<PG>499&#8211;506</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944025"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-22 16:39:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirrs SM, Bichet DG, Casey R, Clarke JTR, Flowerdew G, Lemoine K, et al</AU>
<TI>Agalsidase alfa and agalsidase beta have similar effects on fabry outcomes results from the Canadian fabry disease initiative [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2010</YR>
<VL>33 Suppl 1</VL>
<PG>S126, Abstract no: 396-P</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1000726"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000068"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944026"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944024"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vedder-2007" MODIFIED="2012-11-15 11:53:58 +0000" MODIFIED_BY="[Empty name]" NAME="Vedder 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-11-15 11:52:53 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al</AU>
<TI>Online CONSORT checklist S1 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg' [online]</TI>
<SO>PLoS One</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>7</NO>
<PG>e598</PG>
<IDENTIFIERS MODIFIED="2012-11-15 11:48:46 +0000" MODIFIED_BY="Tracey Remmington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944028"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-15 11:53:58 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al</AU>
<TI>Online supporting information to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg' [online]</TI>
<SO>PLoS One</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>7</NO>
<PG>e598</PG>
<IDENTIFIERS MODIFIED="2012-11-15 11:53:58 +0000" MODIFIED_BY="Tracey Remmington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944029"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-15 11:53:55 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al</AU>
<TI>Online trial treatment protocol S1 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg' [online]</TI>
<SO>PLoS One</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>7</NO>
<PG>e598</PG>
<IDENTIFIERS MODIFIED="2012-11-15 11:53:55 +0000" MODIFIED_BY="Tracey Remmington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944030"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-15 11:53:52 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al</AU>
<TI>Online trial treatment protocol S2 to 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg' [online]</TI>
<SO>PLoS One</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>7</NO>
<PG>e598</PG>
<IDENTIFIERS MODIFIED="2012-11-15 11:53:52 +0000" MODIFIED_BY="Tracey Remmington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944031"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-11-15 11:53:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al</AU>
<TI>Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg</TI>
<SO>PLoS One</SO>
<YR>2007</YR>
<VL>2</VL>
<NO>7</NO>
<PG>e598</PG>
<IDENTIFIERS MODIFIED="2012-11-15 11:53:49 +0000" MODIFIED_BY="Tracey Remmington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944032"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944027"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-07-08 12:36:07 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY DATA_SOURCE="PUB" ID="STD-Alamartine-2005" MODIFIED="2010-04-07 16:03:42 +0100" MODIFIED_BY="[Empty name]" NAME="Alamartine 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-07 16:03:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alamartine E</AU>
<TI>Enzyme replacement therapy in nine patients with Fabry disease</TI>
<SO>Medical Science</SO>
<YR>2005</YR>
<VL>21 Suppl 11</VL>
<PG>62-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944034"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944033"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Banikasemi-2005" NAME="Banikasemi 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Banikasemi M, Ullman T, Desnick RJ</AU>
<TI>Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy</TI>
<SO>Molecular Genetics and Metabolism</SO>
<YR>2005</YR>
<VL>85</VL>
<PG>255-59</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944036"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944035"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beck-2004" MODIFIED="2009-01-30 15:48:49 +0000" MODIFIED_BY="Tracey Remmington" NAME="Beck 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-30 15:48:49 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beck M, Ricci R, Widmer U, Dehout F, Garcia AL, Kampmann C, et al</AU>
<TI>Fabry disease: overall effects of agalsidase alfa treatment</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>2004</YR>
<VL>34</VL>
<NO>12</NO>
<PG>838-44</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944038"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944037"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beer-2006" MODIFIED="2009-01-30 15:48:05 +0000" MODIFIED_BY="Tracey Remmington" NAME="Beer 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-30 15:48:05 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, et al</AU>
<TI>Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy</TI>
<SO>American Journal of Cardiology</SO>
<YR>2006</YR>
<VL>97</VL>
<NO>10</NO>
<PG>1515-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944040"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944039"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breunig-2006" NAME="Breunig 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C</AU>
<TI>Clinical benefit of enzyme replacement therapy in Fabry disease</TI>
<SO>Kidney international</SO>
<YR>2006</YR>
<VL>69</VL>
<NO>7</NO>
<PG>1216-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944042"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944041"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cartwright-2004" MODIFIED="2009-01-30 15:34:13 +0000" MODIFIED_BY="Tracey Remmington" NAME="Cartwright 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-30 15:34:13 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cartwright DJ, Cole AL, Cousins AJ, Lee PJ</AU>
<TI>Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>6</NO>
<PG>791-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944044"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944043"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elliott-2006" MODIFIED="2009-01-30 15:46:36 +0000" MODIFIED_BY="Tracey Remmington" NAME="Elliott 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-30 15:46:36 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R, et al</AU>
<TI>Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A</TI>
<SO>Heart</SO>
<YR>2006</YR>
<VL>92</VL>
<NO>3</NO>
<PG>357-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944046"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944045"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eto-2005" MODIFIED="2015-09-22 16:39:07 +0100" MODIFIED_BY="[Empty name]" NAME="Eto 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-02-02 09:53:52 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eto Y, Ohashi T, Utsunomiya Y, Fujiwara M, Mizuno A, Inui K, et al</AU>
<TI>Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>4</NO>
<PG>575-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944048"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-22 16:39:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuboi K</AU>
<TI>Evaluation of therapeutic efficacy in Fabry disease using Lyso-Gb3 as an indictor</TI>
<SO>Journal of inherited metabolic disease</SO>
<YR>2014</YR>
<VL>37</VL>
<NO>1</NO>
<PG>S154</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944049"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944047"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fellgiebel-2014" MODIFIED="2016-07-08 12:24:06 +0100" MODIFIED_BY="Tracey Remmington" NAME="Fellgiebel 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-07-08 12:23:54 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellgiebel A, Gartenschläger M, Wildberger K, Scheurich A, Desnick RJ, Sims K</AU>
<TI>Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2014</YR>
<VL>38</VL>
<NO>6</NO>
<PG>448-56</PG>
<CY>Switzerland</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1104089"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001422"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4311630"/><IDENTIFIER TYPE="PUBMED" VALUE="25502511"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944050"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernhoff-2011" MODIFIED="2015-09-22 16:39:13 +0100" MODIFIED_BY="[Empty name]" NAME="Fernhoff 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-09-22 16:39:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernhoff P, Goker-Alpan O, Holida M, Nedd K, Barshop BA, Mardach R, et al</AU>
<TI>Safety and tolerability of agalsidase alfa in patients with Fabry disease formerly treated with agalsidase beta</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2011</YR>
<VL>34 Suppl 3</VL>
<PG>S227</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944053"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944052"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Germain-2007" NAME="Germain 2007" YEAR="2007">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al</AU>
<TI>Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>5</NO>
<PG>1547-57</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944055"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944054"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Germain-2013" MODIFIED="2016-01-10 16:01:45 +0000" MODIFIED_BY="[Empty name]" NAME="Germain 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-01-10 16:01:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Germain DP, Weidemann F, Abiose A, Patel MR, Cizmarik M, Cole JA, et al</AU>
<TI>Analysis of left ventricular mass in untreated men and in men treated with agalsidase-&#946;: data from the Fabry Registry</TI>
<SO>Genet Med</SO>
<YR>2013</YR>
<VL>15</VL>
<NO>12</NO>
<PG>958-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944057"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944056"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guffon-2002" MODIFIED="2010-04-07 15:45:43 +0100" MODIFIED_BY="[Empty name]" NAME="Guffon 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-04-07 15:45:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guffon N</AU>
<TI>The clinical benefit of Fabrazyme treatment [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2002</YR>
<VL>25 Suppl 1</VL>
<PG>116</PG>
<CY>Lyon, France</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944059"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944058"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guffon-2004" MODIFIED="2010-04-07 15:46:57 +0100" MODIFIED_BY="[Empty name]" NAME="Guffon 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-07 15:46:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guffon N, Fouilhoux A</AU>
<TI>Clinical benefit in Fabry patients given enzyme replacement therapy - a case series</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>2</NO>
<PG>221-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944061"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944060"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hajioff-2006" MODIFIED="2010-04-07 15:47:28 +0100" MODIFIED_BY="[Empty name]" NAME="Hajioff 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-07 15:47:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hajioff D, Hegemannn S, Conti G, Beck M, Sunder-Plassmann G, Widmer U, et al</AU>
<TI>Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>2006</YR>
<VL>36</VL>
<NO>9</NO>
<PG>663-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944063"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944062"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilz--2004" MODIFIED="2009-08-13 20:42:05 +0100" MODIFIED_BY="[Empty name]" NAME="Hilz  2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-13 20:42:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M</AU>
<TI>Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>7</NO>
<PG>1066-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944065"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944064"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jardim-2006" MODIFIED="2010-04-07 15:46:23 +0100" MODIFIED_BY="[Empty name]" NAME="Jardim 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-07 15:46:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jardim LB, Gomes I, Netto CB, Nora DB, Matte US, Pereira F, et al</AU>
<TI>Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>5</NO>
<PG>653-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944067"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944066"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jardim-2006b" MODIFIED="2010-04-07 15:48:00 +0100" MODIFIED_BY="[Empty name]" NAME="Jardim 2006b" YEAR="2006b">
<REFERENCE MODIFIED="2010-04-07 15:48:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jardim LB, Aesse F, Vedolin LM, Pitta-Pinheiro C, Marconato J, Burin MG, et al</AU>
<TI>White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up</TI>
<SO>Arquivos de Neuro-Psiquiatria</SO>
<YR>2006</YR>
<VL>64</VL>
<NO>3B</NO>
<PG>711-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944069"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944068"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalliokoshi-2006" MODIFIED="2010-04-07 15:48:17 +0100" MODIFIED_BY="[Empty name]" NAME="Kalliokoshi 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-07 15:48:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kalliokoshi RJ, Kantola I, Kalliokoshi KK, Engblom E, Sundell J, Hannujainen JC, et al</AU>
<TI>The effect os 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2006</YR>
<VL>29</VL>
<PG>112-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944071"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944070"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kampmann-2002" NAME="Kampmann 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kampmann C, Ries M, Bahner F, Kim KS, Bajbouj M, Beck M</AU>
<TI>Influence of enzyme replacement therapy (ERT) on Anderson Fabry disease associated hypertrophic infiltrative cardiomyopathy (HIC)</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>161</VL>
<NO>2</NO>
<PG>R5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944073"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944072"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2014" MODIFIED="2016-01-10 16:53:12 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-01-10 16:53:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim CO, Oh ES, Park MS</AU>
<TI>First-in-human study with new recombinant agalsidase beta (ISU303) in healthy subjects</TI>
<SO>J Clin Pharmacol</SO>
<YR>2014</YR>
<VL>54</VL>
<NO>6</NO>
<PG>675-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944075"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944074"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobayashi-2005" MODIFIED="2010-04-07 15:49:09 +0100" MODIFIED_BY="[Empty name]" NAME="Kobayashi 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-07 15:49:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi M, Ida H, Ohashi T, Eto Y</AU>
<TI>Safety of enzyme replacement therapy among 20 Japanese patients with classical type of Fabry disease [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2005</YR>
<VL>28 Suppl 1</VL>
<PG>166</PG>
<CY>Tokyo, Japan</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944077"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944076"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosch-2004" MODIFIED="2009-01-30 15:34:24 +0000" MODIFIED_BY="Tracey Remmington" NAME="Kosch 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-30 15:34:24 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kosch M, Koch H-G, Oliveira JP, Soares C, Bianco F, Breuning F, et al</AU>
<TI>Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>3</NO>
<PG>1279-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944079"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944078"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linthorst-2004" MODIFIED="2009-01-30 15:35:41 +0000" MODIFIED_BY="Tracey Remmington" NAME="Linthorst 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-30 15:35:41 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM</AU>
<TI>Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>4</NO>
<PG>1589-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944081"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944080"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linthorst-2006" MODIFIED="2010-04-07 15:49:35 +0100" MODIFIED_BY="[Empty name]" NAME="Linthorst 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-07 15:49:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Linthorst Ge, Vedder AC, Ormel EE, Johannes AMFG, Hollak CEM</AU>
<TI>Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands</TI>
<SO>Nephrology, Dialysis, Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<PG>355-360</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944083"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944082"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mignani-2004" MODIFIED="2009-01-30 15:36:39 +0000" MODIFIED_BY="Tracey Remmington" NAME="Mignani 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-30 15:36:39 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mignani R, Panichi V, Giudicissi A, Taccola D, Boscaro F, Feletti C, et al</AU>
<TI>Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study</TI>
<SO>Kidney International</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>4</NO>
<PG>1381-85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944085"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944084"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mills-2004" MODIFIED="2010-04-07 15:51:41 +0100" MODIFIED_BY="[Empty name]" NAME="Mills 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-07 15:51:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mills K, Vellodi A, Morris P, Cooper D, Morris M, Young E, et al</AU>
<TI>Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2004</YR>
<VL>163</VL>
<PG>163</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944086"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pisani-2005" MODIFIED="2010-04-07 15:52:02 +0100" MODIFIED_BY="[Empty name]" NAME="Pisani 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-07 15:52:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pisani A, Spinelli L, Sabbatini M, Andreucci MV, Procaccini D, Abbaterusso C, et al</AU>
<TI>Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>1</NO>
<PG>120-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944089"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944088"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramaswami-2007" MODIFIED="2010-04-07 15:52:26 +0100" MODIFIED_BY="[Empty name]" NAME="Ramaswami 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-07 15:52:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, et al</AU>
<TI>Enzyme replacement therapy with agalsidase alfa in children with Fabry disease</TI>
<SO>Acta Paediatrica</SO>
<YR>2007</YR>
<VL>96</VL>
<NO>1</NO>
<PG>122-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944091"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944090"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ries-2006" NAME="Ries 2006" YEAR="2006">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL et al</AU>
<TI>Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease</TI>
<SO>Pediatrics</SO>
<YR>2006</YR>
<VL>118</VL>
<NO>3</NO>
<PG>924-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944093"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944092"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rombach-2012" MODIFIED="2016-07-08 12:36:07 +0100" MODIFIED_BY="Tracey Remmington" NAME="Rombach 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-07-08 12:36:07 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, et al</AU>
<TI>Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome</TI>
<SO>PLoS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>10</NO>
<PG>e47805</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944095"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944094"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffmann-2003" NAME="Schiffmann 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, et al</AU>
<TI>Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>6</NO>
<PG>703-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944097"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944096"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffmann-2006" MODIFIED="2010-04-07 15:53:04 +0100" MODIFIED_BY="[Empty name]" NAME="Schiffmann 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-07 15:53:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO</AU>
<TI>Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting</TI>
<SO>Nephrology, Dialysis, Transplantation</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>2</NO>
<PG>345-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944099"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944098"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffmann-2013" MODIFIED="2016-01-10 16:57:12 +0000" MODIFIED_BY="[Empty name]" NAME="Schiffmann 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-01-10 16:57:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, et al</AU>
<TI>Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa</TI>
<SO>Genet Med</SO>
<YR>2013</YR>
<VL>15</VL>
<NO>12</NO>
<PG>983-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944101"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944100"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiffmann-2014" MODIFIED="2015-09-22 21:57:24 +0100" MODIFIED_BY="[Empty name]" NAME="Schiffmann 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-09-22 21:57:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiffmann R, Pastores GM, Lien YH, Castaneda V, Chang P, Martin R, et al</AU>
<TI>Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study</TI>
<SO>Orphanet J Rare Dis</SO>
<YR>2014</YR>
<VL>26</VL>
<NO>9</NO>
<PG>169</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944103"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944102"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sirrs-2011" MODIFIED="2015-09-22 16:39:36 +0100" MODIFIED_BY="[Empty name]" NAME="Sirrs 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-09-22 16:39:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sirrs SM, Flowerdew G, Whyte J, Lemoine K, Bichet DG, Casey R, et al</AU>
<TI>Rate of decline of GFR in patients with fabry disease (FD): prospective natural history data from the Canadian fabry disease initiative (CFDI) [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2011</YR>
<VL>34 Suppl 3</VL>
<PG>S186, Abstract no: P-325</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1000727"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000069"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944105"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944104"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spinelli-2004" MODIFIED="2010-04-07 15:53:17 +0100" MODIFIED_BY="[Empty name]" NAME="Spinelli 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-07 15:53:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, et al</AU>
<TI>Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease</TI>
<SO>Clinical Genetics</SO>
<YR>2004</YR>
<VL>66</VL>
<PG>158-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944107"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944106"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsuboi-2014" MODIFIED="2016-04-19 14:11:43 +0100" MODIFIED_BY="Tracey Remmington" NAME="Tsuboi 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-04-19 14:11:36 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuboi K, Yamamoto H, Goto H, Somura F, Kurimoto Y</AU>
<TI>Evaluation of the efficacy of enzyme replacement therapy for cardiac hypertrophy in Fabry disease [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2014</YR>
<VL>37 Suppl 1</VL>
<PG>S154, Abstract np: P-425</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1000866"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000101"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944109"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-19 14:11:29 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuboi K, Yamamoto H, Goto H, Somura F, Kurimoto Y</AU>
<TI>Evaluation of therapeutic efficacy in Fabry disease using Lyso-Gb3 as an indictor [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2014</YR>
<VL>37 Suppl 1</VL>
<PG>S154, Abstract no: P-424</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1000865"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000100"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944110"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944108"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-T_x00f8_ndel-2013" MODIFIED="2016-01-10 16:40:12 +0000" MODIFIED_BY="[Empty name]" NAME="Tøndel 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-01-10 16:40:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tøndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, et al</AU>
<TI>Agalsidase benefits renal histology in young patients with Fabry disease</TI>
<SO>J Am Soc Nephrol</SO>
<YR>2013</YR>
<VL>24</VL>
<NO>1</NO>
<PG>137-48</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944112"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944111"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Utsumi-2005" MODIFIED="2009-01-30 15:37:29 +0000" MODIFIED_BY="Tracey Remmington" NAME="Utsumi 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-30 15:37:29 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Utsumi K, Mitsuhashi F, Asahi K, Sakurazawa M, Arii K, Komaba Y, et al</AU>
<TI>Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments</TI>
<SO>Clinica Chimica Acta</SO>
<YR>2005</YR>
<VL>360</VL>
<NO>1-2</NO>
<PG>103-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944114"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944113"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weidemann-2003" NAME="Weidemann 2003" YEAR="2003">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W et al</AU>
<TI>Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>108</VL>
<NO>11</NO>
<PG>1299-301</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944116"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944115"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weidemann-2014" MODIFIED="2016-05-27 17:35:51 +0100" MODIFIED_BY="[Empty name]" NAME="Weidemann 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-05-27 17:35:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, et al</AU>
<TI>Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch</TI>
<SO>J Am Soc Nephrol</SO>
<YR>2014</YR>
<VL>25</VL>
<NO>4</NO>
<PG>837-49</PG>
<IDENTIFIERS MODIFIED="2016-05-27 17:35:51 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944118"/><IDENTIFIER MODIFIED="2016-05-27 17:35:51 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944117"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-West-2011" MODIFIED="2012-11-15 12:04:04 +0000" MODIFIED_BY="[Empty name]" NAME="West 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-11-15 12:04:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West M, Bichet D, Casey R, Clarked J, Sirrs S, LeMoine K, et al</AU>
<TI>Agalsidase alfa and agalsidase beta have similar effects on outcomes in Fabry disease &#8211; results from the Canadian Fabry disease initiative</TI>
<SO>Molecular Genetics and Metabolism</SO>
<YR>2011</YR>
<VL>102</VL>
<PG>S3&#8211;S47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944120"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944119"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-07-14 12:16:31 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY DATA_SOURCE="PUB" ID="STD-Benjamin-2014" MODIFIED="2016-07-08 12:33:13 +0100" MODIFIED_BY="Tracey Remmington" NAME="Benjamin 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-04-19 14:21:45 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benjamin ER, Hamler R, Brignol N, Boyd R, Yu J, Bragat A, et al</AU>
<TI>Migalastat reduces plasma globotriaosylsphingosine (lyso-Gb3) in Fabry patients: results from the FACETS phase 3 study [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2014</YR>
<VL>37 Suppl 1</VL>
<PG>S161, Abstract no: P-448</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1000862"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000097"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944122"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-08 12:33:13 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Germain DP, Bichet DG, Giugliani R, Hughes D, Schiffmann R, Wilcox W, et al</AU>
<TI>Subjects treated with migalastat continue to demonstrate stable renal function and reduced left ventricular mass index over 3 years in a long-term extension study of Fabry disease [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2015</YR>
<VL>38</VL>
<NO>1 Suppl</NO>
<PG>Abstract no: O-050</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1157466"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001544"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4311631"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-29 12:45:43 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicholls K, Castelli J, Winkler R, Sitaraman SA, Benjamin ER, Wu X, et al</AU>
<TI>Migalastat HCl, an investigational pharmacological chaperone therapy: screen results from FACETS, a phase 3 study in male and female fabry patients [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2012</YR>
<VL>35</VL>
<NO>Suppl 1</NO>
<PG>S95: Abstract P-242</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1000728"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000070"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944123"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944121"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-2014" MODIFIED="2016-04-19 14:21:58 +0100" MODIFIED_BY="Tracey Remmington" NAME="Hughes 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-04-19 14:21:58 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes D, Skuban N, Johnson F, Lazauskas R, Williams HN, Kirk J, et al</AU>
<TI>Development of a next-generation ERT, ATB100C, for fabry disease [abstract]</TI>
<SO>Journal of Inherited Metabolic Disease</SO>
<YR>2014</YR>
<VL>37 Suppl 1</VL>
<PG>S158, Abstract no: P-440</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1000863"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500131000000098"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2944125"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2944124"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wijburg-2015" MODIFIED="2016-07-14 12:16:31 +0100" MODIFIED_BY="Tracey Remmington" NAME="Wijburg 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-07-14 12:13:57 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00701415</AU>
<TI>A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms (FIELD)</TI>
<SO>https://clinicaltrials.gov/ct2/show/NCT00701415</SO>
<YR>(accessed 14 July 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4311633"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-14 12:16:19 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE</AU>
<TI>Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain</TI>
<SO>Orphanet Journal of Rare Diseases</SO>
<YR>2013</YR>
<VL>8</VL>
<PG>47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4311634"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-07-14 12:16:31 +0100" MODIFIED_BY="Tracey Remmington" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wijburg FA, Benichou B, Bichet DG, Clarke LA, Dostalova G, Fainboim A, et al</AU>
<TI>Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial</TI>
<SO>PloS One</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>5</NO>
<PG>e0124987</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="1157465"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500135000001543"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4311635"/><IDENTIFIER TYPE="PUBMED" VALUE="25955246"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4311632"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2015-02-10 04:06:47 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-07-15 09:27:19 +0100" MODIFIED_BY="Tracey Remmington">
<ADDITIONAL_REFERENCES MODIFIED="2016-07-15 09:27:19 +0100" MODIFIED_BY="Tracey Remmington">
<REFERENCE ID="REF-Aerts-2008" MODIFIED="2016-07-14 15:28:30 +0100" MODIFIED_BY="Tracey Remmington" NAME="Aerts 2008" TYPE="JOURNAL_ARTICLE">
<AU>Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al</AU>
<TI>Elevated globotriaosylsphingosine is a hallmark of Fabry disease</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>2008</YR>
<VL>105</VL>
<NO>8</NO>
<PG>2812-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arends-2015" MODIFIED="2016-07-14 14:48:36 +0100" MODIFIED_BY="Tracey Remmington" NAME="Arends 2015" TYPE="JOURNAL_ARTICLE">
<AU>Arends M, Hollak CE, Biegstraaten M</AU>
<TI>Quality of life in patients with Fabry disease: a systematic review of the literature</TI>
<SO>Orphanet Journal of Rare Diseses</SO>
<YR>2015</YR>
<VL>10</VL>
<PG>77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2015-09-22 18:15:16 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ</AU>
<TI>What is &#8220;quality of evidence&#8221; and why is it important to clinicians</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>995&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-09-02 15:34:36 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-11-29 15:19:57 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011)</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<YR>20011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollack-2009" MODIFIED="2010-04-07 15:58:15 +0100" MODIFIED_BY="[Empty name]" NAME="Hollack 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hollak CE, Linthorst GE</AU>
<TI>Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?</TI>
<SO>Molecular Genetics and Metabolism</SO>
<YR>2009</YR>
<VL>96</VL>
<NO>1</NO>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2009" MODIFIED="2009-11-16 17:29:22 +0000" MODIFIED_BY="Regina P El Dib" NAME="Jones 2009" TYPE="JOURNAL_ARTICLE">
<AU>Jones AP</AU>
<TI>Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials</TI>
<SO>Clinical trials</SO>
<YR>2009</YR>
<VL>6</VL>
<PG>16-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meikle-1999" NAME="Meikle 1999" TYPE="JOURNAL_ARTICLE">
<AU>Meikle PJ, Hopwood JJ, Clague AE, Carey WF</AU>
<TI>Prevalence of lysosomal storage disorders</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<NO>3</NO>
<PG>249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Niemann-2014" MODIFIED="2015-09-22 21:28:18 +0100" MODIFIED_BY="[Empty name]" NAME="Niemann 2014" TYPE="JOURNAL_ARTICLE">
<AU>Niemann M et al</AU>
<TI>Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease</TI>
<SO>Circ Cardiovasc Genet</SO>
<YR>2014</YR>
<VL>7</VL>
<NO>1</NO>
<PG>8-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riccio-2013" MODIFIED="2016-01-10 18:36:33 +0000" MODIFIED_BY="[Empty name]" NAME="Riccio 2013" TYPE="JOURNAL_ARTICLE">
<AU>Riccio E, Capuano I, Visciano B, Marchetiello C, Petrillo F, Pisani A</AU>
<TI>Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature</TI>
<SO>G Ital Nefrol</SO>
<YR>2013</YR>
<VL>30</VL>
<NO>5</NO>
<PG>gin/30.5.5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ries-2007" MODIFIED="2010-02-02 09:51:50 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Ries 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ries M, Clarke JT, Whybra C, Mehta A, Loveday KS, Brady RO, et al</AU>
<TI>Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alpha in children and adolescents</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2007</YR>
<VL>47</VL>
<NO>10</NO>
<PG>1222-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2000" NAME="Smith 2000" TYPE="JOURNAL_ARTICLE">
<AU>Smith HJ, Taylor R, and Mitchell A</AU>
<TI>A comparison of four quality of life instruments in cardiac patients: SF-36, QLI, QLMI, and SEIQoL</TI>
<SO>Heart</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>4</NO>
<PG>390-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spada-2006" MODIFIED="2010-04-07 15:58:58 +0100" MODIFIED_BY="[Empty name]" NAME="Spada 2006" TYPE="JOURNAL_ARTICLE">
<AU>Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al</AU>
<TI>High incidence of later-onset Fabry disease revealed by newborn screening</TI>
<SO>American Journal of Human Genetics</SO>
<YR>2006</YR>
<VL>79</VL>
<NO>1</NO>
<PG>31-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2001" NAME="Sterne 2001" TYPE="BOOK_SECTION">
<AU>Sterne JAC, Egger M, Davey Smith G</AU>
<TI>Investigating and dealing with publication and other biases</TI>
<SO>Systematic Reviews in Health Care</SO>
<YR>2001</YR>
<PG>189-208</PG>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Publishing Group</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-2000" NAME="Tang 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tang JL, Liu JLY</AU>
<TI>Misleading funnel plot for detection of bias in meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<NO>5</NO>
<PG>477-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornton-2000" NAME="Thornton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Thornton A, Lee P</AU>
<TI>Publication bias in meta-analysis: its causes and consequences</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<NO>2</NO>
<PG>207-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2007" MODIFIED="2010-04-07 16:00:44 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Wang RY, Lelis A, Mirocha J, Wilcox WR</AU>
<TI>Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life</TI>
<SO>Genetics in Medicine</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>1</NO>
<PG>34-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilcox-2008" MODIFIED="2010-04-07 16:00:59 +0100" MODIFIED_BY="[Empty name]" NAME="Wilcox 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, et al</AU>
<TI>Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry</TI>
<SO>Molecular Genetics and Metabolism</SO>
<YR>2008</YR>
<VL>93</VL>
<NO>2</NO>
<PG>112-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wraith-2008" MODIFIED="2010-04-14 12:11:02 +0100" MODIFIED_BY="[Empty name]" NAME="Wraith 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wraith JE, Tylki-Szymanska A, Guffon N, Lien YH, Tsimaratos M, Vellodi A, et al</AU>
<TI>Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease</TI>
<SO>Journal of Pediatrics</SO>
<YR>2008</YR>
<VL>152</VL>
<NO>4</NO>
<PG>563-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-2005" MODIFIED="2016-01-25 11:39:26 +0000" MODIFIED_BY="[Empty name]" NAME="Young 2005" TYPE="JOURNAL_ARTICLE">
<AU>Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S, et al</AU>
<TI>Is globotriaosylceramide a useful biomarker in Fabry disease?</TI>
<SO>Acta Paediatr Suppl</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>447</NO>
<PG>51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-09-22 21:15:33 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-El-Dib-2010" MODIFIED="2012-11-15 12:19:18 +0000" MODIFIED_BY="Tracey Remmington" NAME="El Dib 2010" TYPE="COCHRANE_REVIEW">
<AU>El Dib RP, Pastores GM</AU>
<TI>Enzyme replacement therapy for Anderson-Fabry disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>5</NO>
<IDENTIFIERS MODIFIED="2012-11-15 12:19:06 +0000" MODIFIED_BY="Tracey Remmington"><IDENTIFIER MODIFIED="2012-11-15 12:19:06 +0000" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD006663.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-El-Dib-2013" MODIFIED="2015-09-22 21:15:33 +0100" MODIFIED_BY="[Empty name]" NAME="El Dib 2013" TYPE="COCHRANE_REVIEW">
<AU>El Dib RP, Nascimento P, Pastores GM</AU>
<TI>Enzyme replacement therapy for Anderson-Fabry disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-11-07 11:33:19 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-11-07 11:33:19 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006663.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2016-07-14 12:12:32 +0100" MODIFIED_BY="Tracey Remmington"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-07-15 09:49:13 +0100" MODIFIED_BY="Tracey Remmington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-07-15 09:49:13 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-07-15 09:49:13 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Banikazemi-2007">
<CHAR_METHODS MODIFIED="2016-07-15 09:49:13 +0100" MODIFIED_BY="Tracey Remmington">
<P>Trial design: parallel design double-blind RCT.</P>
<P>Multicenter</P>
<P>Setting: 41 referral centers (university or research hospitals) in nine countries in North America and Europe.</P>
<P>Period: February 2001 to January 2004.</P>
<P>Sample size calculation: reported (80 participants to provide 80% power for detecting a treatment effect on the basis of log rank testing by using a 10% dropout rate; a 14-month enrolment period and 18 months of follow up; type I error of 0.05 (2-sided); and expected events rates over 2 years of 40% and 10% for participants in the placebo and agalsidase beta groups, respectively, as predicted by an estimated 20% to 30% decline per year in estimated).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-23 17:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 252 patients screened, 82 eligible patients (ITT population) were treated at 26 sites in 6 countries.</P>
<P>Mean age: agalsidase beta group 46.9 years and, placebo group 44.3 years.</P>
<P>Sex: agalsidase beta group 88% men and 12% women and, placebo group 87% man and 13 % women.</P>
<P>Inclusion criteria: participants were at least 16 years of age with clinical evidence of AFD.</P>
<P>Exclusion criteria: participants who were undergoing dialysis or were schedule for kidney transplantation; those with documented transient ischemic attacks, ischemic stroke, unstable angina, or myocardial infarction with 3 months of trial entry; and those with confounding conditions or other clinically significant comorbid conditions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 09:35:22 +0100" MODIFIED_BY="Tracey Remmington">
<P>IV infusion of agalsidase beta (mg/kg of body weight) (n = 51) or placebo every two weeks (n = 31).</P>
<P>Follow up: 18 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-04-09 14:11:08 +0100" MODIFIED_BY="[Empty name]">
<P>Primary end point: the time to first clinical event (renal, cardiac, or cerebrovascular event or death).</P>
<P>A renal event was defined as a 33% increase in serum creatinine level from baseline (2 consecutive values) or end-stage kidney disease requiring long-term dialysis or transplantation.</P>
<P>A cardiac event was defined as myocardial infarction; new symptomatic arrhythmia requiring antiarrhythmic medication, pacemaker, direct current cardioversion, or defibrillator implantation; unstable angina defined by national practice guidelines and accompanied by electrocardiographic changes resulting in hospitalization; or worsening congestive heart failure requiring hospitalization.</P>
<P>A cerebrovascular event was defined as a stroke or transient ischemic attack documented by a physician. participants were allowed to transition to open-label agalsidase beta after an independent adjudication board confirmed that a primary end point event had occurred.</P>
<P>The following measures were also performed at baseline and at the final trial visit or time of trial withdrawal: serum creatinine level; proteinuria; ratio of urinary albumin to urinary creatinine; 12-lead electrocardiography; echocardiography; neurologic examination; head magnetic resonance imaging; Brief Pain Inventory; exercise tolerance; plasma globotriaosylceramide level; Fabry symptom assessment; physical examination; blood chemistries; urinalysis; IgG antibody titers to agalsidase beta; and optional skin biopsy. Safety monitoring included physician evaluation and documentation of adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-16 19:10:07 +0000" MODIFIED_BY="[Empty name]">
<P>The Genzyme Corporation and the National Center for Research Resources supported the trial.</P>
<P>We contacted the author on 09 October 2015 for further information and, we are awaiting their reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 09:48:21 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Bierer-2006">
<CHAR_METHODS MODIFIED="2015-10-30 17:25:23 +0000" MODIFIED_BY="[Empty name]">
<P>Trial design: parallel design RCT.</P>
<P>Single-center or multicenter: not reported.</P>
<P>Setting: not reported.</P>
<P>Period: 10 weeks.</P>
<P>Sample size calculation: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-05-21 15:07:15 +0100" MODIFIED_BY="[Empty name]">
<P>15 individuals with AFD, but only 6 participants were randomized (4 treatment; 2 placebo).</P>
<P>Sex: 5 male, and 1 female.</P>
<P>Mean age: male was 35 years and female was 42 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-05 15:17:24 +0000" MODIFIED_BY="Tracey Remmington">
<P>Placebo (saline) or enzyme replacement therapy (agalsidase beta 1 mg/kg every other week - Fabrazyme<SUP>®</SUP>).</P>
<P>Follow up: 18 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-25 13:02:02 +0100" MODIFIED_BY="[Empty name]">
<P>Cardiopulmonar exercise test, forced expiratory volume and forced vital capacity. History and physical examination, a baseline electrocardiogram, transthoracic echocardiogram, and a pulmonary function test (spirometry) were also performed. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-15 09:48:21 +0100" MODIFIED_BY="Tracey Remmington">
<P>First, the authors compared baseline cardiopulmonary exercise tests performed noninvasively, next, they assessed the impact of alfa galactosidase A on exercise tolerance by serial non-invasive cardiopulmonary exercise tests. The 6 participants randomized were part of a phase IV trial evaluating enzyme replacement therapy. Nine additional participants completed invasive cardiopulmonary exercise tests at baseline examinations. These participants did not have follow-up exercise tests and were not randomized to drug or placebo, neither evaluated in this systematic review.</P>
<P>
<BR/>The funding was provided by Genzyme Corporation.</P>
<P>We contacted the author on 09 October 2015 for further information and, we are awaiting their reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 09:48:03 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Clarke-2007">
<CHAR_METHODS MODIFIED="2016-07-15 09:48:03 +0100" MODIFIED_BY="Tracey Remmington">
<P>Trial design: parallel design open label, RCT.</P>
<P>Multicenter.</P>
<P>Setting: participating study sites included the National Institutes of Health, Bethesda, MD (four patients); Hospital for Sick Children, Toronto, ON, Canada (seven participants); Dalhousie University, Halifax, NS, Canada (3 participants), and the Charles University, Prague, Czech Republic (4 participants).</P>
<P>Period: 10 weeks' duration.</P>
<P>Sample size calculation: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 09:47:55 +0100" MODIFIED_BY="Tracey Remmington">
<P>N: 18</P>
<P>Sex: male only</P>
<P>Mean age: overall not reported.</P>
<P>Inclusion criteria: ERT-naive males (18 years or older) with a confirmed diagnosis of Fabry disease were eligible for inclusion in the study. AFD could be confirmed by mutation analysis or by a demonstration of a deficiency of-Gal A activity (4.0 nmol/mL per hour in plasma or serum or 8% of the average mean normal in leukocytes). In addition, participants must have had at least one sign or symptom of AFD, including neuropathic pain, angiokeratoma, corneal verticillata, cardiomyopathy, hypo- or anhydrosis, abdominal pain and/or diarrhoea, serum creatinine 1.0 mg/dL, and proteinuria 300 mg/24 hr.</P>
<P>Exclusion criteria: being on kidney dialysis or having received a kidney transplant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 09:46:53 +0100" MODIFIED_BY="Tracey Remmington">
<P>Participants were randomly assigned to one of five dosing groups stratified by baseline plasma Gb3 levels (low, 4 to11.5 nmol/mL; high,11.5 nmol/mL).</P>
<P>The agalsidade alfa treatment groups were:</P>
<P>(1) 0.1 mg/kg weekly (n = 4);</P>
<P>(2) 0.2 mg/kg every other week (n = 4); (the standard dose);</P>
<P>(3) 0.2 mg/kg weekly (n = 4);</P>
<P>(4) 0.4 mg/kg every other week (n = 3);</P>
<P>(5) 0.4 mg/kg weekly (n = 3). All doses were infused intravenously at a rate of 0.1 mg/kg per 20 minutes.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-24 10:32:14 +0000" MODIFIED_BY="[Empty name]">
<P>To investigate the pharmacokinetics and pharmacodynamics of various dosing regimens of agalsidase alfa.</P>
<P>The primary efficacy endpoint variable was change in plasma Gb3 level from baseline to the day of the final infusion. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-15 16:59:39 +0000" MODIFIED_BY="[Empty name]">
<P>We contacted the author on 09 October 2015 for further information and, we are awaiting their reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 09:46:24 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Eng-2001">
<CHAR_METHODS MODIFIED="2015-10-30 17:25:37 +0000" MODIFIED_BY="[Empty name]">
<P>Trial design: parallel design phase-3 double-blind RCT.</P>
<P>Multicenter</P>
<P>Setting: not reported.</P>
<P>Period: not reported.</P>
<P>Sample size calculation: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-14 12:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>58 participants with AFD (56 males) (29 each group).</P>
<P>Age average in the placebo group 28.4 years and in the treated group 32.0 years.</P>
<P>Inclusion criteria: patients should be over 16 years old, with alfa-galactosidases levels in the plasma lesser than 1.5 nmol/hour/mL or levels of leucocytes activity smaller than 4 nmol/hour/mg and, levels of creatine lesser than or equal to 2.2 mg/dL.</P>
<P>Exclusion criteria: participants who had carried through renal transplant or were carrying through dialysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 09:46:24 +0100" MODIFIED_BY="Tracey Remmington">
<P>Participants received placebo or agalsidase beta 1 mg/kg intravenously every 2 weeks.</P>
<P>Follow up: 5 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 09:46:11 +0100" MODIFIED_BY="Tracey Remmington">
<P>Primay endpoint was percentage of patients in whom renal microvascular endothelial deposits of Gb<SUB>3</SUB> were cleared. It was also evaluated the histologic clearance of microvascular endothelial deposits of Gb<SUB>3</SUB> in the endomyocardium and skin, changes in the level of pain and the quality of life, urinary creatine, urinary proteic excretion, renal function and dermatological characteristics of glicolipides accumulation in the dermis. The individual scores for the kidney-, heart-, and skin-biopsy specimens and the composite scores for all 3 types of specimens were compared at baseline and after the week-20 infusion.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-16 19:09:54 +0000" MODIFIED_BY="[Empty name]">
<P>Authors of the trial belonged to Genzyme Corporation, Cambridge, Massachusetts, USA.</P>
<P>We contacted the author on 09 October 2015 for further information and, we are awaiting their reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-01-16 19:09:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hughes-2008">
<CHAR_METHODS MODIFIED="2015-10-30 17:25:57 +0000" MODIFIED_BY="[Empty name]">
<P>Trial design: parallel design double-blind RCT.</P>
<P>Single-center or multicenter: not reported.</P>
<P>Setting: not reported.</P>
<P>Period: not reported.</P>
<P>Sample size calculation: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-14 12:04:51 +0100" MODIFIED_BY="[Empty name]">
<P>15 male with AFD.</P>
<P>Age: average of 37 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-03 12:47:26 +0000" MODIFIED_BY="Tracey Remmington">
<P>The participants received placebo (N = 8) or enzyme replacement therapy with alfa agalsidase 0.2 mg/kg every 40 minutes, twice a week (n = 7) and, an additional of more 36 months.</P>
<P>Follow up: 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-25 13:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>The primary efficacy endpoint was myocardial Gb<SUB>3</SUB> content; the secondary efficacy endpoint was reduction of the left ventricular mass by MRI assessment. In addition, QRS duration and levels of Gb<SUB>3</SUB> in cardiac tissue, urine sediment and plasma, echocardiography, electrocardiography, pure-tone audiometry, impedance audiometry and otoacoustic emission testing were also performed. Adverse events were computed. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-16 19:09:42 +0000" MODIFIED_BY="[Empty name]">
<P>No conflict of interest reported by the trial investigators.</P>
<P>We contacted the author on 09 October 2015 for further information and, we are awaiting their reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 09:45:38 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Hughes-2013">
<CHAR_METHODS MODIFIED="2016-07-15 09:45:38 +0100" MODIFIED_BY="Tracey Remmington">
<P>Trial design: cross-over double-blinded placebo RCT.</P>
<P>Single-center or multicenter: multicenter.</P>
<P>Setting: 2 hospitals (Royal Free Hospital, London and Addenbrookes Hospital, Cambridge).</P>
<P>Period: 4 weeks.</P>
<P>Sample size calculation: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 09:45:29 +0100" MODIFIED_BY="Tracey Remmington">
<P>N = 18 (cross-over).</P>
<P>Study participants with AFD (confirmed &#945;-galactosidase A deficiency and mutation of the &#945;-galactosidase A gene), were at least 18 years of age, and had been treated with agalsidase alfa (0.2 mg/kg IV every second week) for a minimum of three months to minimise the possibility that differences seen between the schedules were related to ongoing positive trajectory of response at the beginning of therapy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-13 15:40:22 +0000" MODIFIED_BY="[Empty name]">
<P>1) Schedule A (the currently approved treatment): 0.2 mg/kg agalsidase alfa administered every other week as a 40 minute IV infusion. To maintain consistency of weekly infusions in each schedule and therefore the blind, placebo was administered in the alternate week to agalsidase alfa in schedule A.<BR/>2) Schedule B: 0.1 mg/kg agalsidase alfa administered once a week as a 40 minute IV infusion.<BR/>3) Schedule C: 0.2 mg/kg agalsidase alfa administered once a week as a 40 minute IV infusion.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-01-10 18:40:09 +0000" MODIFIED_BY="[Empty name]">
<P>The primary outcome variable was self-assessed health state, measured by the visual analogue scale (&#8216;thermometer&#8217;) item of the European quality of life questionnaire (the EQ-5D: Euroqol Group 1990).<BR/>Secondary outcome variables was pain, assessed as the average composite pain severity dimension of the brief pain inventory (BPI) short form.<BR/>Safety assessments included physical examination, 12-lead electrocardiogram (ECG), clinical laboratory testing, and vital sign measurements and, adverse events (AEs). </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-15 09:44:59 +0100" MODIFIED_BY="Tracey Remmington">
<P>We contacted the author on 09 October 2015 for further information. The authors replied to our comments on 24 October 2015 saying that they have contacted the sponsor of the original study in regard to the randomisation, but no further information was provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 09:44:34 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Schiffmann-2001">
<CHAR_METHODS MODIFIED="2015-10-30 17:26:21 +0000" MODIFIED_BY="[Empty name]">
<P>Trial design: parallel design double-blinded placebo RCT.</P>
<P>Single-center or multicenter: not reported.</P>
<P>Setting: the Clinical Research Center of the National Institutes of Health.</P>
<P>Period: 6 months.</P>
<P>Sample size calculation: not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-04-14 12:05:34 +0100" MODIFIED_BY="[Empty name]">
<P>26 males with AFD.</P>
<P>Age ranged between 16 and 56 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 09:44:34 +0100" MODIFIED_BY="Tracey Remmington">
<P>Placebo (n = 12 and 11 randomized and completed trial, respectively) or alfa galactosidase A (n = 14 randomized and completed trial) , twice a week managed intravenously.</P>
<P>Follow up: not reported.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-24 18:19:50 +0100" MODIFIED_BY="[Empty name]">
<P>Transversal doppler, left ventricular volume, heart rate, stroke volume, cerebral blood flow.</P>
<P>The following Doppler parameters were obtained: peak flow velocity, mean flow velocity, end-diastolic velocity, pulsatility index, and resistance index.</P>
<P>Neuropathic pain measured by the Brief Pain Inventory, renal function, cardiac function, storage material, quantitative sensory testing, skin biopsy, and Gb<SUB>3 </SUB>analyses.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-07-15 09:44:09 +0100" MODIFIED_BY="Tracey Remmington">
<P>No conflict of interest reported by the trial investigators.</P>
<P>We contacted the author on 09 October 2015. The author replied to our comments at the same day.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 09:43:26 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Sirrs-2014">
<CHAR_METHODS MODIFIED="2016-07-15 09:43:26 +0100" MODIFIED_BY="Tracey Remmington">
<P>Trial design: parallel design RCT.</P>
<P>Multicenter study (5 centers).</P>
<P>Setting: Canada.</P>
<P>Period: Median follow up was 23.0 ±8.1 months.</P>
<P>Sample size calculation: There was a sample size calculation done before the start of the study (information retrieved by contact with the author).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 09:42:34 +0100" MODIFIED_BY="Tracey Remmington">
<P>N: 67 randomized participants.</P>
<P>Age: mean of 47.6 years</P>
<P>Sex: 55 females; 37 males</P>
<P>Inclusion criteria: the CFDI is a nationwide study of all patients in Canada with AFD between ages 5 and 85. All Canadian citizens with AFD are eligible for inclusion.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-01-13 20:30:56 +0000" MODIFIED_BY="[Empty name]">
<P>Participants newly meeting criteria for ERT and randomized 1:1 to agalsidase beta 1.0 mg/kg q2wks (n = 30) or agalsidase alfa 0.2 mg/kg q2wks (n = 62) (Cohort 1b).</P>
<P>Follow up: 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-20 22:06:00 +0100" MODIFIED_BY="[Empty name]">
<P>Compare the effects of agalsidase alfa and agalsidase beta on a composite clinical outcome consisting of renal (dialysis, transplant, or reduction in GFR by 50%), cardiac (admission for cardiac event), neurologic (stroke or sudden unilateral hearing loss) or death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-16 19:08:00 +0000" MODIFIED_BY="[Empty name]">
<P>Cohort 1a - participants on ERT when the CFDI began who maintained their baseline treatment assignment (not randomised and therefore not included in the review).</P>
<P>No data are available for only the original 1b cohort and, therefore no data can be used in analysis.</P>
<P>We contacted the author on 08 October 2015 for further information. The author replied to our comments at the same day.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-07-15 09:42:52 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Vedder-2007">
<CHAR_METHODS MODIFIED="2015-10-30 17:26:56 +0000" MODIFIED_BY="[Empty name]">
<P>Trial design: parallel design open-label RCT.</P>
<P>Multicenter.</P>
<P>Setting: two centers in Norway (the Academic Medical Center and the Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital).</P>
<P>Period: May 2002 and December 2004.</P>
<P>Sample size calculation: reported (90% and an alpha of 5% (one-sided), it was predicted that at least 18 patients (9 in each group) with an increased LVmass were required, i.e. a 10% larger reduction in LVmass by agalsidase alfa treatment than agalsidase beta treatment).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 09:42:52 +0100" MODIFIED_BY="Tracey Remmington">
<P>36 randomized participants (18 males and 18 females).</P>
<P>Age range: 19 and 76 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-11-03 12:52:08 +0000" MODIFIED_BY="Tracey Remmington">
<P>Agalsidase alfa (n = 20 and 18 randomized and analysed, respectively) or agalsidase beta (n = 16 randomized and analysed) at equal dose of 0.2 mg/kg biweekly for at least 12 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 09:41:35 +0100" MODIFIED_BY="Tracey Remmington">
<P>Primary endpoint:</P>
<UL>
<LI>Reduction of left ventricular mass on echocardiography</LI>
</UL>
<P>Secondary endpoints:</P>
<UL>
<LI>Improvement of renal function as measured by GFR.</LI>
<LI>Reduction of glycolipid accumulation in skin tissue (LM and biochemistry).</LI>
<LI>Reduction in pain as measured by the BPI.</LI>
<LI>Reduction in glycosphingolipid in plasma and 24-hour urine.</LI>
</UL>
<P>Tertiary endpoint:</P>
<UL>
<LI>Quality of life scores (SF-36).</LI>
<LI>Treatment failure defined as:</LI>
</UL>
<UL>
<UL>
<LI>progression of renal disease (33% increase in serum creatinine, need for dialysis or transplantation);</LI>
<LI>progression of cardiac disease (new infarction, need for cardioversion, or anti-arrhythmic drugs, heart-failure necessitating hospitalizations;</LI>
<LI>occurrence of a new CVA as diagnosed by a neurologist or new lacunar infarctions on MRI as assessed by an experienced neuroradiologist.</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-01-16 19:08:05 +0000" MODIFIED_BY="[Empty name]">
<P>We contacted the author on 09 October 2015 for further information and, we are awaiting their reply.</P>
<P>International Standard Randomized Clinical Trial: <A HREF="http://www.controlled-trials.com/ISRCTN45178534">ISRCTN45178534</A>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AEs: adverse events<BR/>AFD: Anderson-Fabry disease<BR/>BPI: Brief Pain Inventory<BR/>CFDI: Canadian Fabry Disease Initiative<BR/>CVA: cerebral vascular accident<BR/>ECG: electrocardiogram<BR/>ELISA: enzyme-linked immunosorbent assay<BR/>GRF: glomerular filtration rate<BR/>ITT: intention-to-treat<BR/>IV: intravenous<BR/>MRI: magnetic resonance imaging<BR/>QoL: quality of life<BR/>RCT: randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-07-15 09:40:46 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Alamartine-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Banikasemi-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beck-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beer-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Breunig-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cartwright-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elliott-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-15 09:36:54 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Eto-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-15 09:36:54 +0100" MODIFIED_BY="Tracey Remmington">
<P>Case series (all participants received 1 mg/kg of agalsidase beta, no comparator treatment). The authors reported the results of an open-label phase-2 study that was undertaken to evaluate whether ethnic differences exist that would affect agalsidase beta treatment of people with AFD.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-15 09:36:59 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Fellgiebel-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-15 09:36:59 +0100" MODIFIED_BY="Tracey Remmington">
<P>Phase 4 agalsidase beta placebo-controlled analysis of untreated and treated AFD patients with mild-to-moderate renal involvement.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-21 23:07:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fernhoff-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-21 23:07:07 +0100" MODIFIED_BY="[Empty name]">
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-15 09:37:04 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Germain-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-15 09:37:04 +0100" MODIFIED_BY="Tracey Remmington">
<P>Case series (58 people who had classic AFD and completed a 20-week, double-blind, randomized, placebo-controlled, phase-3 study of agalsidase were transitioned to an open-label extension trial to receive bi-weekly 1 mg/kg agalsidase for up to an additional 54 months, no placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-10 16:02:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Germain-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-10 16:02:10 +0000" MODIFIED_BY="[Empty name]">
<P>Cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guffon-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guffon-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case-control study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hajioff-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hilz--2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jardim-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jardim-2006b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kalliokoshi-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-15 09:40:46 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Kampmann-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-15 09:40:46 +0100" MODIFIED_BY="Tracey Remmington">
<P>Controlled trial with a cross-over to open label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-10 16:53:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-10 16:53:39 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, but evaluated only pharmacokinetic parameters and safety.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kobayashi-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kosch-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Linthorst-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Linthorst-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mignani-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mills-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pisani-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ramaswami-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ries-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-10 16:07:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rombach-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-10 16:07:39 +0000" MODIFIED_BY="[Empty name]">
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schiffmann-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-15 09:29:59 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Schiffmann-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-15 09:29:59 +0100" MODIFIED_BY="Tracey Remmington">
<P>Case series (participants who had completed a 6-month randomized placebo-controlled trial enrolled in an open-label extension study. All the participants received agalsidase alfa 0.2 mg/kg).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-10 16:57:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schiffmann-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-10 16:57:33 +0000" MODIFIED_BY="[Empty name]">
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-15 09:35:35 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Schiffmann-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-15 09:35:35 +0100" MODIFIED_BY="Tracey Remmington">
<P>6-week, open-label, every-other-week, IV 0.2 mg/kg agalsidase alfa. The study was divided into two phases (before and after an agalsidase alfa manufacturing process change).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-24 06:55:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sirrs-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-24 06:55:49 +0000" MODIFIED_BY="[Empty name]">
<P>Cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spinelli-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-04-19 14:14:47 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Tsuboi-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-04-19 14:14:47 +0100" MODIFIED_BY="Tracey Remmington">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-01-10 16:40:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-T_x00f8_ndel-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-01-10 16:40:40 +0000" MODIFIED_BY="[Empty name]">
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Utsumi-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weidemann-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-22 22:01:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weidemann-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-22 22:01:19 +0100" MODIFIED_BY="[Empty name]">
<P>Observational study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-21 23:28:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-West-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-21 23:28:42 +0100" MODIFIED_BY="[Empty name]">
<P>Cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>IV: intravenous</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-07-15 09:40:27 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-07-15 09:39:14 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Benjamin-2014">
<CHAR_METHODS MODIFIED="2016-04-29 12:32:32 +0100" MODIFIED_BY="Tracey Remmington">
<P>Randomized controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 09:37:34 +0100" MODIFIED_BY="Tracey Remmington">
<P>People with AFD. As of 15 December 2011, 60 males and 120 females have been screened. The mean (SD) age was 41 (14) years. 154/180 participants carried a missense mutation. 136/154 (88 %) participants carried an addressable mutation. For 18/154 (12%), the mutation was not considered addressable. 68 unique missense mutations were confirmed. Of these, 56 (82%) were considered addressable. 15 mutations were not previously described. Frequent substitutions were N215S (17 participants), R342Q (8 participants), R112H (7 participants), and R301Q (7 participants). All four were addressable. In summary, a majority of those with AFD screened for FACETS carried addressable missense mutations and were potentially eligible for the study. Screening for FACETS is complete and 67 participants have been randomized.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 09:39:14 +0100" MODIFIED_BY="Tracey Remmington">
<P>Migalastat HCl (AT-1001, GR181413A), an investigational pharmacological chaperone was studied in Phase 3 for AFD (FACETS study) (AT1001-011).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-29 12:29:30 +0100" MODIFIED_BY="Tracey Remmington">
<P>Plasma lyso-Gb3 levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-29 12:25:11 +0100" MODIFIED_BY="Tracey Remmington">
<P>FACETS study (NCT00925301). Conflict of Interest declared.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-15 09:39:57 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Hughes-2014">
<CHAR_METHODS MODIFIED="2016-07-15 09:34:23 +0100" MODIFIED_BY="Tracey Remmington">
<P>Migalastat - new Intervention (investigational) that is seeking marketing approval mid-2015 for people with AFD with amenable mutations.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 09:37:39 +0100" MODIFIED_BY="Tracey Remmington">
<P>The Phase 1, randomized single IV dose study is evaluating the safety and tolerability in a 2-way cross-over arm, the absolute bioavailability of migalastat in healthy volunteers (Study 018). This study will identify the optimal dose of migalastat for use in ATB100C, and will inform the design of Study 019 in people with AFD.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 09:39:57 +0100" MODIFIED_BY="Tracey Remmington">
<P>A next-generation AFD ERT based on CHARTTM, in which the migalastat chaperone binds and stabilizes alpha-Gal A in its properly folded and active form (denoted ATB100C), may result in increased uptake of active enzyme into target tissues and improved tolerability. A Phase 1 pharmacokinetics study of IV migalastat (Study 018), will be followed by a Phase 1/2 study to evaluate the activity, safety, and pharmacokinetics of ATB100C (Study 019). Study 018 will characterize the pharmacokinetics of IV migalastat, and inform dosing for further study with ATB100C. Study 019 is designed to provide proof-of-concept for this next-generation ERT in AFD.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 09:33:29 +0100" MODIFIED_BY="Tracey Remmington">
<P>Key measurements in Study 019 will include plasma lyso-GB3, antibodies, plasma &#945;-Gal A activity, and pharmacokinetics of migalastat and ATB100C.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-29 12:34:34 +0100" MODIFIED_BY="Tracey Remmington">
<P>Conflict of Interest declared.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-07-15 09:32:37 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-Wijburg-2015">
<CHAR_METHODS MODIFIED="2016-07-14 14:20:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>Randomized, open-label, parallel-group, phase 3B clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-07-15 09:32:33 +0100" MODIFIED_BY="Tracey Remmington">
<P>Males aged 5 - 18 years with complete &#945;-galactosidase A deficiency, without symptoms of major organ damage.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-07-15 09:32:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>2 doses of agalsidase beta compared.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-07-15 09:32:18 +0100" MODIFIED_BY="Tracey Remmington">
<P>Plasma and urinary GL-3 levels, plasma lyso-GL-3, GL-3 accumulation, mean GFR, median urinary albumin/creatinine ratio.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES>
<P>ERT: enzyme replacement therapy<BR/>AFD: Anderson-Fabry disease<BR/>GFR: glomerular filtration rate<BR/>IV: intravenous<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-02-10 04:06:47 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-07-15 09:46:36 +0100" MODIFIED_BY="Tracey Remmington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-07-15 09:44:02 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-06 13:30:51 +0000" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Banikazemi-2007">
<DESCRIPTION>
<P>Randomization codes were computer-generated.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 10:31:25 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Bierer-2006">
<DESCRIPTION>
<P>Stated as "randomized".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-23 14:26:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-2007">
<DESCRIPTION>
<P>"Patients were randomly assigned to one of five dosing groups stratified by baseline plasma Gb3 levels (low, 4 to 11.5 nmol/mL; high,11.5 nmol/mL)".</P>
<P>No direct statement of how the sequence is generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-04 10:31:34 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Eng-2001">
<DESCRIPTION>
<P>Stated as "randomized".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-15 17:01:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2008">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-21 14:32:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2013">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 09:44:02 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Schiffmann-2001">
<DESCRIPTION>
<P>Random tables (information retrieved by contact with the author).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 09:43:07 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Sirrs-2014">
<DESCRIPTION>
<P>Randomization was done manually in blocks of 4 (information retrieved by contact with the author).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 09:41:19 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Vedder-2007">
<DESCRIPTION>
<P>Permuted block randomisation, with a block size of 4 participants. Manual randomization, envelopes generated by people not involved in obtaining informed consent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-07-15 09:43:52 +0100" MODIFIED_BY="Tracey Remmington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-29 16:44:31 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Banikazemi-2007">
<DESCRIPTION>
<P>Randomization codes were maintained centrally at a secure location. The 2:1 randomization scheme was blocked (block size of 3, which was not revealed to investigators) at each site.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-15 17:06:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bierer-2006">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-23 14:26:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clarke-2007">
<DESCRIPTION>
<P>"Patients were randomly assigned to one of five dosing groups stratified by baseline plasma Gb3 levels (low, 4 to11.5 nmol/mL; high,11.5 nmol/mL".</P>
<P>No direct statement of how the generated sequence is concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-15 17:06:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eng-2001">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-15 17:02:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2008">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-21 14:32:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2013">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-07-15 09:43:52 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Schiffmann-2001">
<DESCRIPTION>
<P>Randomization schedule was prepared prior to the start of the trial and was provided to an unblinded pharmacist in the research pharmacy at the National Institutes of Health. No other medical or sponsor personnel had access to the randomization code until the trial was completed.</P>
<P>The randomization was generated by the biotechnology company (the latter information was retrieved by contact with the author).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-16 18:56:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirrs-2014">
<DESCRIPTION>
<P>Randomization was done by a third party [information retrieved by contact with the author].</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-15 17:05:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vedder-2007">
<DESCRIPTION>
<P>Envelopes checked by two persons not involved in obtaining informed consent.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-07-15 09:46:36 +0100" MODIFIED_BY="Tracey Remmington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-12-12 15:49:55 +0000" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Banikazemi-2007">
<DESCRIPTION>
<P>Trial materials were packaged identically, and sponsor staff, investigators, and patients were blinded to treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-11-04 10:31:29 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Bierer-2006">
<DESCRIPTION>
<P>Stated as "randomized in a double-blind fashion".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-07-15 09:46:36 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Clarke-2007">
<DESCRIPTION>
<P>Although the authors referred this was an open label study, the outcome is objective, and then it leads to lower probability to detection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-12-12 15:50:17 +0000" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-Eng-2001">
<DESCRIPTION>
<P>Stated as "double-blind". Information given on two outcomes: each renal biopsy was reviewed under light microscopy by three independent renal pathologists who were blinded to treatment status of the patient at the time of biopsy; immunofluorescence trials were scored blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-07-15 09:45:46 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Hughes-2008">
<DESCRIPTION>
<P>Stated as double blind. All data were independently analysed by Royal Free Hospital investigators. The data remained blinded until the database was unlocked and the statistical analyses performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-05-21 14:32:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hughes-2013">
<DESCRIPTION>
<P>All participants received weekly infusions, which ensured that the blinding was upheld and during the schedule of infusions every second week.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-05-20 22:05:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schiffmann-2001">
<DESCRIPTION>
<P>There was no detail whether clinicians, patients, outcome assessors were blinded to the treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-01-16 19:06:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirrs-2014">
<DESCRIPTION>
<P>Although the authors stated that "the sites and the patients are informed of the drug choice after randomization so the treatment assignment is not blinded" [information retrieved by contact with the author], we considered it as low risk of bias as the composite clinical outcome is objective and less likely to be affected by unmasking.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-12-12 15:29:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vedder-2007">
<DESCRIPTION>
<P>The authors reported that the envelopes were opened by the investigator in the presence of the patient.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-07-15 09:44:51 +0100" MODIFIED_BY="Tracey Remmington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-01-09 16:49:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Banikazemi-2007">
<DESCRIPTION>
<P>Withdrawals and drop outs, were noted by Banikazemi to be less than 20%. ITT was used for the primary outcome only.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-01-15 17:06:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bierer-2006">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-01-15 17:00:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2007">
<DESCRIPTION>
<P>All participants completed the 10-week study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-01-15 17:01:23 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eng-2001">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-01-15 17:02:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hughes-2008">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-07-15 09:44:51 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-Hughes-2013">
<DESCRIPTION>
<P>20 participants entered the study, 19 received at least one dose of study medication and therefore constitute the safety population.<BR/>One participant was screened but did not proceed to study medication due to travel difficulties. 18 completed all three dosing schedules and constitute the ITT population.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-12-12 15:51:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schiffmann-2001">
<DESCRIPTION>
<P>1 participant, randomized to the placebo trial arm, withdrew from the trial for personal reasons and 3 further participants (1 from the ERT group and 2 from the placebo group) declined the follow-up acetazolamide challenge arm of the trial at completion of the trial. A further patient had suffered a lacunar infarct 10 years prior to commencement of the present trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-01-15 17:06:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sirrs-2014">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-12-12 15:29:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vedder-2007">
<DESCRIPTION>
<P>In the LVMass analysis there were withdrawal rates of 50% and 62.5% in the agalsidase alfa and beta groups, respectively.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-01-15 17:06:21 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-09 20:23:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Banikazemi-2007">
<DESCRIPTION>
<P>No evidence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-15 17:06:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bierer-2006">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-02 12:54:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2007">
<DESCRIPTION>
<P>No evidence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-09 20:22:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eng-2001">
<DESCRIPTION>
<P>No evidence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-21 15:12:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hughes-2008">
<DESCRIPTION>
<P>No evidence. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-02 13:01:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hughes-2013">
<DESCRIPTION>
<P>No evidence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-21 14:32:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schiffmann-2001">
<DESCRIPTION>
<P>No evidence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-02 13:00:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirrs-2014">
<DESCRIPTION>
<P>No evidence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-09 17:01:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vedder-2007">
<DESCRIPTION>
<P>Quality of life is included as an outcome in the protocol, but not stated in the paper. However, we contacted the author to know if they have assessed this outcome. The author replied and said that they evaluated the QoL using SF36 questionnaires, but for the analysis presented in the paper, they did not use these data. They are willing to send us the data and we will include these in a future update. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-01-15 17:02:29 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-09 16:49:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Banikazemi-2007">
<DESCRIPTION>
<P>The Genzyme Corporation and the National Center for Research Resources supported the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-29 16:47:15 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Bierer-2006">
<DESCRIPTION>
<P>The funding was provided by Genzyme Corporation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-02 12:54:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Clarke-2007">
<DESCRIPTION>
<P>No evidence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-15 17:01:33 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Eng-2001">
<DESCRIPTION>
<P>Authors of the trial belonged to Genzyme Corporation, Cambridge, Massachusetts, USA.</P>
<P>We contacted the author on 09 October 2015 for further information and, we are awaiting their reply.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-01-15 17:02:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hughes-2008">
<DESCRIPTION>
<P>Trial authors received travel and research funding and honoraria for speaking and advisory boards from Shire HGT, Genzyme and Amicus.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-02 13:01:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hughes-2013">
<DESCRIPTION>
<P>No evidence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-12 15:51:50 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Schiffmann-2001">
<DESCRIPTION>
<P>No conflict of interest reported by the trial investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-03-02 13:01:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sirrs-2014">
<DESCRIPTION>
<P>No evidence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-12 15:51:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vedder-2007">
<DESCRIPTION>
<P>No conflict of interest was reported by the trial investigators.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-05-27 17:39:46 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-05-27 17:39:46 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-09-22 18:11:16 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Enzyme replacement therapy for Anderson-Fabry disease</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: Anderson-Fabry disease</P>
<P>
<B>Settings</B>: outpatients</P>
<P>
<B>Intervention</B>: agalsidase alfa</P>
<P>
<B>Comparison</B>: placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2">
<P>
<B>Illustrative comparative risks (95% CI)</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH>
<P>Assumed risk</P>
</TH>
<TH>
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Placebo</B>
</P>
</TD>
<TD>
<P>
<B>Agalsidase alfa</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Changes in globotriaosylceramide (Gb<SUB>3</SUB>) concentration in plasma </B>
</P>
<P>Follow up: 6 months (umol/l)</P>
</TD>
<TD>
<P>The mean in changes in Gb<SUB>3</SUB> concentration in plasma score ranged between 0.63 and 10.19 umol/l</P>
</TD>
<TD>
<P>The mean in changes in Gb<SUB>3</SUB> concentration in plasma score in the intervention group was on average 2.07 fewer<BR/>(6.64 fewer to 2.50 more) umol/l</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>39</P>
<P>
<I>2 studies</I>
</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P>We found no statistically significant differences between studied groups in changes from baseline for Gb<SUB>3</SUB>for which data were available.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Death</B>
</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
<TD>
<P>Outcome not reported.</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Pain</B>
</P>
<P>
<B>The Brief Pain Inventory severity</B>
</P>
<P>Follow up: over 5 months and up to 6 months</P>
</TD>
<TD>
<P>The mean for change in pain by the BPI severity was 4.7 (SD 2.25)</P>
</TD>
<TD>
<P>The mean for changes in pain by the BPI severity in the intervention group was on average 2.00 fewer (3.66 fewer to 0.34 fewer)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>26</P>
<P>
<I>1 study</I>
</P>
</TD>
<TD>
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>4</SUP>
</P>
</TD>
<TD>
<P>We found a statistically significant differences favouring agalsidase alfa compared to placebo in pain for which data were available.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Renal function by creatinine clearance</B>
</P>
<P>Follow up: at up to 6 months (mg/dL)</P>
</TD>
<TD>
<P>The mean in changes in renal function was 84.5 (SD: 35.15) mg/dL</P>
</TD>
<TD>
<P>The mean for changes in renal function in the intervention group was on average 10.30 more (15.37 fewer to 35.97 more) mg/dL</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>24</P>
<P>
<I>1 study</I>
</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very</B> <B>low</B>
<SUP>2,4</SUP>
</P>
</TD>
<TD>
<P>We found no statistically significant differences between studied groups in renal function for which data were available.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Symptoms and complications of disease</B>:<B> cardiac events</B>
</P>
</TD>
<TD>
<P>Outcome not reported.</P>
</TD>
<TD>
<P>Outcome not reported.</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Symptoms and complications of disease</B>: <B>cerebrovascular events</B>
</P>
</TD>
<TD>
<P>Outcome not reported.</P>
</TD>
<TD>
<P>Outcome not reported.</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>NA</B>: not applicable; <B>SD</B>: standard deviation</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. We downgraded the quality of evidence by 1 for high risk due to conflict of interest in one trial.</P>
<P>2. We downgraded the quality of evidence by 1 due to imprecision.</P>
<P>3. We downgraded the quality of evidence by 1 due to inconsistency.</P>
<P>4. We downgraded the quality of evidence by 2 due to only one single study reporting this outcome (lack of statistical power).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-03-18 09:45:32 +0000" MODIFIED_BY="Tracey Remmington" NO="2">
<TITLE MODIFIED="2015-09-22 18:41:31 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Enzyme replacement therapy for Anderson-Fabry disease</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: Anderson-Fabry disease</P>
<P>
<B>Settings</B>: outpatients</P>
<P>
<B>Intervention</B>: agalsidase beta</P>
<P>
<B>Comparison</B>: placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2">
<P>
<B>Illustrative comparative risks (95% CI)</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH>
<P>Assumed risk</P>
</TH>
<TH>
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Placebo</B>
</P>
</TD>
<TD>
<P>
<B>Agalsidase beta</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Changes in globotriaosylceramide (Gb<SUB>3</SUB>) concentration in plasma </B>
</P>
<P>Follow up: up to 18 months (umol/l)</P>
</TD>
<TD>
<P>The mean in changes in Gb<SUB>3</SUB> concentration in plasma score was 5.5 (SD: 1.6) umol/l</P>
</TD>
<TD>
<P>The mean in changes in Gb<SUB>3</SUB> concentration in plasma score in the intervention group was on average 4.80 fewer<BR/>(5.45 fewer to 4.15) umol/l; respectively.</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>58</P>
<P>
<I>1 study</I>
</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P>A statistically significant improvement on agalsidade beta compared to placebo was observed also observed in the domains of kidney (mean difference -1.70, (95% CI -2.09 to -1.31)) and heart (mean difference -0.90, 95% CI (-1.18 to -0.62)) .</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Death</B>
</P>
<P>Follow up: 18 months</P>
</TD>
<TD>
<P>0 per 1000</P>
</TD>
<TD>
<P>0 per 1000 (0 to 0)</P>
</TD>
<TD>
<P>1.85 (0.08 to 43.96)</P>
</TD>
<TD>
<P>82</P>
<P>
<I>1 study</I>
</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P>We found no statistically significant differences between studied groups in death which data were available.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Pain</B>
</P>
</TD>
<TD>
<P>Outcome not reported.</P>
</TD>
<TD>
<P>Outcome not reported.</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Renal function events (ITT population)</B>
</P>
<P>Follow up: 18 months</P>
</TD>
<TD>
<P>225 per 1000</P>
</TD>
<TD>
<P>195 (83 to 459)</P>
</TD>
<TD>
<P>0.87 (0.37 to 2.04)</P>
</TD>
<TD>
<P>82</P>
<P>
<I>1 study</I>
</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P>We found no statistically significant differences between studied groups in renal function events which data were available.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Symptoms and complications of disease: cardiac events</B>
</P>
<P>Follow up: up to 18 months</P>
</TD>
<TD>
<P>129 per 1000</P>
</TD>
<TD>
<P>59 (14 to 245)</P>
</TD>
<TD>
<P>0.46 (0.11 to 1.90)</P>
</TD>
<TD>
<P>82</P>
<P>
<I>1 study</I>
</P>
</TD>
<TD>
<P/>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P>We found no statistically significant differences between studied groups in cardiac events which data were available.</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Symptoms and complications of disease: cerebrovascular events (ITT population)</B>
</P>
<P>Follow up: 18 months</P>
</TD>
<TD>
<P>64 per 1000</P>
</TD>
<TD>
<P>7 (1 to 158)</P>
</TD>
<TD>
<P>0.12 (0.01 to 2.48)</P>
</TD>
<TD>
<P>82</P>
<P>
<I>1 study</I>
</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P>We found no statistically significant differences between studied groups in cerebrovascular events which data were available.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI</B>: confidence interval; <B>RR</B>: risk ratio; <B>NA</B>: not applicable; <B>SD</B>: standard deviation.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. We downgraded the quality of evidence by 1 for high risk due to conflict of interest.</P>
<P>2. We downgraded the quality of evidence by 1 due to only one single study reporting this outcome (lack of statistical power).</P>
<P>3. We downgraded the quality of evidence by 1 due to imprecision.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-03-18 09:44:20 +0000" MODIFIED_BY="Tracey Remmington" NO="3">
<TITLE MODIFIED="2015-09-22 19:05:56 +0100" MODIFIED_BY="[Empty name]">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Enzyme replacement therapy for Anderson-Fabry disease</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: Anderson-Fabry disease</P>
<P>
<B>Settings</B>: outpatients</P>
<P>
<B>Intervention</B>: agalsidase alfa</P>
<P>
<B>Comparison</B>: agalsidase beta</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2">
<P>
<B>Illustrative comparative risks (95% CI)</B>
</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH>
<P>Assumed risk</P>
</TH>
<TH>
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Agalsidase alfa</B>
</P>
</TD>
<TD>
<P>
<B>Agalsidase</B> <B>beta</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Changes in globotriaosylceramide (Gb<SUB>3</SUB>) concentration in plasma and tissue</B>
</P>
<P>Follow up: 12 months</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Death</B>
</P>
<P>Follow up: not reported</P>
</TD>
<TD>
<P>0 per 1000</P>
</TD>
<TD>
<P>0 (0 to 0)</P>
</TD>
<TD>
<P>3.00 (0.13 to 69.09)</P>
</TD>
<TD>
<P>36</P>
<P>
<I>1 study</I>
</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P>We found no statistically significant differences between studied groups in death which data were available.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Pain</B>
</P>
<P>Acroparaesthesia and Fabry crises</P>
<P>Follow up: not reported</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Renal function</B>
</P>
<P>Follow up: up to 24 months.</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
<TD>
<P>Outcome not reported</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Symptoms and complications of disease: cardiac events</B>
</P>
<P>Follow up: not reported</P>
</TD>
<TD>
<P>142 per 1000</P>
</TD>
<TD>
<P>66 (7 to 653)</P>
</TD>
<TD>
<P>0.47 (CI 0.05 to 4.60)</P>
</TD>
<TD>
<P>29</P>
<P>
<I>1 study</I>
</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P>We found no statistically significant differences between studied groups in death which data were available.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Symptoms and complications of disease: cerebrovascular events</B>
</P>
<P>Follow up: median 23.0 months</P>
</TD>
<TD>
<P>Outcome not reported.</P>
</TD>
<TD>
<P>Outcome not reported.</P>
</TD>
<TD>
<P>Not estimable.</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>NA</B>: not applicable.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. We downgraded the quality of evidence by 1 for high risk due to lack of blinding, incomplete outcome data and, selective reporting.</P>
<P>2. We downgraded the quality of evidence by 1 due to only one single study reporting this outcome (lack of statistical power).</P>
<P>3. We downgraded the quality of evidence by 1 due to imprecision.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-07-28 12:58:15 +0100" MODIFIED_BY="Nikki Jahnke"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-07-14 15:52:09 +0100" MODIFIED_BY="Tracey Remmington">
<COMPARISON ID="CMP-001" MODIFIED="2016-07-14 15:43:46 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<NAME>Agalsidase alfa vs placebo</NAME>
<CONT_OUTCOME CHI2="11.311020200843679" CI_END="2.4972409037498355" CI_START="-6.642744381753312" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0727517390017383" ESTIMABLE="YES" I2="91.15906450308161" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2016-07-14 15:39:57 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="7.704882258767753E-4" P_Q="1.0" P_Z="0.3740271630075399" Q="0.0" RANDOM="YES" SCALE="10.55" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="9.983011471861447" TOTALS="SUB" TOTAL_1="20" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="0.8889552073524013">
<NAME>Plasma Gb3</NAME>
<GROUP_LABEL_1>Agalsidase-alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.311020200843679" CI_END="2.4972409037498355" CI_START="-6.642744381753312" DF="1" EFFECT_SIZE="-2.0727517390017383" ESTIMABLE="YES" I2="91.15906450308161" ID="CMP-001.01.01" MODIFIED="2009-08-10 16:37:36 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="7.704882258767753E-4" P_Z="0.3740271630075399" STUDIES="2" TAU2="9.983011471861447" TOTAL_1="20" TOTAL_2="19" WEIGHT="100.0" Z="0.8889552073524013">
<NAME>At up to 6 months</NAME>
<CONT_DATA CI_END="-1.9145610786294416" CI_START="-7.305438921370557" EFFECT_SIZE="-4.609999999999999" ESTIMABLE="YES" MEAN_1="5.58" MEAN_2="10.19" ORDER="23475" SD_1="1.98" SD_2="4.21" SE="1.3752492100017326" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="14" TOTAL_2="11" WEIGHT="45.785293568413216"/>
<CONT_DATA CI_END="0.48607901195079356" CI_START="-0.34607901195079366" EFFECT_SIZE="0.06999999999999995" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.63" MODIFIED="2009-07-26 03:29:14 +0100" MODIFIED_BY="Regina P El Dib" ORDER="127" SD_1="0.46" SD_2="0.28" SE="0.2122891110412088" STUDY_ID="STD-Hughes-2008" TOTAL_1="6" TOTAL_2="8" WEIGHT="54.214706431586784"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2016-07-14 15:40:19 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urine sediment Gb3</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.02.01" MODIFIED="2009-08-10 16:36:15 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>At up to 6 months</NAME>
<CONT_DATA CI_END="273.82577918214815" CI_START="-1897.8257791821482" EFFECT_SIZE="-812.0" ESTIMABLE="YES" MEAN_1="1683.0" MEAN_2="2495.0" MODIFIED="2009-08-10 16:36:15 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="157" SD_1="1657.0" SD_2="1104.0" SE="554.0029244144297" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2016-07-14 15:40:33 +0100" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="26.12" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Kidney Gb3</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.01" MODIFIED="2009-08-10 16:37:03 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>At up to 6 months</NAME>
<CONT_DATA CI_END="4.4719504986085425" CI_START="-9.471950498608546" EFFECT_SIZE="-2.5000000000000018" ESTIMABLE="YES" MEAN_1="15.6" MEAN_2="18.1" MODIFIED="2009-08-10 16:37:03 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="158" SD_1="5.98" SD_2="10.54" SE="3.55718296540263" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="14" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2016-07-14 15:40:55 +0100" MODIFIED_BY="Tracey Remmington" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="6" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Myocardial globotriaosylceramide levels</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" MODIFIED="2009-08-14 15:26:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Over 3 months and up to 6 months</NAME>
<CONT_DATA CI_END="0.48607901195079356" CI_START="-0.34607901195079366" EFFECT_SIZE="0.06999999999999995" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.63" ORDER="23478" SD_1="0.46" SD_2="0.28" SE="0.2122891110412088" STUDY_ID="STD-Hughes-2008" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2016-07-14 15:41:18 +0100" MODIFIED_BY="Tracey Remmington" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="42" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>The Brief Pain Inventory Severity</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.01" MODIFIED="2016-07-14 15:34:41 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Over 1 month and up to 3 months</NAME>
<CONT_DATA CI_END="-0.41398607894491257" CI_START="-3.786013921055088" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="5.2" ORDER="23480" SD_1="2.02" SD_2="2.32" SE="0.8602269910846068" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" MODIFIED="2016-07-14 15:34:48 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Over 3 months and up to 5 months</NAME>
<CONT_DATA CI_END="-0.154389822285375" CI_START="-3.6456101777146257" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="5.2" ORDER="23481" SD_1="2.5" SD_2="2.04" SE="0.8906338032146385" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.03" MODIFIED="2016-07-14 15:35:00 +0100" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Over 5 months and up to 6 months</NAME>
<CONT_DATA CI_END="-0.3446341636172343" CI_START="-3.6553658363827655" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="4.7" ORDER="23482" SD_1="2.02" SD_2="2.25" SE="0.8445899258558219" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2016-07-14 15:41:44 +0100" MODIFIED_BY="Tracey Remmington" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="42" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>The Brief Pain Inventory pain-related QoL</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" MODIFIED="2016-07-14 15:35:10 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Over 1 month and up to 3 months</NAME>
<CONT_DATA CI_END="0.9297317432823109" CI_START="-2.7297317432823096" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="4.1" ORDER="23483" SD_1="2.28" SD_2="2.45" SE="0.933553757984841" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" MODIFIED="2016-07-14 15:35:18 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Over 3 months and up to 5 months</NAME>
<CONT_DATA CI_END="0.16528483087032964" CI_START="-3.7652848308703293" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="4.6" ORDER="23484" SD_1="2.5" SD_2="2.59" SE="1.0027147673999346" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.03" MODIFIED="2016-07-14 15:35:32 +0100" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Over 5 months and up to 6 months</NAME>
<CONT_DATA CI_END="-0.28437027407663273" CI_START="-3.9156297259233677" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="4.2" ORDER="23485" SD_1="2.09" SD_2="2.56" SE="0.9263587189585232" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="14" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2016-07-14 15:42:06 +0100" MODIFIED_BY="Tracey Remmington" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" MODIFIED="2009-08-10 16:53:39 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>At up to 6 months</NAME>
<CONT_DATA CI_END="35.974668207415846" CI_START="-15.374668207415848" EFFECT_SIZE="10.299999999999997" ESTIMABLE="YES" MEAN_1="94.8" MEAN_2="84.5" ORDER="23486" SD_1="27.76" SD_2="35.15" SE="13.099561221499146" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2016-07-14 15:42:31 +0100" MODIFIED_BY="Tracey Remmington" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="34.16" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="13" TOTAL_2="11" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Inulin clearance</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.01" MODIFIED="2009-08-10 16:53:03 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0" Z="0.0">
<NAME>At up to 6 months</NAME>
<CONT_DATA CI_END="20.355853633377862" CI_START="-21.355853633377862" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="71.5" MODIFIED="2009-08-10 16:53:03 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="159" SD_1="16.11" SD_2="32.03" SE="10.640937179400321" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="13" TOTAL_2="11" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2016-07-14 15:42:52 +0100" MODIFIED_BY="Tracey Remmington" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Glomeruli with mesangial widening</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.01" MODIFIED="2009-08-10 16:58:02 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At up to 6 months</NAME>
<CONT_DATA CI_END="7.320963666927245" CI_START="-36.72096366692725" EFFECT_SIZE="-14.7" ESTIMABLE="YES" MEAN_1="25.7" MEAN_2="40.4" ORDER="23488" SD_1="20.78" SD_2="28.5" SE="11.235391997315151" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2016-07-14 15:43:07 +0100" MODIFIED_BY="Tracey Remmington" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="19.57" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Glomeruli with segmental sclerosis</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.10.01" MODIFIED="2009-08-10 16:58:38 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At up to 6 months</NAME>
<CONT_DATA CI_END="9.954297314652841" CI_START="-2.3542973146528405" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="3.0" MODIFIED="2009-08-10 16:58:38 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="160" SD_1="8.66" SD_2="5.7" SE="3.14000530785114" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2016-07-14 15:43:19 +0100" MODIFIED_BY="Tracey Remmington" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="46.48" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="9" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Obsolescent glomeruli</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.11.01" MODIFIED="2009-08-10 16:58:41 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>At up to 6 months</NAME>
<CONT_DATA CI_END="21.932029230750537" CI_START="-8.932029230750539" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="19.5" MEAN_2="13.0" MODIFIED="2009-08-10 16:58:41 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="161" SD_1="20.78" SD_2="15.3" SE="7.87362898118354" STUDY_ID="STD-Schiffmann-2001" TOTAL_1="12" TOTAL_2="9" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2016-07-14 15:43:46 +0100" MODIFIED_BY="Tracey Remmington" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="23.53" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="32" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Echocardiographic data on left ventricular structure and function over 3 months and up to 6 months</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Mean left ventricular wall thickness (mm)</NAME>
<CONT_DATA CI_END="2.042210124232501" CI_START="-3.622210124232503" EFFECT_SIZE="-0.7900000000000009" ESTIMABLE="YES" MEAN_1="12.61" MEAN_2="13.4" ORDER="23491" SD_1="2.18" SD_2="3.22" SE="1.4450317182216683" STUDY_ID="STD-Hughes-2008" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Left ventricular internal diameter (mm) (diastolic)</NAME>
<CONT_DATA CI_END="4.326934930600322" CI_START="-11.726934930600327" EFFECT_SIZE="-3.700000000000003" ESTIMABLE="YES" MEAN_1="48.4" MEAN_2="52.1" ORDER="23492" SD_1="6.24" SD_2="9.07" SE="4.095450219450848" STUDY_ID="STD-Hughes-2008" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Left ventricular internal diameter (mm) (systolic)</NAME>
<CONT_DATA CI_END="4.50796907619741" CI_START="-9.907969076197409" EFFECT_SIZE="-2.6999999999999993" ESTIMABLE="YES" MEAN_1="27.7" MEAN_2="30.4" ORDER="23493" SD_1="5.85" SD_2="7.91" SE="3.677602819772684" STUDY_ID="STD-Hughes-2008" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.12.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Left ventricular ejection fraction</NAME>
<CONT_DATA CI_END="8.436256528125472" CI_START="-4.676256528125481" EFFECT_SIZE="1.8799999999999955" ESTIMABLE="YES" MEAN_1="81.0" MEAN_2="79.12" ORDER="23494" SD_1="6.71" SD_2="5.43" SE="3.3450903076997287" STUDY_ID="STD-Hughes-2008" TOTAL_1="6" TOTAL_2="8" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-07-14 15:48:50 +0100" MODIFIED_BY="Tracey Remmington" NO="2">
<NAME>Agalsidase beta vs placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2016-07-14 15:44:20 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="6.59" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="87" TOTAL_2="87" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Microvascular endothelial deposits of globotriaosylceramide</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.01" MODIFIED="2016-07-14 15:35:52 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Kidney - over 3 months and up to 6 months</NAME>
<CONT_DATA CI_END="-1.3131092791112644" CI_START="-2.0868907208887357" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="2.1" ORDER="23382" SD_1="0.7" SD_2="0.8" SE="0.19739685215671327" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.02" MODIFIED="2016-07-14 15:35:59 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Heart - over 3 months and up to 6 months</NAME>
<CONT_DATA CI_END="-0.6157411402755545" CI_START="-1.1842588597244452" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="0.3" MEAN_2="1.2" ORDER="23383" SD_1="0.5" SD_2="0.6" SE="0.14503269548146958" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.01.03" MODIFIED="2016-07-14 15:36:05 +0100" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Composite - over 3 months and up to 6 months</NAME>
<CONT_DATA CI_END="-4.148935401631292" CI_START="-5.451064598368708" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="5.5" ORDER="23385" SD_1="0.8" SD_2="1.6" SE="0.3321819194149599" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:44:35 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Death (ITT population)</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="43.95969977380186" CI_START="0.07753201321224296" EFFECT_SIZE="1.8461538461538463" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6430547177135453" LOG_CI_START="-1.1105189389040069" LOG_EFFECT_SIZE="0.26626788940476925" ORDER="23386" O_E="0.0" SE="1.6174627963065789" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="2.6161858974358974" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:44:48 +0100" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Renal events (ITT population)</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favuors placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0449853761036194" CI_START="0.36872004555512605" EFFECT_SIZE="0.8683473389355743" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.310690206670886" LOG_CI_START="-0.43330325122672697" LOG_EFFECT_SIZE="-0.06130652227792051" ORDER="23387" O_E="0.0" SE="0.43702543999607035" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="0.1909912352037589" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2016-07-14 15:45:08 +0100" MODIFIED_BY="Tracey Remmington" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="51.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="8" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Cardiopulmonary exercise test</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Average heart rate reserve</NAME>
<CONT_DATA CI_END="43.876411583259824" CI_START="-1.2764115832598293" EFFECT_SIZE="21.299999999999997" ESTIMABLE="YES" MEAN_1="33.8" MEAN_2="12.5" ORDER="23389" SD_1="13.1" SD_2="13.4" SE="11.518788998848795" STUDY_ID="STD-Bierer-2006" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.02" MODIFIED="2015-11-03 12:42:40 +0000" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Average maximum oxygen uptake measured at peak exercise (L/min)</NAME>
<CONT_DATA CI_END="1.3799857707828296" CI_START="-0.9399857707828296" EFFECT_SIZE="0.21999999999999997" ESTIMABLE="YES" MEAN_1="1.68" MEAN_2="1.46" ORDER="23390" SD_1="0.67" SD_2="0.69" SE="0.5918403500945166" STUDY_ID="STD-Bierer-2006" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.03" MODIFIED="2015-11-03 12:39:51 +0000" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Maximum oxygen uptake measured at peak exercise (ml/kg/min)</NAME>
<CONT_DATA CI_END="18.363399500634358" CI_START="-13.16339950063436" EFFECT_SIZE="2.599999999999998" ESTIMABLE="YES" MEAN_1="22.4" MEAN_2="19.8" ORDER="23391" SD_1="13.2" SD_2="6.5" SE="8.042698552103019" STUDY_ID="STD-Bierer-2006" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Oxygen pulse average at peak exercise</NAME>
<CONT_DATA CI_END="7.871087243788477" CI_START="-3.671087243788474" EFFECT_SIZE="2.1000000000000014" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="8.7" ORDER="23392" SD_1="3.4" SD_2="3.4" SE="2.944486372867091" STUDY_ID="STD-Bierer-2006" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:45:28 +0100" MODIFIED_BY="Tracey Remmington" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Cardiopulmonary exercise test</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-28 02:47:27 +0000" MODIFIED_BY="Regina P El Dib" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>Decrease in diastolic blood pressure</NAME>
<DICH_DATA CI_END="6.702042481097103" CI_START="0.33571855241831927" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.8262071762965648" LOG_CI_START="-0.47402465818520234" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-02-28 02:44:46 +0000" MODIFIED_BY="Regina P El Dib" ORDER="23394" O_E="0.0" SE="0.7637626158259733" STUDY_ID="STD-Bierer-2006" TOTAL_1="4" TOTAL_2="2" VAR="0.5833333333333333" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:45:35 +0100" MODIFIED_BY="Tracey Remmington" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Cardiac events</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9028043414373763" CI_START="0.10922232790691963" EFFECT_SIZE="0.45588235294117646" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.2793941336350541" LOG_CI_START="-0.9616885713789814" LOG_EFFECT_SIZE="-0.34114721887196364" MODIFIED="2010-02-28 02:32:31 +0000" MODIFIED_BY="Regina P El Dib" ORDER="56" O_E="0.0" SE="0.7290181243837147" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="0.5314674256799493" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:45:49 +0100" MODIFIED_BY="Tracey Remmington" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="260.07" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Cerebrovascular events (ITT population)</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.482620880144642" CI_START="0.006101587687122127" EFFECT_SIZE="0.12307692307692308" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.39491040371392483" LOG_CI_START="-2.2145571430157487" LOG_EFFECT_SIZE="-0.9098233696509119" ORDER="23395" O_E="0.0" SE="1.5328141540216904" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="2.3495192307692307" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="53" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:46:13 +0100" MODIFIED_BY="Tracey Remmington" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="81" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Participants achieving zero scores in skin over 3 months and up to 6 months</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours agalsidase beta</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="1" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Superficial endothelial cells</NAME>
<DICH_DATA CI_END="93.63497735575075" CI_START="4.130697616428942" EFFECT_SIZE="19.666666666666668" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="1" LOG_CI_END="1.971438109796219" LOG_CI_START="0.6160234040487443" LOG_EFFECT_SIZE="1.2937307569224819" ORDER="23396" O_E="0.0" SE="0.7961773075670681" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" VAR="0.6338983050847458" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="2" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Deep endothelial cells</NAME>
<DICH_DATA CI_END="42.07602276587005" CI_START="2.8757470893410852" EFFECT_SIZE="11.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" LOG_CI_END="1.6240346814197002" LOG_CI_START="0.45875068889675014" LOG_EFFECT_SIZE="1.0413926851582251" ORDER="23397" O_E="0.0" SE="0.684493585456773" STUDY_ID="STD-Eng-2001" TOTAL_1="26" TOTAL_2="26" VAR="0.46853146853146854" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="3" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Smooth muscle cells</NAME>
<DICH_DATA CI_END="22.62176227582904" CI_START="0.09946174716918879" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3545264342258836" LOG_CI_START="-1.002343916114521" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="23398" O_E="0.0" SE="1.3844373104863457" STUDY_ID="STD-Eng-2001" TOTAL_1="3" TOTAL_2="1" VAR="1.9166666666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.08.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Perineurium</NAME>
<DICH_DATA CI_END="15.716706127790523" CI_START="0.06927958517860539" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1963615327710861" LOG_CI_START="-1.1593947213830598" LOG_EFFECT_SIZE="0.018483405694013133" ORDER="23399" O_E="0.0" SE="1.3837828848716724" STUDY_ID="STD-Eng-2001" TOTAL_1="23" TOTAL_2="24" VAR="1.914855072463768" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="66" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:46:38 +0100" MODIFIED_BY="Tracey Remmington" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="81" TOTAL_2="80" WEIGHT="0.0" Z="0.0">
<NAME>Participants achieving zero score or reduction in skin over 3 months and up to 6 months</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours agalsidase beta</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="10" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Superficial endothelial cells</NAME>
<DICH_DATA CI_END="4.585445868702303" CI_START="1.7214081819517904" EFFECT_SIZE="2.8095238095238093" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="10" LOG_CI_END="0.6613815709553282" LOG_CI_START="0.23588386286112165" LOG_EFFECT_SIZE="0.44863271690822487" ORDER="23400" O_E="0.0" SE="0.24993945998216113" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" VAR="0.06246973365617433" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="26" EVENTS_2="9" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Deep endothelial cells</NAME>
<DICH_DATA CI_END="4.666518188668537" CI_START="1.6674452172494774" EFFECT_SIZE="2.789473684210526" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="9" LOG_CI_END="0.6689929629154795" LOG_CI_START="0.22205157438044057" LOG_EFFECT_SIZE="0.4455222686479601" ORDER="23401" O_E="0.0" SE="0.26253558402103616" STUDY_ID="STD-Eng-2001" TOTAL_1="26" TOTAL_2="26" VAR="0.06892493287726653" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="3" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Smooth muscle cells</NAME>
<DICH_DATA CI_END="22.62176227582904" CI_START="0.09946174716918879" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.3545264342258836" LOG_CI_START="-1.002343916114521" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="23402" O_E="0.0" SE="1.3844373104863457" STUDY_ID="STD-Eng-2001" TOTAL_1="3" TOTAL_2="1" VAR="1.9166666666666665" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-002.09.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Perineurium</NAME>
<DICH_DATA CI_END="3.2465568445103874" CI_START="0.6844594436734153" EFFECT_SIZE="1.4906832298136645" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5114230114105489" LOG_CI_START="-0.16465228005103638" LOG_EFFECT_SIZE="0.1733853656797563" ORDER="23403" O_E="0.0" SE="0.39712997283120166" STUDY_ID="STD-Eng-2001" TOTAL_1="23" TOTAL_2="24" VAR="0.15771221532091098" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:46:54 +0100" MODIFIED_BY="Tracey Remmington" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="281.85" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Chest pain</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-02 14:37:59 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="118.3632889646253" CI_START="0.38713426779476656" EFFECT_SIZE="6.769230769230769" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.0732170244113948" LOG_CI_START="-0.41213838472473124" LOG_EFFECT_SIZE="0.8305393198433318" MODIFIED="2009-08-13 20:23:28 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="1.4599100700342513" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="2.1313374125874125" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:47:12 +0100" MODIFIED_BY="Tracey Remmington" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Pain related to AFD</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-002.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-14 15:37:07 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Over 3 and up to 6 months</NAME>
<DICH_DATA CI_END="27.179863114101853" CI_START="0.33112749546301024" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4342472651654263" LOG_CI_START="-0.48000475572610146" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-08-13 20:29:39 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="1.124441112772009" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" VAR="1.2643678160919538" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:47:28 +0100" MODIFIED_BY="Tracey Remmington" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="277.35" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Fatigue</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-002.12.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-02 14:38:15 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="118.3632889646253" CI_START="0.38713426779476656" EFFECT_SIZE="6.769230769230769" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.0732170244113948" LOG_CI_START="-0.41213838472473124" LOG_EFFECT_SIZE="0.8305393198433318" MODIFIED="2009-08-13 20:25:25 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="1.4599100700342513" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="2.1313374125874125" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:47:42 +0100" MODIFIED_BY="Tracey Remmington" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="80" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event: rigors</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="0" I2="0.0" ID="CMP-002.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-14 15:37:18 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Over 3 and up to 6 months</NAME>
<DICH_DATA CI_END="464.37667111294314" CI_START="1.8110298219426626" EFFECT_SIZE="29.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.6668703939661826" LOG_CI_START="0.2579256018317294" LOG_EFFECT_SIZE="1.462397997898956" MODIFIED="2009-08-13 19:33:03 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="1.4150260953688143" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" VAR="2.002298850574713" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="1" I2="0.0" ID="CMP-002.13.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-02 14:34:18 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="77.95328785124792" CI_START="1.5356548243222967" EFFECT_SIZE="10.941176470588236" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="1.891834437235464" LOG_CI_START="0.18629360844382042" LOG_EFFECT_SIZE="1.0390640228396424" MODIFIED="2009-09-02 14:34:18 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="111" O_E="0.0" SE="1.001843125395474" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="1.0036896479021717" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="21" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:47:54 +0100" MODIFIED_BY="Tracey Remmington" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="80" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event: fever</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-002.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-14 15:37:32 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Over 3 and up to 6 months</NAME>
<DICH_DATA CI_END="53.35651979122511" CI_START="0.9183507506060845" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.727187494732371" LOG_CI_START="-0.0369914147038575" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2009-08-13 20:00:19 +0100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="1.0362874242292837" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" VAR="1.0738916256157633" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="1" I2="0.0" ID="CMP-002.14.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-02 14:35:10 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="61.575316922238315" CI_START="1.176068048094626" EFFECT_SIZE="8.509803921568627" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="1.7894066557888524" LOG_CI_START="0.07043245104029641" LOG_EFFECT_SIZE="0.9299195534145743" MODIFIED="2009-09-02 14:35:10 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="112" O_E="0.0" SE="1.0097339569288475" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="1.0195626637751876" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:48:09 +0100" MODIFIED_BY="Tracey Remmington" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="281.85" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event: chills</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-002.15.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-14 15:37:41 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Over 3 and up to 6 months</NAME>
<DICH_DATA CI_END="159.9412453779377" CI_START="0.5064359715881839" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2039604733159854" LOG_CI_START="-0.2954754544373356" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2009-08-13 20:05:17 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="1.4681810363696828" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" VAR="2.155555555555556" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:48:22 +0100" MODIFIED_BY="Tracey Remmington" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="249.81" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="80" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event: hypertension</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-002.16.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-14 15:37:53 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Over 3 and up to 6 months</NAME>
<DICH_DATA CI_END="129.74412565322564" CI_START="0.3776664242276759" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2009-08-13 20:08:09 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-002.16.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-02 14:36:14 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="9.599063653533644" CI_START="0.4715092885445555" EFFECT_SIZE="2.127450980392157" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.9822288715878696" LOG_CI_START="-0.32650974741464567" LOG_EFFECT_SIZE="0.32785956208661193" MODIFIED="2009-09-02 14:36:14 +0100" MODIFIED_BY="Nikki Jahnke" ORDER="113" O_E="0.0" SE="0.7687595431627232" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="0.5909912352037588" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:48:37 +0100" MODIFIED_BY="Tracey Remmington" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="260.07" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event: vomiting</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-002.17.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-02 14:36:28 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="51" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>At 24 months</NAME>
<DICH_DATA CI_END="137.2733411537796" CI_START="0.46622308062207346" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.1375862042873495" LOG_CI_START="-0.3314062303034626" LOG_EFFECT_SIZE="0.9030899869919435" MODIFIED="2009-08-13 20:21:15 +0100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="1.4502983777883034" STUDY_ID="STD-Banikazemi-2007" TOTAL_1="51" TOTAL_2="31" VAR="2.1033653846153846" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:48:50 +0100" MODIFIED_BY="Tracey Remmington" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Adverse event: headache</NAME>
<GROUP_LABEL_1>Agalsidase beta</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase beta</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-002.18.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-14 15:38:04 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Over 3 and up to 6 months</NAME>
<DICH_DATA CI_END="11.860821152232644" CI_START="0.5269449661015688" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0741147572861083" LOG_CI_START="-0.27823473994203307" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2009-08-13 20:27:36 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.7943767889097848" STUDY_ID="STD-Eng-2001" TOTAL_1="29" TOTAL_2="29" VAR="0.6310344827586207" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-07-14 15:49:58 +0100" MODIFIED_BY="Tracey Remmington" NO="3">
<NAME>Agalsidase alfa vs agalsidase beta</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:49:09 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Agalsidase beta</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours agalsidase beta</GRAPH_LABEL_2>
<DICH_DATA CI_END="69.09028858730679" CI_START="0.1302643277951726" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8394170067179525" LOG_CI_START="-0.8851744972786274" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-10-18 00:03:23 +0100" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="1.6004385363930504" STUDY_ID="STD-Vedder-2007" TOTAL_1="18" TOTAL_2="18" VAR="2.5614035087719293" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:49:24 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Cardiac events</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Agalsidase beta</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours agalsidase beta</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.595838195435937" CI_START="0.04738586706426042" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6623647301845877" LOG_CI_START="-1.3243511682674365" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2012-10-18 00:21:18 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="1.1670067531530235" STUDY_ID="STD-Vedder-2007" TOTAL_1="15" TOTAL_2="14" VAR="1.361904761904762" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:49:38 +0100" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Any adverse event</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Agalsidase beta</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours agalsidase beta</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.585802058877472" CI_START="0.07971975592963187" EFFECT_SIZE="0.35555555555555557" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.20024897736864225" LOG_CI_START="-1.0984340396074799" LOG_EFFECT_SIZE="-0.4490925311194189" MODIFIED="2012-10-18 00:41:06 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.7628528327563872" STUDY_ID="STD-Vedder-2007" TOTAL_1="18" TOTAL_2="16" VAR="0.5819444444444444" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-07-14 15:49:58 +0100" MODIFIED_BY="Tracey Remmington" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>Any serious adverse events</NAME>
<GROUP_LABEL_1>Agalsidase alfa</GROUP_LABEL_1>
<GROUP_LABEL_2>Agalsidase beta</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours agalsidase alfa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours agalsidase beta</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-07-14 15:49:42 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>New Subgroup</NAME>
<DICH_DATA CI_END="2.570915025008434" CI_START="0.034147956795504975" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41008772239166785" LOG_CI_START="-1.4666352767257553" LOG_EFFECT_SIZE="-0.5282737771670437" MODIFIED="2012-10-18 00:34:03 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="1.102396379610246" STUDY_ID="STD-Vedder-2007" TOTAL_1="18" TOTAL_2="16" VAR="1.2152777777777777" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-07-14 15:51:04 +0100" MODIFIED_BY="Tracey Remmington" NO="4">
<NAME>0.2 mg/kg/every 2 weeks vs 0.1 mg/kg/every week</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2016-07-14 15:50:36 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>0.2 mg/kg/every 2 weeks</GROUP_LABEL_1>
<GROUP_LABEL_2>0.1 mg/kg/every week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.1 mg/kg/week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.2 mg/kg/2 weeks</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3833023099101043" CI_START="-1.2633023099101042" EFFECT_SIZE="0.06000000000000005" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="1.63" MODIFIED="2015-03-21 03:59:26 +0000" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="2.07" SD_2="1.98" SE="0.6751666460956139" STUDY_ID="STD-Hughes-2013" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2016-07-14 15:51:04 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Self-assessed health state</NAME>
<GROUP_LABEL_1>0.2 mg/kg/every 2 weeks</GROUP_LABEL_1>
<GROUP_LABEL_2>0.1 mg/kg/every week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.1 mg/kg/week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.2 mg/kg/2 weeks</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.704129926428358" CI_START="-14.104129926428364" EFFECT_SIZE="-1.2000000000000028" ESTIMABLE="YES" MEAN_1="74.3" MEAN_2="75.5" MODIFIED="2015-03-20 13:47:40 +0000" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="20.0" SD_2="19.5" SE="6.5838607383678935" STUDY_ID="STD-Hughes-2013" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2016-07-14 15:52:09 +0100" MODIFIED_BY="Tracey Remmington" NO="5">
<NAME>0.1 mg/kg/every week vs 0.2 mg/kg/every week</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2016-07-14 15:51:48 +0100" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>0.1 mg/kg/every week</GROUP_LABEL_1>
<GROUP_LABEL_2>0.2 mg/kg/every week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.2 mg/kg/week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.1 mg/kg/week</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3733221274659397" CI_START="-1.25332212746594" EFFECT_SIZE="0.05999999999999983" ESTIMABLE="YES" MEAN_1="1.63" MEAN_2="1.57" MODIFIED="2015-03-20 13:51:32 +0000" MODIFIED_BY="[Empty name]" ORDER="60" SD_1="1.98" SD_2="2.04" SE="0.6700746227100381" STUDY_ID="STD-Hughes-2013" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.02" MODIFIED="2016-07-14 15:52:09 +0100" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Self-assessed health state</NAME>
<GROUP_LABEL_1>0.1 mg/kg/every week</GROUP_LABEL_1>
<GROUP_LABEL_2>0.2 mg/kg/every week</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 0.2 mg/kg/week</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 0.1 mg/kg/week</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.303720582947667" CI_START="-12.703720582947673" EFFECT_SIZE="0.29999999999999716" ESTIMABLE="YES" MEAN_1="75.5" MEAN_2="75.2" MODIFIED="2015-03-20 13:53:21 +0000" MODIFIED_BY="[Empty name]" ORDER="61" SD_1="19.5" SD_2="20.3" SE="6.634673231508007" STUDY_ID="STD-Hughes-2013" TOTAL_1="18" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-07-15 09:46:37 +0100" MODIFIED_BY="Tracey Remmington">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-07-14 14:48:16 +0100" MODIFIED_BY="Tracey Remmington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram for the second update.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAPbCAYAAAB2Sg13AABls0lEQVR42u29D4SVT///f5MkSSJJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-07-15 09:46:37 +0100" MODIFIED_BY="Tracey Remmington" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAXKUlEQVR42u1dW2wc13n+Ke7cuLzNLBmbdiBIIuEXxUAqQ5aomI6x
klMTdqskSFADbRFLDzSEyC6KvNgFekkfKsGAH5w4QSUUVds4QY0KKqTUlmrJa1hLtTDVCihip4VB
iqpcc+mQnCElkrszs+T2XGbnsjfuLpfLofR/vMzMmXPO/+/Zb845M3u+/QEQiMpoARUbAVEJxjZs
A8QaQI4gkCMI5AgCOYJAjiCQIwjkCOJeRwSboAQMbALfs1XkSFi615D16FkcaxA4H0EgRxDIEQRy
BIEcaRj0phdEVOJInEBUxkrli2+Wgw+Xsa1F1/DwodIF46Vzt6eRC9X1I4lEYlr8eqgcHCReleol
vvPZGgUPlC6Yf6UFx7dV7HeqHmu0yRWAHkWUVXKxdctiEsCOivShm90mtZGGjJ8SD2pJSeIXniaJ
MtnT26SozrKcifOLlPzZ7WLUJntdwyLJYg+LZ9w0Vt2ISjKNRcW2MW5Kc+uJd0vEB4H4EGc/MObY
7s7b3dWpUduKZxvcunqpPacg8d3nA0WvwuyRF/miJJHXlRaF4SRox3chGaqejwyQpCXdalsm+7mp
9w8CxMRp+h6okilvJ9uR6X8xn0vNd7HcS21WG3lvty+Yl0h7x+TUS15NMcOSYnTn5+93kuI/6DrG
0sQYPyucpLXu/cyaO0S2q1PtS249cDZFfLCJDwl+xccd26t5u9nDzLbi2aZ1fWDN7SXv+r8vdecL
xgTrfMT1gcL8vG0v21n8A3OemOx61z73NMBhG8lQFUfofMS8SlpZAf1r5HhSG3qCtOqEdp2+LRMw
Tp/QXteUfZOa8gQrEbG1cXKBZgUYUkjOcc33UYcpgG7yWoYArD0zGZZmmPzsJMsra6BYZHtLoxad
emCP5vrAKUFs2yyXY9faXWib1vU4KGTPvimYrg83YY/s+kAxp83KbCczBLSyyMF0mji2GzlSDoF1
8fEEJN/+S9rl71zJHkjQY/onmWxDj0Qrn8j+SM4vZ1/45xk2uoxa9HQ+J92QRPGSe5TIzxVHKSfc
vGQ3afuLjHIbng/FtgGeuURtr3zPsx2sC3wFif9eQfp/5DTd2L0/fGUwQWvJdc1wf/Iw8POarFq2
MYYe285uJsSrgdtIOipcI5uhounL8vQ/3SHnyGyXtHGLDmPenecoSbzk5hxlc4ZRnhHcvC0kwbuE
r7mngz4U2U6MUdspn22vrlHf9JPs67mAx72g/wPb6cx13mGvIHWKbMewv6iavUeA9COr/zN+yEuS
drHORlBg4KPC7Epaa6HnbDhDenmpH2i50aS+g3b9Nlxpc3OKN2yZpak8TdoJh0YBroyBpriZnHoo
iA97XWq9VmhbfJTY1vK203z0cOoSd9kSoQ5jnjkAN8yAx2l4hM9eV2YP05kRqeV5wqJHRSRD1T2c
sk+HtqN9vhNzNpt6JmJiuuhu8j1NWJon57rEY3doTpGWW4j3tdJy3cLr3lMM5fV2g6Xt52lzWYnm
NZ6S0ne87oHXQxE92keZKT7I7oBjYiZgW3iA2E4LS6SuRLeo3uW9Iq/LyLRfIfOMdtZlmsLhbPD1
Daf5nOlURx+l2Hv7xC6S9QFcJVHVfKQhiCeqznr1meW6n6L2pbSGPs4N1IfzEf98pPEc8c/9KiF3
KCnMC3WbOfPSYiO9jr55BJAjzeLIvQBcq+hbq2jgKFyxfRCAawMQyBEEcgSBHEFsPnDOivc1a83b
kSNh6V5Rg4XACwaBHEEgRxAI5AgiZBzZQCGCvvku3GdoBaWum+cD8xmA+CT9LYU3suXOVIVKZX/E
78rUiFW5zI9Ku+CkFZ7KaRnfUaal+e9ES7iIseryIlNnP2J/9IcVz1cWQK0Lg7yX2G+sna8GDVZ2
P/Y7jR1rdOuzv3bb1I6K7TbZyJIG0COLI65yym4XuABKFpI8K8ujt4mK7squnLSoSEVWKUWUr/AL
XRUlrYdJrpxzPH+cyzD7rwmQFkW5x5VZMU+YPVuRXBeCtrgPzCfXVlKgtQjX+pEMDeXIgKkJbpvG
RCsSA+hWOpYBFi9bg65yKhaxRfogNzeVOMiy8jyqZClMUMVkV07avPWvKsBR3VKedXg4PZ+xmOSK
ntuRz+9UbYkAXe1W+yKxMm9Jr3JP5tnKW1Xq2J/PF7TFUqYucREYtfUcYUuHdfkugGgiGRrKEUuD
867gwZyAmyaVSc1mmLDpiKucev4mTLwIVDk1xJVTPI/sCqqY7IqlKVxIdVEBwyluaMp+Lrmi5zyZ
ljM2fAog/HnyUy7r0n/M7ZG956kGa/ZiPl/QFsVtbeh5tkNtHaBrK5O7ifufriAZys6U6lhzpT9I
3rnRaa1IH0Xen97skJmoJICCAkGVp81K2qDveOG0K7zyC7N8Mi2WX6BjSrc99F+zBRqsa2aRBisg
3vJ8cmyRWlo6ZlGDVThBU9fXGANCIpEQB5yjUVeiRdCVu/i3br5resEdKM9Dk1sK07h86uFtb90t
MnctINNyWpSUEpamX130y7poRjNfo+dC8I7Bzvvk2CK1KKQWvQU7jEayd47qlYSjztHLA7BLBogM
9JL/2dndr7tvfGYA+v23lE4eKuYSCtIyXHy1KowXfxKd8YRZtEdhirrIJ2QcSWvSql/qJaWYwCvS
3zOczxe0RdEJn0j87o7bkpNaiowzn+An4A3lyIsT5N/Em871eMIU7DmA+eW75P1Z6Oj7G5L2Wh/r
r0zRCnQkPM/tmJi5XZBmdElUfBVdfKVYNmN4wixKBDa1ET8G6FDFg+8zWdfvcFnX5ICYIa7Nf/fu
uXy+2zHJZ4vizvFn5tiOY6v9bZFqOj9GnV5D5yMhgP77F4RG1mf/7s9Rg1VmPrJl9TVqYycQuZi/
w0OO+DmyZUdho7FzzJbg5Hq1+S9oNbRNjTO1kp0UNkF4ezgEcgSBHEEgRxD3IXDOWvKmCZsANVhb
rXvdGH8qfdSdw7EGgfMRBHIEgRxBIEcQyJHmQ1/jGNEIjtCoE3IvW1saDBMVLxOL6kx7icS0mKvH
kTLxqSpmDuw9XJDn4ZriYEXPIBeq6kcSiWmFLyctUi+VjEV1rFRqV/t6PrWvX7k1WHxcgwbrs2PY
71Q51mjGqttzqDwyFRU08QQupbKjUje/CvvFxyGeZgKofDQrVY4/8VUamcqJWkWlVLITNatXEana
yqmXS6+cchS9bayMm8+JckWQZBGxPPuumorv8Tqo4sqJiEUqOOPFwSqQgZWxo4kYB6va+YgvBgSX
Lb2tpPKP43JTd2hULCF1gh9bX5B/p6dpXKu98zyaFUxR7dN2yZR/Rg4upAD+atrImKn5boDfi1rR
Jbfenyq3ln3lAH7zf23b2Y6Tb7HN0vnz4G+wiFh5+xFxmq9HhdjFaar95XVQu28vmLM0+tkvu465
MrDzNo+7xcpWsPMFxjiqiiNkQvLV19yjSSZbOjuuOW+JE4TKvKk95lzHv6JdujZBZVUCKFToNsEu
8X0TMH6BbL9Cjh7TlP17NIXU9OZsPrgW3VyY6POVI8hqs/vYjpNPsFl8KvCicnH7Mo/KRWB+RbsF
/jr+mOwdykfc4sjsAeofuIG7ytn5FXKkHPzrWak8qfeO6VMvkT8vtFUwKhaAu0clTVAokyqImMXi
Ttmrg4mS0ivwC7OcfGNPrcAiW9es75xXDpS379n2RdGqGAerpB3JJ+Y08POaXHkN1kzhTcm2Qh0V
uAk53T0KyqSKhU9sMpub9d0HBaRXFD35Mk6+x5dTbd/ndygtsaul7AOPpOXV4UTEGi3QYAVfUhk7
eg47jCoJqrYW3sr2w45AAo2KNcr2BKrU2wH9EpNJ+WYyrxUJn1gnP5v2XaqR/tRwoFwaHsn489EI
W3/HJ0b/HYjKdSPvENmj6U4dhA2v8T3xBlV1OTKwj6FfDr6g0nYU1NdUOR8RMx8WZLhuSecCCXO2
eJrvMaVeq2jNMQlV2uskiqJWMSx0fNdn7YP0jo8C5dqGl6/780W/LSwt8GcXRx/0R+U6LL3h7H1T
oowmdSzfIaR7EAa7xeUPacStOwY7pkQYZv75UMbOn+IqiWrmI1VDtdj3NOgPTWnxxL3RDnbH1CZr
sMI7H6mdI+12LhKd4TfK5lK1Ua/CjvYZ/3d+IUfWx5H7AbhWEeNgVd0+CMC1AQjkCAI5gkCOIDYf
OGfF+5q15u3IkdB0r823iRosBM5HEMgRBHIEgRxBIEdqgV7XqVqL6P5TqIVoFOr53LfqNSNeRkcF
UQpsyXtttcmBLxhX7UUv3TFE8pJ6SznqpBWeahc3+/tZw3bvqza7MQbLn9pfe20HAp2HFxHrgGso
weqtQYNlpLHfaTB5490jIrli7ePSVXAlV+qIpCVZejwtKbzN9TfEqM4FUlGWC7z8tB72k1KoRmsu
OsLkUlekkXRSHmEpYpQvNLSjI5TXPYrkRNnqPc4EVMAjYrnprL7uEadeHgeLy8GYX6wqmdYZp5WN
UHlZWhSPJ0FYxjhYje7gVk8u0AhVb3WcANgumxKVNekn5zPPsnSQUz/lfZU6aM2qTBClzps/2cHS
8vmdCzoBJ6TObgBNOM2iZn07Nag9NzVIqjkxb0lc7xURT9KOcfE9c5CHwrr7j1aUDzHWO750prxq
OenUS239xGK2uL+sqqlLO9nOXv10lIxzXVHrsacBei0kQ4M5wvVQPOKUPQ4TVLzgRa6CrHaYr/2T
HweF7ykCHOHvQz6/i1M3Z0yAF2/CBI0aMqcdGZzUjpBqfuxGuHpxgsmtaJQtLqXKzILuxNba7U+n
mPCtTLUPc1u3XA3WdW2IL8+/yKVd4l8kD5P5zadZJENj56xBIVWR5IpuhAJZVCm5lU8oBYVyKa8w
uHIruzeb5Wosu9d+0vQiYrnpAd/KxcHiCWNPr2SdOFi3+ng9OGdt/Jy1VFwr58ZT5zVfCwSpsiGY
35knjrrVfC9Qy4Bb2BFedeZmnLi8XbnZC07T6v70Eh4W+NYL+gts5+st7zpxsN4hg4+OT4o2hrw8
4pRwHvoLJFc7YIAHm8qMMVnUqO2LZuXkH9X0HZwgYn+vxKNmnQrU0mmDOsz2pF1MeLUym2ZRtmzI
Xk7HHB8Uf/roWL4wJ16xb0ugdPKrSJBpFU40rfP4CfjGcGQ+TSNO3f6+aAZjTcE5ybzFO6qnRCqQ
Etrzka7Azd++1EffF/EBMDLfusKiZtnBScGJbiHzH2xvLivRvO/zKFuktoUn+xxpGFWEeemiOy0h
9XJbBXGwFuSeP2E70cUhKuFyomm9gDq9Rs5HGviUrQFoTESsEGiwQjsf2RiOSM0MqKzNNSDcUU7z
rz1Djvg5sjGjcFNjbjckaFpLcHniZgSlCm0gLJyplQJqsDa3g0MgRxDIEQRyBIHAOevaQA0WarCw
e2XIVXcOxxoEXjAI5AgCOYJAjiCQI0HoTSixvnKIQjR8bYDdtZKT59wVHYUrSZR0rYtL5EzpEuoa
n/eWKVdOgxXu72fdhHvfDdRgdUqpaYiVPT1Yc6irA2WCcGWydZVzUHjqtor9TtPGmtUJTbuT8Ue4
cqJT2cNudKphmxzl0+lF3S27kbTOiG10obsbScvRUpEsPCqX7AThOi8IdZUDW2H5AXpkiWuwhOEk
aMcxDlbTOCLsVG2wAPZ+YM3tZSnbF8xL5L2I/MCNTnXtS/Clf8unU6Sm3PwvTV8gvZAqmTKVTp1N
OVoqJ3qWKk05S3GOi/WVg9jnbdyvxcvmPDnV/a597mmAw6ivaRpHbq9YUaXHL77KCjBE9iQvOtU7
FthCPp0irbn5DW2PScpMwDgVWuxxF5neYtGzlJv5qFz2p/WVgzltlgcryQwB1WW1HmRxsHajTq9p
c1Y6uOy00hWjU+l9Jp1RQl5hxRRSbn545lJpmZYXlQu4ZKqecp48zO794SuDCdC//GSiaybkcbDu
rTmrpIO2sELIVyE6lSZ0R/zyLEZWJ/8Y6B9w6dRQKUrr4Mjptun1laMaLB7HqXO1k2o5tOVfnCLb
MYyD1bSxJrPL1rvIXOGKG+FK4OIrf3Qqcc+Mm+4gn/8Q3JDIOQUGPuInRv3S4Ew/xHgM1sgn9ZWD
ZXiES2lW5g7T+y9F054n/HgU9TVN44hhtD+YNXiEKy65SnSJx3h0qsvkTWTRqb64lnbT8+Wc/K3C
N2+RczEx7dyeCv5g5NdN6Rx3WRyurxy0DadvsZ33O/po0nv7xC6S9QFcJdHM+ch6sPYDNi3DvvhI
f+jzWD3lys2hXjkZ5jhYmzofCRtH1oirlZNaWhf4Q1zNWqyrXGlE3zwCyJGtwZFwANcqYhysqtsH
Abg2AIEcQSBHEMgRxOYD56x4X7PWvB05siW619xmWsSxBoHzEQRyBIEcQSBHEMiRTQTKIZAj5aAp
IouH9Wd8uWsR4oEN4j7kSM9vvWfpz/UC/LpyvgS+/fctRzI3hkD5z99wEZYqC0kaR0tkMba6+AJa
W2ZHAClFlK8AJAVR7kEy3EccsSfIv5sSF3ytTCUOAsTmLelVktr6OcuhTl3iCx2P6pbyLGFLh3X5
LpKhDO7FdWh8bSsPlxQ/q9ENFc/QhLNs0SrdjJz2ycOjLRd3+5azhm+t4iY8i1dD2xiNAIthk9fL
8Lf+a/F4POce0c3f8zufzpepaG8+d7APx5r7aawRf5v8+0YgrsFoQO8Fdv62+OFtbzmxsJRFJMN9
xBE5nYZkZtQvw3rZBjXq5eiET3iYrlVhnH7yLSe1X64gGcqgFZR77jUt39W2/UL/GXnrIys7JwHI
34fdR25El+kexc5f/9H45VZ6tNg6M9k3Cd0t2v9e9UkrMi3IDMXXGLgGvBg4Z73X56yIxgLXoZXE
KjYBcqQycPy91+9rEMgRBHIEgRxBIEcQyBEEcgSBQI4gkCPrhbHJ5cNVAXIEgf0IAjmC2Gjg+pEN
Gc3vAeB3b1bbQHVybL0XXggqwLEGgfMRBHIEgXNWRHgm8DhnLTtlU9lGrX7+55Zh25qKevNEtT7b
3jxTrdoDfsrzupxR5EjZ5iN/7LdqiuRbV3WOqi8auJ2qx7ZX3IBqPTAKXmlZozgfafT9cv13nYba
MHI31Br2Iw1/54y66WIUPpip3bZatQdq1S8YOVKxazDor1H1vD4/1JBtrUXBLVmn7aJ66vKgVBnk
yNojvFrT9azWXVRdt+31elC6DM5HGjjUGOscKdY/zKnrn+EUl0GONJpO9X8e2KhPEhv9iSQ+Q6s8
fTTyzxlqejpRa9GiByz1VqDW4nyp5yMlymBcTsSaxMOxBrEWkCMI5AgCOYJAjiCQI4iwI1Jwf49A
OFBLcASflCCgVJeBYw0C5yMI5AgCOYJAjiC20L1vhbvgsN7xoKObxpHC3mV1q7ifDa2jBcFOcluI
IjjWIJAjiCZyxKjybFE+w/BSm/G83yhpyQif866j5eyHpFEbpZ1YS1Ua6qnaZjuvhrtRax9rDMNh
vstkg/04Z/xXCM9pFDDfyebl3rgOJW/J73p+Y4THeV4xBJwNUaPW3I+UEpQaavCM/zivMHaFPUER
8saSRPV+iy17joXAeVppwFKIGrXOsUY1nJ+Czk4t6giLOkS1eZ2kWtKQGtxuovNGQZsWexOKRm2g
llP1ff/G2i2jGs2fnVSY422K81VotsLQqJHGXraU7WsoTA3fl6g0mSRqwIGt4XwI/NpWd6ehQsGX
mVR7c+yb7W5MqxpFXbOxxo1xKJw31vPEYSMbNVLja1DLd2feGU6eYE7VcE/yMxs31hRU7bdM9xwH
wuV8SadC0qg+LadRNjL0amg/Kiv8vCa0jhZ+XqOu9dBj811WyzQyYrPeEQjvZ8HIkXAgzGsFSnNk
y4RSz24VR3NbmL+RrUZqdLTpwLUBCOQIAjmCQI4gkCMI5Ahiq8N/74tfLoFYgyP41RIIHGsQyBEE
cgSBHEEgRxDIEQRyBIFAIErg/wHBjHxgJBQkgwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-07-15 09:46:37 +0100" MODIFIED_BY="Tracey Remmington" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASwAAAIoCAIAAABcZkGpAAAY5ElEQVR42u3dv27k1hXH8QECBClU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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-07-14 14:48:00 +0100" MODIFIED_BY="Tracey Remmington"/>
<APPENDICES MODIFIED="2016-07-14 14:48:01 +0100" MODIFIED_BY="Tracey Remmington">
<APPENDIX ID="APP-01" MODIFIED="2016-07-14 14:48:01 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<TITLE MODIFIED="2009-11-04 11:17:13 +0000" MODIFIED_BY="Nikki Jahnke">Glossary</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-14 14:48:01 +0100" MODIFIED_BY="Tracey Remmington">
<TABLE COLS="2" ROWS="47">
<TR>
<TH>
<P>
<B>Term</B>
</P>
</TH>
<TH>
<P>
<B>Explanation</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Acroparaesthesia</P>
</TD>
<TD>
<P>Pain, tingling and numbness of the hands and forearms</P>
</TD>
</TR>
<TR>
<TD>
<P>Angiokeratoma</P>
</TD>
<TD>
<P>Skin condition characterized by intradermal hemangioma over which there is thickening of the epidermis</P>
</TD>
</TR>
<TR>
<TD>
<P>Angiokeratoma corporis diffusum</P>
</TD>
<TD>
<P>X-linked disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A, also known as Anderson-Fabry disease</P>
</TD>
</TR>
<TR>
<TD>
<P>Cardiac</P>
</TD>
<TD>
<P>Relating to the the heart</P>
</TD>
</TR>
<TR>
<TD>
<P>Catabolism</P>
</TD>
<TD>
<P>The breaking down in living organisms of more complex substances into simpler ones</P>
</TD>
</TR>
<TR>
<TD>
<P>Cerebro-vascular disease</P>
</TD>
<TD>
<P>Group of brain dysfunctions related to disease, usually an obstruction, of the blood vessels supplying the brain</P>
</TD>
</TR>
<TR>
<TD>
<P>Deacylated</P>
</TD>
<TD>
<P>Describing a compound from which one or more acyl groups (an organic radical derived from an organic acid by the removal of the carboxylic hydroxyl group) has been removed</P>
</TD>
</TR>
<TR>
<TD>
<P>Dermatologic</P>
</TD>
<TD>
<P>Relating to the skin</P>
</TD>
</TR>
<TR>
<TD>
<P>Dyspnoea</P>
</TD>
<TD>
<P>Debilitating symptom or experience of unpleasant or uncomfortable respiratory (breathing) sensations</P>
</TD>
</TR>
<TR>
<TD>
<P>Echocardiography</P>
</TD>
<TD>
<P>Standard ultrasound techniques imaging two-dimensional slices of the heart to diagnose cardiovascular disease</P>
</TD>
</TR>
<TR>
<TD>
<P>Electrocardiography</P>
</TD>
<TD>
<P>Transthoracic interpretation of the electrical activity of the heart captured and externally recorded by skin electrodes</P>
</TD>
</TR>
<TR>
<TD>
<P>Endothelial</P>
</TD>
<TD>
<P>Thin layer of cells that line the interior surface of blood vessels</P>
</TD>
</TR>
<TR>
<TD>
<P>Gastrointestinal</P>
</TD>
<TD>
<P>Relating to the digestive system</P>
</TD>
</TR>
<TR>
<TD>
<P>Globotriaosylceramide</P>
</TD>
<TD>
<P>Type of glycolipid compound which accumulates in the blood vessel walls of people with Fabry disease as a result of a deficiency in alpha-galactosidase A, a lysosomal enzyme</P>
</TD>
</TR>
<TR>
<TD>
<P>Glomerular filtration rate</P>
</TD>
<TD>
<P>Volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman´s capsule (a cup-like sac at the beginning of the tubular component of a nephron in the mammalian kidney) per unit time</P>
</TD>
</TR>
<TR>
<TD>
<P>Glomeruli </P>
</TD>
<TD>
<P>Capillary tuft surrounded by Bowman's capsule in nephrons of the vertebrate kidney</P>
</TD>
</TR>
<TR>
<TD>
<P>Glycolipid</P>
</TD>
<TD>
<P>Any of a group of lipids containing a carbohydrate group, commonly glucose or galactose</P>
</TD>
</TR>
<TR>
<TD>
<P>GlycosphingolipidIt</P>
</TD>
<TD>
<P>Subtype of glycolipids containing the amino alcohol sphingosine; a ceramide (a sphingolipid) linked to one or more sugars via the terminal hydroxyl group</P>
</TD>
</TR>
<TR>
<TD>
<P>Hemangioma</P>
</TD>
<TD>
<P>A congenital benign skin lesion consisting of dense, usually elevated masses of dilated blood vessels</P>
</TD>
</TR>
<TR>
<TD>
<P>IgE antibodies</P>
</TD>
<TD>
<P>Type of immunoglobulin made by the body which are implicated in allergic reactions</P>
</TD>
</TR>
<TR>
<TD>
<P>IgG antibodies</P>
</TD>
<TD>
<P>Type of immunoglobulin involved in fighting foreign bodies, bacterial and viral infections</P>
</TD>
</TR>
<TR>
<TD>
<P>Left ventricular ejection fraction</P>
</TD>
<TD>
<P>Fraction of blood pumped out of the left ventricle with each heart beat</P>
</TD>
</TR>
<TR>
<TD>
<P>Lyonization</P>
</TD>
<TD>
<P>Phenomenon wherein one of the two copies of the X chromosome present in female mammals is inactivated</P>
</TD>
</TR>
<TR>
<TD>
<P>Lysosomal hydrolase alpha-galactosidase</P>
</TD>
<TD>
<P>Enzyme involved in glycolipid catabolism, which requires an acidic environment as maintained in the lysosome</P>
</TD>
</TR>
<TR>
<TD>
<P>Lysosomal inclusions</P>
</TD>
<TD>
<P>Storage bodies associated with lysosomal dysfunction, usually a deficiency of an enzyme involved in catabolism</P>
</TD>
</TR>
<TR>
<TD>
<P>Lysosome</P>
</TD>
<TD>
<P>Any of numerous small particles, containing digestive enzymes, that are present in the cytoplasm of most cells</P>
</TD>
</TR>
<TR>
<TD>
<P>Mammalian cell expression system</P>
</TD>
<TD>
<P>Elements involved in the translation of genetic information to form a particular protein</P>
</TD>
</TR>
<TR>
<TD>
<P>Mesangial widening</P>
</TD>
<TD>
<P>Thickening of the mesangium, a part of the renal glomerulus between capillaries</P>
</TD>
</TR>
<TR>
<TD>
<P>Microvascular disease</P>
</TD>
<TD>
<P>Angiopathy or condition affecting small blood vessels in the body</P>
</TD>
</TR>
<TR>
<TD>
<P>Myocardial infarction</P>
</TD>
<TD>
<P>Commonly known as a heart attack, resulting from an interruption of blood supply to part of the heart</P>
</TD>
</TR>
<TR>
<TD>
<P>Nephron</P>
</TD>
<TD>
<P>Any of the minute urine-secreting tubules that form the functional unit of the kidneys</P>
</TD>
</TR>
<TR>
<TD>
<P>Neurologic disease</P>
</TD>
<TD>
<P>Disorder of the brain, spinal cord and nerves</P>
</TD>
</TR>
<TR>
<TD>
<P>Neuropathic</P>
</TD>
<TD>
<P>Referring to disorders of the peripheral nervous system</P>
</TD>
</TR>
<TR>
<TD>
<P>Parametric data</P>
</TD>
<TD>
<P>Parametric statistical tests assume that the data are 'normally distributed', that is, when graphed, the data follow a 'bell shaped curve'</P>
</TD>
</TR>
<TR>
<TD>
<P>Perineurium cells</P>
</TD>
<TD>
<P>Cells from the perineurium, the middle layer of the protective perineural sheath surrounding peripheral nerves</P>
</TD>
</TR>
<TR>
<TD>
<P>Proteinuria</P>
</TD>
<TD>
<P>Presence of an excess of serum proteins in the urine</P>
</TD>
</TR>
<TR>
<TD>
<P>Renal</P>
</TD>
<TD>
<P>Relating to the kidneys</P>
</TD>
</TR>
<TR>
<TD>
<P>Segmental sclerosis</P>
</TD>
<TD>
<P>Scarring or degeneration, often used in relation to disease of a kidney section</P>
</TD>
</TR>
<TR>
<TD>
<P>Sero-converted</P>
</TD>
<TD>
<P>Development of antibodies in the blood as a result of the introduction of a foreign body, infection or immunization</P>
</TD>
</TR>
<TR>
<TD>
<P>Serum creatinine</P>
</TD>
<TD>
<P>By-product of metabolism that is measured in serum as a indicator of kidney function</P>
</TD>
</TR>
<TR>
<TD>
<P>Substrate</P>
</TD>
<TD>
<P>Molecule that is acted upon by an enzyme</P>
</TD>
</TR>
<TR>
<TD>
<P>Thrombo-embolic</P>
</TD>
<TD>
<P>Blocking of a blood vessel by a blood clot dislodged from its site of origin</P>
</TD>
</TR>
<TR>
<TD>
<P>Transduced</P>
</TD>
<TD>
<P>Conversion of one type of energy or signal into another; in genetics the introduction of DNA into a different cell type, to induce the formation of the corresponding gene product</P>
</TD>
</TR>
<TR>
<TD>
<P>Transthoracic echocardiogram</P>
</TD>
<TD>
<P>A test that uses high frequency sound waves, called ultrasound, to examine and take pictures of your heart</P>
</TD>
</TR>
<TR>
<TD>
<P>Urinary albumin</P>
</TD>
<TD>
<P>Presence of albumin, a protein, in the urine</P>
</TD>
</TR>
<TR>
<TD>
<P>X-linked</P>
</TD>
<TD>
<P>Relating to genes or characteristics or conditions carried on the X chromosome</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-07-14 14:47:07 +0100" MODIFIED_BY="Tracey Remmington" NO="2">
<TITLE MODIFIED="2016-07-14 14:47:07 +0100" MODIFIED_BY="Tracey Remmington">Search strategy - Clinical Trials (<I>The Cochrane Library</I>, Issue 9, 2015)</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-29 12:21:09 +0100" MODIFIED_BY="Nikki Jahnke">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search Strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>((Fabry Disease) OR (Disease, Fabry ) OR (Angiokeratoma Corporis Diffusum) OR (Anderson-Fabry Disease) OR (Anderson Fabry Disease) OR (Disease, Anderson-Fabry) OR (Fabry's Disease) OR (Disease, Fabry's) OR (Fabrys Disease)) AND ((agalsidase beta) OR (Fabrazyme) OR (Genzyme brand of agalsidase beta))</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-11-20 14:29:00 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2015-11-20 14:26:24 +0000" MODIFIED_BY="[Empty name]">Search strategy - EMBASE (1980 - 24 September 2015)</TITLE>
<APPENDIX_BODY MODIFIED="2015-11-20 14:29:00 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search Strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>1. Randomized controlled trial/</P>
<P>2. Controlled study/</P>
<P>3. Randomization/</P>
<P>4. Double blind procedure/</P>
<P>5. Single blind procedure/</P>
<P>6. Clinical trial/</P>
<P>7. (clinical adj5 trial$).ti,ab,hw.</P>
<P>8. ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw.</P>
<P>9. Placebo/</P>
<P>10. Placebo$.ti,ab,hw.</P>
<P>11. Random$.ti,ab,hw.</P>
<P>12. Methodology.sh.</P>
<P>13. latin square.ti,ab,hw.</P>
<P>14. crossover.ti,ab,hw.</P>
<P>15. cross-over.ti,ab,hw.</P>
<P>16. Crossover Procedure/</P>
<P>17. Drug comparison/</P>
<P>18. Comparative study/</P>
<P>19. (comparative adj5 trial$).ti,ab,hw.</P>
<P>20. (control$ or prospectiv$ or volunteer$).ti,ab,hw.</P>
<P>21. exp "Evaluation and Follow Up"/</P>
<P>22. Prospective study/</P>
<P>23. or/1-22</P>
<P>24. animal/ not (human/ and animal/)</P>
<P>25. 23 not 24</P>
<P>26. ((Fabry Disease) OR (Disease, Fabry) OR (Angiokeratoma Corporis Diffusum) OR (Anderson-Fabry Disease) OR (Anderson Fabry Disease) OR (Disease, Anderson-Fabry) OR (Fabry's Disease) OR (Disease, Fabry's) OR (Fabrys Disease)) AND ((agalsidase beta) OR (Fabrazyme) OR (Genzyme brand of AGAL) OR (Agalsidase alfa) OR (Replagal) OR (Shire HGT brand of AGAL))</P>
<P>27. 25 and 26</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2015-11-20 14:26:33 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2015-11-20 14:26:33 +0000" MODIFIED_BY="[Empty name]">Search strategy - PubMed (1966 - 24 September 2015)</TITLE>
<APPENDIX_BODY MODIFIED="2015-11-16 15:04:18 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search Strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>(((Fabry Disease) OR (Disease, Fabry) OR (Angiokeratoma Corporis Diffusum) OR (Anderson-Fabry Disease) OR (Anderson Fabry Disease) OR (Disease, Anderson-Fabry) OR (Fabry's Disease) OR (Disease, Fabry's) OR (Fabrys Disease)) AND ((agalsidase beta) OR (Fabrazyme) OR (Genzyme brand of AGAL) OR (Agalsidase alfa) OR (Replagal) OR (Shire HGT brand of AGAL))) AND (randomized controlled trial [Publication Type] OR controlled clinical trial [Publication Type] OR randomized controlled trials [MeSH Terms] OR random allocation [MeSH Terms] OR double blind method [MeSH Terms] OR single blind method [MeSH Terms] OR clinical trial [Publication Type] OR clinical trials [MeSH Terms] OR (clinical* [Text Word] AND trial* [Text Word]) OR single* [Text Word] OR double* [Text Word] OR treble* [Text Word] OR triple* [Text Word] OR placebos [MeSH Terms] OR placebo* [Text Word] OR random* [Text Word] OR research design [MeSH Terms] OR comparative study [MeSH Terms] OR evaluation studies [MeSH Terms] OR follow-up studies [MeSH Terms] OR prospective studies [MeSH Terms] OR control* [Text Word] OR prospectiv* [Text Word] OR volunteer* [Text Word])</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2015-11-20 14:26:38 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2015-11-20 14:26:38 +0000" MODIFIED_BY="[Empty name]">Search strategy - LILACS (1982 - 24 September 2015)</TITLE>
<APPENDIX_BODY MODIFIED="2015-11-16 15:04:05 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search Strategy</P>
</TH>
</TR>
<TR>
<TD>
<P>(((Fabry Disease) OR (Disease, Fabry) OR (Angiokeratoma Corporis Diffusum) OR (Anderson-Fabry Disease) OR (Anderson Fabry Disease) OR (Disease, Anderson-Fabry) OR (Fabry's Disease) OR (Disease, Fabry's) OR (Fabrys Disease)) AND ((agalsidase beta) OR (Fabrazyme) OR (Genzyme brand of AGAL) OR (Agalsidase alfa) OR (Replagal) OR (Shire HGT brand of AGAL))) AND ((Pt randomized controlled trial) OR (Pt controlled clinical trial) OR (Mh randomized controlled trials) OR (Mh random allocation) OR (Mh double blind method) OR (Mh single blind method) AND NOT (Ct animal) AND NOT (Ct human and Ct animal) OR (Pt clinical trial) OR (Ex E05.318.760.535$) OR (Tw clin$) AND (Tw trial$) OR (Tw ensa$) OR (Tw estud$) OR (Tw experim$) OR (Tw investiga$) OR (Tw singl$) OR (Tw simple$) OR (Tw doubl$) OR (Tw doble$) OR (Tw duplo$) OR (Tw trebl$) OR (Tw trip$) AND (Tw blind$) OR (Tw cego$) OR (Tw ciego$) OR (Tw mask$) OR (Tw mascar$) OR (Mh placebos) OR (Tw placebo$) OR (Tw random$) OR (Tw randon$) OR (Tw casual$) OR (Tw acaso$) OR (Tw azar) OR (Tw aleator$) OR (Mh research design) AND NOT (Ct animal) AND NOT (Ct human and Ct animal) OR (Ct comparative study) OR (Ex E05.337$) OR (Mh follow-up studies) OR (Mh prospective studies) OR (Tw control$) OR (Tw prospectiv$) OR (Tw volunt$) OR (Tw volunteer$) AND NOT ((Ct animal) AND NOT (Ct human and Ct animal)))</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in quantitative synthesis 7&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of studies included in qualitative synthesis 9 (represented by 34 individual references)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# articles assessed for eligibility 85&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records screened 600&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records after duplicates removed 600&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;# of records identified through database searching 662&lt;/p&gt;&lt;p&gt;CENTRAL 167&lt;/p&gt;&lt;p&gt;PubMed 224&lt;/p&gt;&lt;p&gt;Embase 268&lt;/p&gt;&lt;p&gt;Lilacs 3&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;# of additional records identified through other sources 0&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of records excluded 515&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# of articles excluded, with reasons 45 (to 43 trials) (case-series, non-RCTs, observational); # awaiting assessment 7 (to 3 trials)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1510221157036750405538456489083_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="z1510221157036750405538456489083"><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>Universidade Federal do Paraná (UFPR)</ORGANISATION><CITY>Curitiba</CITY><REGION>Paraná</REGION><COUNTRY CODE="BR">Brazil</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>